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Breast cancer is the second leading cause of cancer related deaths in women in the
United States. The human Epidermal Growth Factor 2 (ErbB2) gene amplification and/or
receptor overexpression subtype of breast cancer accounts for 25% of all breast cancers. A
crucial regulator of the ErbB2 signaling pathway is the heat shock protein 90 (Hsp90) and its
interacting protein complex. One such complex is the R2TP/Prefoldin-like complex that is
composed of four proteins, RUVBL1, RUVBL2, PIH1D1, and RPAP3 and seven prefoldin-like
proteins. This complex has been shown to be involved in telomere elongation, ribosome
biogenesis, protein stability; etc. We and others have recently shown that Ecdysoneless (ECD)
protein functions as a mediator for interaction of HSP90 and the R2TP complex and determines
which intracellular molecules the chaperone complex will regulate. Ecdysoneless, was first
discovered as a Drosophila fly mutation and we later identified the mammalian ortholog of ECD
in human epithelial cells as a binding partner of human papilloma virus 16 E6 oncoprotein. Using
knockout gene strategy we demonstrated that ECD deletion is embryonic lethal and its
knockdown or knockout (using fl/fl mouse embryonic fibroblasts and adenovirus cre mediated
deletion) in vitro led to block in cell cycle progression. Subsequently, we demonstrated ECD is
overexpressed in breast cancers, specifically in ErbB2+ breast cancers and its overexpression
correlates with poor prognosis and poor survival in these patients.

As part of my thesis work, I investigated how ECD regulates cell cycle progression and
the role of ECD in ErbB2-driven oncogenesis. We showed that ECD is phosphorylated on several
serine residues by CK2 that are important for ECD’s cell cycle function. In second goal, we have
shown a novel interaction between ErbB2 and ECD, and knockdown of ECD deregulates the
stability of the ERBB2 and HSP90 complex and leads to downregulation of ErbB2 and
consequently decreased expression of downstream effectors. We speculate ECD functions as a
co-oncogene in ErbB2-driven breast cancer and future studies using transgenic models will
explore this possibility.

i

Table of Contents
Page No.
Table of Contents…………………………………………………………….……………………….i
List of Figures………………………………………………………………………..….………………iv
List of Tables………………………………………………………………………….…………….….viii
Abbreviations………………………………………………………………….……………………..xvii
Acknowledgements………………………………………………………………..…………………vi
i:
Chapter 1: Introduction……………………………………………………..………….............1
1.1: The Ecdysoneless protein: Discovery and History.………………………………2
1.2: Domains of Ecdysoneless Protein……………………………………………………….4
1:3: Expression of ECD in Different Cancers……………………………………………….5
1.4: ECD Known Protein Interactions and Pathways………………………………….13
1.5: ECD potential roles through different protein-protein interactions.....29
1.6: Rationale, Hypothesis, and Specific Aims……………………………………….....39
ii:
Chapter 2: ECD Regulates HER2 Signaling in Breast Cancers……………………42
2.1: Abstract……………………………………………………………..………………………….....44
2.2: Introduction…………………………………………………………….……………………....45

ii

2.3: Results ……………………………………………………………………………………………..47
2.3.1: ECD associates with ErbB2 protein………………..………………………47
2.3.2: ECD regulates levels of ErbB2 protein……….………………………….48
2.3.3: Knockdown of ECD decreases ErbB2 interactions with
HSP90…………………………………………………………………………………………….49
2.3.4: ECD downregulates ErbB2 mRNA by altering its stability………50
2.3.5: ECD knockdown dramatically inhibits invasion and migration of
ErbB2+ breast cancer cells………………………………………………………………51
2.4: Discussion………………………………………………………………………...................51
2.5: Experimental procedures………………………………………………………………….55
2.6: Figure Legends……………………………………………………………….....................59
2.7: Figures:……………………………………………………………………………...................64
2.8: Supplementary Figures Legends and Figures……………………………………..69
Iii:
Chapter 3: Ongoing Studies and Future Directions…………………………………73
3.1: ECD localization and expression in ERBB2 exogenous overexpressed cell
lines.……………………………………………………………….………………………………………74

iii

3.2: Potential role of ECD and the R2TP complex in ErbB2 signaling
pathway………………………………………………………………………………………………..83
3.3: Role of ECD in downstream ErbB2 Signaling Pathway……………………..110
3.4: Potential Role of ECD in Different Subtypes of Breast of Cancer………112
3.5: Role of ECD in Endoplasmic Reticulum Stress Pathway…………………….116
3.6: ECD potential role as a therapy target in cervical cancer………………….134
iv:
Chapter 4: Summary and Conclusions…………………………………………………137
v:
Chapter 5: References………………………………………………………………………….144
vi:
Appendix…………………………………………………………………..………………………….170
Appendix A: Transcriptional Regulation of ERBB2…………………………………..170
Appendix B: Casein kinase 2-dependent phosphorylation of Ecdysoneless
and its interaction with R2TP complex component RUVBL1 regulates its
function in cell cycle progression……………………………………….…………….…….200

iv

List of Figures
Page No.
Figure 1.1: Ecd is overexpressed in various breast cancer cell lines.……. 12
Figure 1.2: Ecd is overexpressed in various prostate cancer cell lines.... 14
Figure 1.3: ECD and its Different Interacting partners………………………….15
Figure 1.4: Endogenous association of ECD with HSP90, and the four R2TP
components using Proximity Ligation Assay …………………………….………...31
Figure 1.5: Potential Functions of ECD with the HSP90 and the
R2TP/Prefoldin-like Complex…………………………………………………………………34
Figure 2.1: ECD associates with ErbB2……………………………………………...….64
Figure 2.2 ECD regulates levels of ErbB2 protein……..………………………...….65
Figure 2.3: Knockdown of ECD decreases interaction of ErbB2 with
HSP90………………………………………………………….……………………………………….... 66
Figure 2.4: ECD knockdown decreases ErbB2 mRNA levels by enhancing its
turn over……………………………………………………………..……………………………….….67
Figure 2.5: Knockdown of ECD decreases invasion and migration ability of
ErbB2 positive breast cancer cell lines ……………………………………………….….68

v

Figure Supplementary Figure 1 ..………………………………………….………………….71
Figure Supplementary Figure 2……………………………………………………………….72
Figure 3.1: ECD and ERBB2 Localization in ERBB2+ Breast Cancer Cell
Lines………………………………………………………………………………………………………..76
Figure 3.2: ECD is overexpressed in overexpressed ERBB2 transfected cell
lines………………………………………………………………...…………………………………..80
Figure 3.3: ECD mRNA is unaffected in overexpressed ERBB2 transfected
cell lines.…………………………………………………………………………………………..….82
Figure 3.4: ECD and HSP90 Co-localization in SKBR3 cells.…………………….84
Figure 3.5: ECD, HSP90, and members of the R2TP complex is
overexpressed in various breast cancer cell lines..…………………………………85
Figure 3.6: ECD siRNA mediated knockdown does not downregulate
members HSP90/R2TP complex in various breast cancer cell lines…….…..88
Figure 3.7: ERBB2+ cell lines treated with Trastuzumab causes
downregulation of ECD and members of the R2TP complex.………………….92
Figure 3.8: ERBB2+ Trastuzumab resistant cell lines treated with
Trastuzumab does not change ECD and members of the R2TP complex
levels…………………………………………………………………………………..………………….95

vi

Figure 3.9: ERBB2+ cell lines treated with Lapatinib causes downregulation
of ECD and members of the R2TP complex……………………………………………99
Figure 3.10: MCF7 and MDA MB 231 cell lines treated with Lapatinib causes
no downregulation of ECD and members of the R2TP complex………………102
Figure 3.11:

ERBB2+ cell lines treated with 17-AAG leads to

downregulation of ECD…………………………………………………………………………..105
Figure 3.12: BT474 ERBB2+ breast cancer cell line treated with 17-AAG lead
to downregulation of ECD and members of the R2TP complex……………….106
Figure 3.13: ERBB2+ cell lines treated with 17-AAG leads to downregulation
of ECD and members of the R2TP complex………………………………..…..………108
Figure 3.14: ERBB2+ cell lines treated with Rapamycin causes
downregulation of ECD and members of the R2TP complex………..…..…….113
Figure 3.15: ERBB2+ cell lines treated with MK-2206 HCl causes
downregulation of ECD…………………………………………………………………………115
Figure 3.16: Proximity Ligation Assay depicting Interaction between ECD
and ER Stress Components……………………………………………………………………..128
Figure 3.17: Proximity Ligation Assay depicting Interaction between ECD
and ER Stress Component ATF6……………………………………………………...131

vii

Figure 3.18:

ERBB2+ cell lines treated with Bortezomib causes

upregulation of ECD……………….……………………………………………………….133
Figure 3.19: Cervical cancer cell lines treated with 17-AAG causes
downregulation of ECD in a dose dependent and time dependent
manner……………………………………………………………………………………………….…135

viii

List of Tables
Page No.
Table 1.1: The classification of the six breast cancer subtypes. ……….. 7
Table 1.2: The molecular components of the R2TP/Prefoldin Like complex
with their common designations in S. cerevisiae and in humans..…….. 23
Table 3.1: Summary of experimental results for TCGA samples for ECD,
TEL2, and R2TP components……………………………………………………………….117
Table 3.2: An ANOVA test was then performed on each gene, starting with
ECD, between each subtype group to determine if there was any significant
change in mRNA expression for ECD………………………………………………………119
Table 3.3: Student T-Test was then performed for each gene between each
subtype to determine if there was a significant change in mRNA expression
for ECD……………………………………………………………………………………………………119
Table 3.4: An ANOVA test was then performed on each gene between each
subtype group to determine if there was any significant change in mRNA
expression for RUVBL1……………………………………………………………………………120
Table 3.5: Student T-Test was then performed for each gene between each
subtype to determine if there was a significant change in mRNA expression

ix

for RUVBL1………………….…………………………………………………………………………120
Table 3.6: An ANOVA test was then performed on each gene between each
subtype group to determine if there was any significant change in mRNA
expression for RUVBL2.……………………………….………………………………………….121
Table 3.7: An ANOVA test was then performed on each gene between each
subtype group to determine if there was any significant change in mRNA
expression for PIH1D1……..……………………………………………………………………122
Table 3.8: Student T-Test was then performed for each gene between each
subtype to determine if there was a significant change in mRNA expression
for PIH1D1……………………………………………………………………………………………..122
Table 3.9: An ANOVA test was then performed on each gene between each
subtype group to determine if there was any significant change in mRNA
expression for RPAP3……………………………………………………………………………123
Table 3.10: Student T-Test was then performed for each gene between
each subtype to determine if there was a significant change in mRNA
expression for RPAP3…………………………………………………………………………….123
Table 3.11: An ANOVA test was then performed on each gene between
each subtype group to determine if there was any significant change in
mRNA expression for TEL02……………………………………………………………………124

x

Table 3.12: Student T-Test was then performed for each gene between
each subtype to determine if there was a significant change in mRNA
expression for TEL02………………………………………………………………………………124

xi

Abbreviations
17-AAG: 17-allylamino-17-demethoxygeldanamycin
AAA+: ATPases associated with diverse cellular activities
ACK1: Activated Cdc42-associated Kinase 1
ACTB: Beta-Actin
ANOVA: One way analysis of variance
AKT: Protein kinase B (PKB ALSO CALLED)
ATF6: activating transcription factor 6
BCL2: B-cell lymphoma 2
C-MYB: MYB- proto-oncogene
CDK: Cyclin Dependent Kinase
CDK4: Cyclin Dependent Kinase 4
CHOP: CCAAT/enhancer-binding protein-homologous protein
CLOCK: Clock Circadian Regulator
CK2: Casein Kinase 2
CRY1: Cryptochrome Circadian Clock 1 (mCry1)
C-terminal: Carboxy terminal
DAPI: 4'-6-Diamidino-2-phenylindole
DCIS: Ductal Carcinoma In Situ
DNA: Deoxyribonucleic Acid
factor 2 alpha

xii

E6: HPV oncoprotein E6
ECD: Ecdysoneless
EGFR: Epidermal Growth Factor 1
EGFs: Epidermal Growth Factors
EMT: Epithelial to Mesenchymal Transition
ER: Estrogen Receptor
ERBB: Epidermal Growth Factor Receptor Family
FACS: Flourescence Assisted Cell Sorting
FGF: Fibroblast Growth Factor
FGFR: Fibroblast Growth Factor Receptors
FKBP12: immunophilin FK506-binding protein
G1/S: G1 to S transition
G1: Gap 1 phase
G2/M: G2 to M transition
G2: Gap 2 phase
GATA3: Trans-acting T-cell-specific transcription factor
GCR1: Glycolysis Regulation 1
GCR2: Glycolysis Regulation 2
GLUT4: Glucose transporter type 4
HAT: Histone Acetyl Transferase
hECD; Human Ecdysoneless
HER2/ErbB2: Human Epidermal Growth Factor Receptor 2

xiii

HER3/ErbB3: Human Epidermal Growth Factor Receptor 3
HER4/ErbB4: Human Epidermal Growth Factor Receptor 4
hMECs: Human Mammary Epithelial Cells
HPV16: Human Papilloma Virus 16
hSGT1: Human Suppressor of GCR two
HRP: HorseRadish Peroxidase
HSC70: Heat Shock Chaperone 70
HSP90: Heat Shock Protein 90
hTERT: Human Telomerase Reverse Transcriptase
IDC: Infiltrating Ductal Carcinoma
IHC: Immunohistochemistry
IRE1α: inositol-requiring kinase 1 alpha
KD: Knock Down
KO: Knock Out
M: Mitotic phase
mAb: Monoclonal Antibody
MAPK: Mitogen Activated Protein Kinase
MDM2: Murine Double Minute 2
MEFs: Mouse Embryonic Fibroblasts
mTOR: Mammalian Target of Rapamycin
mTORC1: Mammalian Target of Rapamycin Complex 1
mRNA: Messenger RNA

xiv

MUC4: Mucin 4
MybBP1A: Myb-Binding Protein 1A
NRGs: Neuregulins
NUFIP: Nuclear Fragile X Mental Retardation Protein Interacting Protein
N-teminal: Amino terminal
PBS: Phosphate Buffered Saline
PCR: Polymerase Chain Reaction
PERK: PKR-like ER kinase
PEST: Proline (P); Glutamic acid (E); Serine (S); Threonine (T)
PFA: Paraformaldehyde
PGC1-α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase
PIH1: Protein Interacting with Hsp90 1
PIH1D1: PIH1 domain containing 1
PIKK: Phosphatidylinositol-3 Kinase related protein Kinase
POU2F1: POU class 2 homeobox 1
PR: Progesterone Receptor
PKB: Protein kinase B (AKT)
PREP1: Pbx-regulating protein-1
PRP8: Pre-mRNA processing Factor 8
OCT-1: octamer-binding transcription factor -1
R2TP: RUVB1/RUVB2/Tah1/PiH containing complex

xv

RB: Retinoblastoma
RELA: v-Rel Avian Reticuloendotheliosis Viral Oncogene Homolg A
RNA: Ribonucleic Acid
RNAPII: RNA polymerase II complex
rRNA: Ribosomal RNA
RT: Room Temperature
RUVB1: RuvB-like AAA ATPase 1
RUVB2: RuvB-like AAA ATPase 2
S: Synthesis phase
S6K1: S6 kinase
SD: Standard Deviation
siRNA: Small- Interfering RNA
snoRNP: Small Nucleolar Ribonucloprotein
SPCA2: Secretory Pathway Calcium ATPase
Spok: Spookier
TAH1: Telomere Associated Homeobox-containing protein 1
TBST: Tris-buffered Saline with Tween-20
TCGA: The Cancer Genome Atlas Network
TEL2/TELO2: Telomere Elongation Regulation Protein
TGF- α: Transforming Growth Factor-α
TNBC: Triple Negative Breast Cancer
TPR: Tetratricopeptide Repeat

xvi

tRNA: Translational RNA
TRRAP: Transformation/Transcription Domain-Associated Protein
TRX: Thioredoxin
TXNIP: Thioredoxin Interacting Protein
VDUP1: Vitamin D3-Upregulated Protein 1
WT: Wildtype

xvii

Acknowledgements
I would like to thank my mentor Dr. Vimla Band who has helped me to fine tune my
ideas by providing feedback and suggesting more comprehensive experiments. She has always
made me think about my results and helped provide intuitive leaps to assist me in realizing the
value of my data. My mentor has also reviewed my papers, fellowships, and conference
abstracts at multiple steps in the process and has made herself available for discussions about
writing techniques and experimental planning. Dr. Band has also edited all of my proposals has
also provided invaluable feedback to me to help strength my writing skills. She has also
providing multiple opportunities for me to present my work and therefore has assisted me with
my public speaking skills and has also made me a stronger scientific presenter. She always
encouraged me to think independently which provided me a platform to develop my own
hypothesis and ask relevant scientific questions. I am extremely thankful to Dr. Band for making
sure that I had all the reagents available for my research and having faith in me and my project.
Without her guidance and mentorship, I would not have become a successful scientist.
I am extremely thankful to my committee members Dr. Hamid Band, Dr. Karen
Gould, Dr. Kay-Uwe Wagner and Dr. Kaustubh Datta for their valuable suggestions and guidance
throughout my Ph.D. career. I really appreciate all the time and advice they have provided me.
This dissertation would not have been possible without their support. I would also like to
sincerely thank all my lab members for their suggestions during my time in the laboratory and
intriguing scientific discussions. I would like to thank Dr. Sameer Mirza, with whom I have
collaborated on various projects. I would like to thank Dr. Mirza for all of his help in making
these projects successful and for providing invaluable guidance in my scientific career. I would
also like to thank Dr. Aditya Bele, Dr. Shakur Mohbi, and Dr. Riyaz Mir for helping me learn

xviii
different scientific technical skills and also helping me to discuss and critically analyze all of my
data. I would also like to thank all the graduate students in lab, Shashank, Divya, Nick,
Aniruddha, and Appo for being such amazing peers. I want to thank them for sharing reagents
with me; contributing in thought provoking scientific discussions; supporting me in all my
accomplishments; and helping me keep up with all of my deadlines. The Band lab has been such
a wonderful and supporting environment. I would like to personally thank all of them for
making it so.
Lastly, I would like to thank my family for all their love and support throughout this
entire process. I would like to thank my Father, Michael Ammons for being my biggest
supporter, for always being there to listen to my ideas, to make me feel better when times got
tough, and for always being on my side. I love you dad. Thank you to my sisters, Yomi and
Michelle, for always cheering me on, for making me laugh in times I need it the most, and for
letting me know how proud they are of me. I love you both so much. I would also like to thank
my boyfriend, Prathamesh for always supporting me, for his patience, for always making me
think through my research problems, for his new perspectives on my results, for his coaching on
all my presentations, for staying up with me through all my practice talks, and for his friendship.
I love you. I also would like to thank all of my friends for their unending support and
encouragement. Thanks for always being there for me. And last, I would like to thank my
mother, Migdalia Ammons, who always inspired me to reach for the stars. Thank you for
teaching me to dream big and to always be strong. Thank you for encouraging me to be the
best person I could be. I miss you every day. This one is for you Mom!

1

Chapter 1
Introduction
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1.1 The Ecdysoneless Protein: Discovery and History
Numerous genetic studies of the Ecdysoneless (ecd1) mutation in Drosophila melanogaster
have been studied for years in a variety of biological process such as embryogenesis,
metamorphosis, and larval molting (Garen, Kauvar, & Lepesant, 1977) In ecd1 mutants; that
contain a temperature sensitive allele; cause larval developmental arrest when embryos are
contained in a restrictive temperature. This phenomenon was thought to be caused by a
deficiency in the steroid hormone, ecdysone (Garen, Kauvar, & Lepesant, 1977). In Drosophila,
ecdysone has been implicated to be involved in reproduction, embryogenesis, and
developmental processes. The Ecdysoneless gene encodes for the protein that has been shown
to have a separate function other than steroid biosynthesis. The ecd protein in Drosophila has
been molecularly identified to be involved in cell survival through mutation studies, although
the mechanism of this has not been clearly defined (Gaziova, Bonnette, Henrich, & Jindra, 2004).
There have been several studies in Saccharomyces cerevisiae that imply ECD (hSTG1 is the name
used in these studies) may have a role in the transcription of glycolytic genes. One group was
able to identify hSTG1 as a complement for the growth defect caused by the GCR2 mutant in
Saccharomyces cerevisiae. hSTG1 not only rescued the growth defect caused by the GCR2, it was
also able to restore the glycolytic enzyme activity (Sato, Jigami, Suzuki, & Uemura, 1999).
Interestingly, hSTG1 has no sequence similarity to GCR2 and even though it may have a role in
transcription, does not have structural homologue in Saccharomyces cerevisiae (Uemura,
Koshio, Inoue, Lopez, & Baked, 1997). Human ECD was identified, in Dr. Vimla Band’s
laboratory, as a Human Papilloma Virus 16 E6 (HPV16 E6) binding protein using a yeast twohybrid system. This interaction was able to open many doors about the function of ECD in cells
and other ECD interacting partners.

3
My mentor’s laboratory has published hECD as a p53, a tumor suppressor, interacting
protein and this interaction helps to stabilize p53 (Zhang, 2006). Association studies using the
proteasomal inhibitor MG-132 showed hECD stabilizing p53 by associating and inhibiting murine
double minute-2 (MDM2)(Zhang, 2006). Overexpression of hECD lead to increased levels of p53
and an increase in the transcription of p53 target genes. Whereas, knocking down of hECD leads
to a decrease in p53 expression levels(Zhang, 2006). The mode of action by which hECD does
this is through its interaction with MDM2 and inhibits its’ mediated degradation of p53 (Zhang,
2006). In order to study the physiological function of ECD, my mentor’s laboratory generated
conditional deletion ECD flox/flox mice because complete knock out of ECD is embryonically
lethal to mice at the blastocyst stage (J. H. Kim et al., 2009). Mouse embryonic fibroblasts
(MEFs) were derived from these mice and these cells have the ability to delete ECD upon
introduction of Cre-recombinase in an in vitro setting. In order to study the cellular function of
ECD, our laboratory deleted ECD in MEFs and observed these cells undergoing a proliferative
block. This block was due to a delay in G1-S phase of the cell cycle and this phenotype was able
to be rescued by introducing human ECD into these MEFs (J. H. Kim et al., 2009). ECD was
shown to bind to Retinoblastoma (RB) protein and competes with E2F transcription factors for
binding. ECD facilitates the dissociation of RB from E2F transcription factors and loss of ECD
leads to a delay in this dissociation thus leading to a proliferative block in G1-S phase of the cell
cycle and a delay in cell cycle progression(J. H. Kim et al., 2009). Loss of ECD also showed a
reduction in the levels of E2F transcription factors target genes such as CDK2, Cyclin A, Cyclin B1,
and Cyclin E (J. H. Kim et al., 2009). ECD plays an important role in cell cycle progression through
its interaction with RB, however how ECD protein is stabilized and modified in cells and how this
effects ECD function still needed to be determined.
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1.2 Domains of the Ecdysoneless Protein
The Human ecd gene is located on chromosome 10 at the locus of 10q22.3. The ecd gene
has 15 exons and its amino acid sequence has been shown to be evolutionary conserved from
humans to yeast in the C-terminal region (aa 439-644)(J. H. Kim, Gurumurthy, Band, & Band,
2010). The structure of ECD is currently unknown and it does not have an identifiable DNA
binding-domain. Our laboratory was able to show that ECD has an intrinsic transactivation
activity and it resides in the C-terminal region of ECD (J. H. Kim et al., 2010). ECD also shuttles
between the nucleus and the cytoplasm of a cell which indicates that ECD has a strong nuclear
export signal, but it has not been identified yet (J. H. Kim et al., 2010). In collaboration with Dr.
Mir I have shown that ECD is a phosphoprotein and it has over 100 potential phosphorylation
sites (Aditya Bele Thesis, 2015; Mir et al., 2015). ECD is constitutively phosphorylated and there
is an extensive list of potential kinases that possibly interact with ECD, list is located in Aditya
Bele Thesis 2015 in Appendix B. We have determined that ECD is phosphorylated on several
serine residues and these residues are located in functional domain that has been shown to be
involved in protein-protein interactions (Hořejší et al., 2014; Mir et al., 2015). This domain
contains a large number negatively charged amino acids and can be characterized as a PEST (
Proline (P); Glutamic acid (E); Serine (S); Threonine (T)) domain (Aditya Bele Thesis, 2015; Mir et
al., 2015). PEST domains have been shown to be involved in stability and degradation of multiple
proteins (Rogers, Wells, & Rechsteiner, 1986). ECD has also been shown to contain two “DSDD”
motifs which assist in determination of substrate specificity for PIH1D1, a member of the R2TP
co-chaperone complex (von Morgen, Hořejší, & Macurek, 2015). ECD has also been shown to
interact with PIH1D1 in a phospho-dependent manner on serine residues 505 and 518 (Horejsí
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et al., 2010). Our laboratory has discovered different phosphorylation sites and domains on
ECD, and this has helped us understand the role ECD may be playing in cells as well as in cancer.

1.3 Expression of ECD in Different Cancers
As discussed below ECD is overexpressed in several cancers, including breast cancer, the
focus of my studies. Breast cancer is the second leading cause of cancer related deaths in
women in the United States and it is a very heterogeneous disease (American Cancer Society,
2015). Unlike other cancers, defining the progression of breast cancer has proved difficult, but it
can be classified broadly into two categories, in situ carcinoma and invasive infiltrating
carcinoma. Breast carcinomas can then be further classified into two subclasses, ductal
carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) (Connolly J, Kempson R, LiVolsi V,
Page D, Patchefsky A, 2004; Malhotra, Zhao, Band, & Band, 2010). Ductal carcinoma in situ is
more common in patients than lobular carcinoma in situ. Currently, based on expression
profiling, breast cancer is categorized into six molecular subtypes; luminal subtype A which is
Estrogen Receptor (ER)/ Progesterone Receptor (PR) positive and Epidermal Growth Factor
Receptor 2 (ErbB2/HER2) negative, luminal subtype B which is ER+/PR+ and ErbB2+, ErbB2+
positive , basal-like or triple negative which is ER-, PR-, and ErbB2-, claudin-low, and normal-like
(Malhotra et al., 2010; Prat et al., 2010; Sorlie et al., 2003; Sørlie et al., 2001) (Table 1). Each
subtype is classified according to particular set of gene expression as well as based upon the
receptor expression profile. The subtype of a breast cancer patient helps to determine the
prognosis, as well as the treatment options (Malhotra et al., 2010; Prat et al., 2010; Sorlie et al.,
2003; Sørlie et al., 2001). Due to the heterogeneity of these tumors, there are different survival
trends in these subtypes. The worst outcome, according to survival data analysis, is basal-like
subtype followed by ErbB2 overexpressing subtype, claudin-low, normal-like, and the luminal
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subtypes (Prat et al., 2010; Sørlie et al., 2001). These subtypes have been classified based on
different molecular markers, and one such marker that is highly expressed in more than one
subtype of cancer is ErbB2.
Human Epidermal Growth Factor Receptor 2 (HER2/ErbB2) is a member of the Epidermal
Growth Factor Receptor (ErbB) family. There are four members of the ErbB family of receptors,
Epidermal Growth Factor 1 (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2/ErbB2),
Human Epidermal Growth Factor Receptor 3 (ErbB3/HER3), Human Epidermal Growth Factor
Receptor 4 (HER4/ErbB4) (Burden & Yarden, 1997; Yarden & Sliwkowski, 2001). Each of these
receptors compromise of three domains: an extracellular domain, where ligand binding and
dimerization occurs; an alpha-helical transmembrane segment; and an intracellular tyrosine
kinase domain (Baselga & Swain, 2009; Olayioye, Neve, Lane, & Hynes, 2000). In order to
activate these receptors, an extracellular signal is received in the form of ligand binding (Baselga
& Swain, 2009). Some of the common ligands that bind to these receptors include epidermal
growth factors (EGFs), transforming growth factor-α (TGF- α), and Neuregulins (NRGs) (Baselga
& Swain, 2009; Olayioye et al., 2000; Yarden & Sliwkowski, 2001). Once a ligand is bound, the
receptors need to undergoes a conformational change to expose the dimerization domain
leading to dimerization, either homodimerization, between two of the same type of receptor, or
heterodimerization, between two different Erbb family receptors (Baselga & Swain, 2009). After
dimerization, the intracellular tyrosine kinases are activated through trans-phosphorylation;
thus in turn causing the activation of the tightly regulated downstream signaling pathways of
the Erbb family of receptors (Baselga & Swain, 2009; Yarden & Sliwkowski, 2001). These
signaling pathways control a number of cellular functions such as cellular proliferation, organ
development, cell to cell interactions, and organ repair (Baselga & Swain, 2009; Yarden &
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Sliwkowski, 2001). The receptor tyrosine kinase family signaling pathways are tightly regulated
and necessary for cells to function normally.
Table 1.1: Breast Cancer Subtypes

Subtype of Breast Characteristic Features
Cancer
of Subtype
Luminal A
ER high, HER2 low
Luminal B

+

ER low, PR or PR

-

Properties

+

Known Markers

+

ER and/or PR ,

HER 2 Enriched
Claudin Low

+

-

HER2 , ER , PR

-

-

ER-, Claudin ,

+
vimentin , E-cadherin

+

~40%

Best

ER and/or PR ,
High Ki67 when
HER2- low

+

+

~20%

Good

CD24 low/ CD44
high
Vimentin High
TWIST1 high

~6-10%

Moderate

HER2

~10-25%

Poor

Claudin 3, 4,7 low.
Vimentin High

~12-14%

Poorer

Keratin 5 and
Keratin 14 positive

~15-20%

Poorest

ER and/or PR

Proliferation High

+

Overexpression of
the HER2 receptor
Claudin low
Vimentin High

Prognosis

+

HER2 , low Ki67

HER 2 low or Her 2with Ki-67 high
Normal Breast Like
High expression of
Adipose tissue gene
genes that characterize
signature
basal epithelial cells
and adipose cells.
ER-

Prevalence

low
High enrichment of
EMT markers
Basal Like

-

-

-

ER , PR , HER2

EGFR

+

Table 1.1: The classification of the six breast cancer subtypes. This classification is based off of
microarray dataset analysis of human patient tumor samples (Prat et al., 2010, 2014; Sorlie et
al., 2003; Sørlie et al., 2001). The table also includes the known markers, prognostic prevalence,
and predicted survival pattern of each subtype (Malhotra et al., 2010; Prat et al., 2010, 2014;
Sorlie et al., 2003; Sørlie et al., 2001)

8
Human Epidermal Growth Factor Receptor 2 (HER2/ErbB2) is a member of the Epidermal
Growth Factor Receptor family and it is the only family member that does not bind to a ligand
(Baselga & Swain, 2009). ErbB2 is able to homodimerize with itself and heterodimerize with
other ErbB family members, increasing the signaling potential of this receptor (Rouzier et al.,
2005). There are two major signaling pathways that are activated by the ErbB family of
receptors. The first is the Mitogen Activated Protein Kinase (MAPK) pathway that is involved in
proliferation. Once the MAPK pathway is activated, it leads to the activation of downstream
transcription factors that regulate genes that are involved in cell proliferation, migration,
differentiation, and angiogenesis (Baselga & Swain, 2009). The second pathway is the
Phosphatidylinositol-4,5-bisphosphate 3-kinase (P13K)- Protein kinase B (AKT/PKB) pathway,
which is involved in cell survival. The PI3K-AKT pathway activates several factors that are
involved in cell survival and anti-apoptosis signaling (Baselga & Swain, 2009; Yarden &
Sliwkowski, 2001). Both of these pathways have been shown to be deregulated in variety of
cancers such as breast, lung, ovarian, and prostate (Baselga & Swain, 2009). ErbB2/HER2
enriched tumors express abnormal levels of the ErbB2 receptor (Sørlie et al., 2001). ErbB2
overexpression accounts for 25% of all breast cancers and has a poor prognosis (Bertucci et al.,
2004). ErbB2 overexpression has been linked to amplification of the ErbB2 gene on chromosome
17 in the regions q 12-21 (Hynes & MacDonald, 2009), increased transcriptional activity (Ehrlich
et al., 2009), and an increase in the stability of the receptor (Onitilo, Engel, Greenlee, & Mukesh,
2009). Erbb2 is a highly regulated gene, and its overexpression has been linked to the
overexpression of several transcription factors that regulate its expression. The regulation of the
erbb2 gene is discussed more in Appendix B of this thesis. It is a transmembrane receptor
tyrosine kinase that is involved in a variety of signal transduction pathways within the cell, some
of which help promote proliferation and cell survival (Harari & Yarden, 2000).
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Sustaining proliferative signaling and resisting cell death mechanisms are two hallmarks of
cancer and have been shown to be a major driving forces of oncogenesis in multiple cellular
systems (Hanahan & Weinberg, 2011). ErbB2, as well as the rest of the ErbB family of receptors,
are trans-membrane tyrosine receptor kinases that are involved in various signaling
transduction pathways that are important in normal cell development as well as oncogenesis
(Yarden & Sliwkowski, 2001). Studies have shown that patients with ErbB2+ tumors are shown
to have a worsen prognosis as compared to patients with ER+/PR+ tumors (Prat et al., 2010;
Slamon et al., 1987). A study conducted by The Cancer Genome Atlas (TCGA) Network of
approximately 500 breast tumors has shown the biological heterogeneity of clinical ErbB2overexpressing cancers (HER2+), as defined by gene amplification (Prat et al., 2014). This group
further characterized these cancers by gene expression into two subclasses, HER2-enriched
(HER2E) and luminal HER2+ (Prat et al., 2014). HER2E and HER2+ tumors exhibited higher
frequencies of aneuploidy, somatic mutations, and TP53 mutations and also show genetic
amplification of Fibroblast Growth Factor Receptors (FGFRs), Epidermal Growth Factor Receptor
(EGFR), cyclin dependent kinase 4 (CDK4), and Cyclin D1 in these patients (Prat et al., 2014).
Luminal HER2+ displayed a higher expression of a luminal gene cluster which included transacting T-cell-specific transcription factor (GATA3), B-cell lymphoma 2 (BCL2), and Estrogen
Receptor 1 (ESR1) (Prat et al., 2014). Although, not all tumors of the HER2-enriched gene
expression subtype are erbb2 amplified, it is thought that some breast cancers with a single
copy of erbb2 gene harbor an expression signature of ErbB2 dependence and may benefit from
anti-ErbB2 therapy (Prat et al., 2014). Current therapy methods have attempted to target the
ErbB2 receptor through its extracellular domain using Trastuzumab. Trastuzumab is a
humanized monoclonal antibody that contains two antigen-specific sites that binds to the
juxtamembrane of the extracellular domain of the ErbB2 receptor and is currently the approved
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treatment for patients that overexpress ErbB2 (Hudis, 2007; Nahta & Esteva, 2006; Vu & Claret,
2012).
In some ErbB2 positive breast cancer patients, there is a chance of relapse and metastasis.
These patients usually develop acquired or de novo resistance to Trastuzumab that lead to
metastasis, but the mechanism behind this is not yet fully understood (Nahta & Esteva, 2006; Vu
& Claret, 2012). One promising therapy option that has recently come to light to combat
acquired resistance are Hsp90 inhibitors (Maloney & Workman, 2002; Workman, Burrows,
Neckers, & Rosen, 2007). The Hsp90 inhibitor, 17-AAG has been shown to cause the rapid
degradation of ErbB2 (Goetz, Toft, Ames, & Erlichman, 2003; Modi et al., 2011; Sausville,
Tomaszewski, & Ivy, 2003). Although 17-AAG seems like a potent drug, it still causes toxicity to
patients. Therefore is an increasing the need for other molecular therapy targets that cause less
toxicity to patients. This thesis will attempt to validate the potential of Ecd as a novel molecular
therapy target in ErbB2 positive breast cancer cells.
We speculate that ECD may be one such molecule as our laboratory has shown that ECD
expression was low in normal breast tissue and also in hyperplasia of breast tissue (X. Zhao et
al., 2012). However, ECD levels were shown to be high in ducal carcinoma in situ (DCIS), benign
breast hyperplasia, and in infiltrating ductal carcinoma (IDC) samples (X. Zhao et al., 2012). After
examining a larger cohort of over 900 samples, strong positive correlations between ECD
expression and higher histological grade, mitotic index, and Nottingham Prognostic Index score
could be observed (X. Zhao et al., 2012). Interestingly, a positive association between ECD high
expression and ErbB2/HER2 overexpression was also seen. Patients with high ECD expression
and ErbB2/HER2 overexpression showed a poorer overall survival outcome compared to
patients with low ECD expression and ErbB2/HER2 overexpression (X. Zhao et al., 2012).
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ECD has also been shown to be overexpressed in pancreatic cancer (Dey et al., 2012).
Pancreatic cancer is one of the most aggressive and lethal malignancies seen today in patients.
It is characterized by an extremely poor prognosis, late clinical presentation, and poor response
to therapy methods (Chakraborty, Baine, Sasson, & Batra, 2011). Since cell cycle regulation is
highly deregulated in pancreatic cancer, ECD expression was observed for its cell cycle
regulation function (Dey et al., 2012). ECD expression is low in normal pancreatic tissue but is
overexpressed in ductal adenocarcinoma form of pancreatic cancer (Dey et al., 2012).
Interestingly, ECD expression correlated to primary pancreatic tumors with distant metastatic
sites. ECD knockdown showed a reduction of cellular proliferation in pancreatic cells in vitro and
a reduction of tumor size and less metastasis in mice in vivo (Dey et al., 2012). Another study has
proposed that ECD is involved in gastric cancer epithelial to mesenchymal transition (EMT) and
metastasis through Cdc-42-associated kinase 1 (ACK1)-AKT- POU class 2 homeobox 1 (POU2F1)
pathway (S.-H. Xu et al., 2015). Gastric cancer is the second leading cause of cancer mortality
worldwide and is usually detected at an advanced disease state for most patients (Deng et al.,
2012). The authors suggest that ECD is a downstream effector of ACK1 and ECD expression is
regulated by the transcription factor POU2F1 (POU2F1 is also known as octamer-binding
transcription factor-1 (OCT-1))(S.-H. Xu et al., 2015). The proposed mechanism is that ACK1,
which is overexpressed in gastric cancer, activates AKT and AKT in turn activated POU2F1.
POU2F1 then binds to the ecd gene and upregulates ecd transcription. Overexpression of ECD
promotes invasion, migration, and induces EMT in gastric cancer (S.-H. Xu et al., 2015). The
authors believe the dysregulation of the signaling pathway outlined previously induces EMT in
gastric cancer patients which lead to metastasis and ECD is playing a critical role in this(S.-H. Xu
et al., 2015).
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Figure 1.1: Ecd is overexpressed in various breast cancer cell lines.
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Figure 1.1: Ecd is overexpressed in various breast cancer cell lines. Various breast cancer cell
lines were harvested using RIPA Buffer and Ecd expression was determined by western blotting
using anti-Ecd, anti-ErbB2, and anti-β-actin (as loading control). 76N.TERT and MCF10A serve as
normal immortalized breast epithelial cell lines. Cell lines are separated via subtype. The graph
below is the densitometry analysis of ECD levels as compared to β-actin. Densitometry
performed using ImageJ.
In addition, our laboratory has seen overexpression of ECD in prostate (Figure 1.2) and in
cervical cancers. In prostate cancer ECD overexpression is correlated to a poorer overall survival
outcome in these patients (Bele, 2015). ECD overexpression is observed in adeno carcinomas
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and in squamous cell carcinomas of the cervix (Bele, 2015). In a variety of cancers, ECD
overexpression is observed and this overexpression is correlated with poor prognosis for many
patients. Taken together, these studies suggest a clear role for ECD overexpression in tumor cell
survival and potential therapy resistance. For my thesis I focused on two questions i) what is the
mechanism of ECD mediated cell cycle progression and ii) how ECD connects with ErbB2.

1.4 ECD Known Protein Interactions and Pathways
Human ECD was first identified as a Human Papilloma Virus 16 E6 (HPV16 E6) binding protein in
Dr. Vimla Band’s laboratory. ECD has been shown to be overexpressed in variety of cancers (Dey
et al., 2012; S.-H. Xu et al., 2015; X. Zhao et al., 2012). These observations lead to our lab’s
desire to study the different protein interactions and functions of ECD (Figure 1.3). Previous
lab members originally showed hECD as a p53 interacting protein and it was concluded that ECD
stabilizes p53 by associating and inhibiting MDM2 (Zhang, 2006). Another study in the lab
highlighted the role of ECD in the cell cycle as an RB binding protein (J. H. Kim et al., 2009). ECD
binds to RB and competes with E2F transcription factors for binding. ECD facilitates the
dissociation of RB from E2F transcription factors, which leads to cell cycle progression (J. H. Kim
et al., 2009). Recently, a previous graduate student in the lab was able to show ECD has a
synergistic role with the potent oncogene H-RAS and together, both proteins cause oncogenic
transformation in human mammary epithelial cells (Bele et al., 2015). ECD overexpression alone
was able to show some oncogenic properties but ECD+RAS overexpressing HMECs completely
underwent transformation (Bele et al., 2015). ECD+RAS cells exhibited better survival, cell
migration, invasion, and acinar formation in 3D Matrigel cultures as compared to vector
expressing, RAS overexpressing, and ECD overexpressing HMECs alone (Bele et al., 2015).
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Figure 1.2: Ecd is overexpressed in various prostate cancer cell lines. Various prostate cancer
cell lines were harvested using RIPA Buffer and Ecd expression was determined by western
blotting using anti-Ecd and anti-β-actin (as loading control). PSV40 and PHPV18 serve as
immortalized prostate epithelial cell lines.

ECD

β-Actin
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Figure 1.3: ECD and its Different Interacting partners.
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Figure 1.3: ECD and its Different Interacting partners. A schematic depicting the various
proteins that interact with ECD and the different phosphorylation sites and domains of the ECD
protein. Ecd contains a PEST domain. It also consists of two ‘DSDD’ motifs. There are also several
major serine residues that are phosphorylated by CK2, but only the two serine residues that
interact with PIH1D1 are indicated with red boxes. (Bele, 2015; Bele et al., 2015; Claudius,
Romani, Lamkemeyer, Jindra, & Uhlirova, 2014; J. H. Kim, 2009; J. H. Kim et al., 2009; Mir et al.,
2015; Zhang, 2006)
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ECD overexpression may be contributing to oncogenesis through the interactions. ECD may also
play a role in the regulation of the Secretory Pathway Calcium ATPase (SPCA2). SPCA2 has been
shown to be overexpressed in breast cancer, particularly in the ErbB2+ subtype. It plays a role in
oncogenesis by promoting calcium dependent signaling through the store operated calcium
channel Orai1 (Feng et al., 2010). Our lab has shown using a global microarray based expression
profile, that SPCA2 expression levels are high in ECD+RAS HMECs as compared to ECD
overexpressing and RAS overexpressing HMECs alone (Bele, 2015). Recently, another laboratory
has published that ECD interacts with a protein called TXNIP, also known as vitamin D3 upregulated protein 1 (VDUP1) or thioredoxin (TRX) – binding protein-2 (Suh et al., 2013).
TXNIP, which is a member of the tumor suppressor family, is involved in a number of cellular
processes such as apoptosis. The authors concluded that ECD interacts with TXNIP to decrease
MDM2-mediated ubiquitination of p53. This interaction leads to p53 stabilization and an
increase in p53 activity (Suh et al., 2013). Another laboratory has reported that in Drosophila
cells, ECD interacts with Pre-mRNA processing Factor 8 (PRP8), a member of the U5 snRNP
spliceosomal complex (Claudius et al., 2014). ECD also interacts with core components of the U5
snRNP spliceosomal complex, and along with PRP8, are necessary for cell survival in larval
imaginal discs. Deletion of ecd or prp8 prevents the splicing of an intron from
CYP307A2/spookier (spok) pre-mRNA causing a block in entry to metamorphosis by the
elimination of the ecdysone-biosynthetic enzyme (Claudius et al., 2014). Interestingly, human
ECD was able to rescue this phenotype, further confirming the conservative nature of the ECD.
These studies show ECD interactions are important in a number of cellular processes and that
ECD may function similarly in a variety of species.
A previous graduate student in the lab performed a mass spectrometry analysis of human
ECD and was able to show that ECD interacts with a number of proteins, and one such protein
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was, Myb-Binding Protein 1A (MYBBP1A). MYBBP1A is mainly localized in the nucleolar and is a
transcriptional regulator that regulates the activity of several transcription factors such as MYBproto-oncogene (c-myb), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(PGC1-α), v-Rel Avian Reticuloendotheliosis Viral Oncogene Homolg A (RelA), Cryptochrome
Circadian Clock 1 (mCry1), PREP1: Pbx-regulating protein-1 (Prep1), and Clock Circadian
Regulator (CLOCK) (Díaz et al., 2007; Fan et al., 2004; Favier & Gonda, 1994; Hara et al., 2009;
Tavner et al., 1998). MYBBP1A is involved in a number of cellular processes such as, mitosis,
transcriptional regulation, rRNA synthesis, and ribosome biogenesis (Akaogi, Ono, Hayashi,
Kishimoto, & Yanagisawa, 2013; Bele, 2015; Mori et al., 2012; Ono et al., 2013, 2014). A
previous graduate student was able to observe that loss of ECD leads to a down regulation of
MYBBP1A and ECD co-localizes with MYBBP1A when ECD is overexpressed (Bele, 2015). Taken
together, it is plausible to conclude that ECD plays a role in MYBB1A stability and may also play a
role in the functions of MYBBP1A. Our laboratory has also shown that ECD interacts with p300
and may be playing an important role in chromosome integrity. In a study using primary mouse
embryonic fibroblasts (MEFs), upon ECD deletion, higher frequencies for chromosome
aberrations including chromosome breaks, fragments, deletions, and translocations were
observed (Bele, 2015). We hypothesize that ECD is functionally important in the maintenance of
chromosomes through histone acetylation. Our laboratory has shown that ECD interacts with
the histone acetyltransferase, p300 and enhances its HAT activity (J. H. Kim, 2009). ECD
however, does not have a DNA binding domain and therefore is not a transcription factor, but
ECD may play a role in transcription through its interaction with p300.
Recently, another graduate student in my mentor’s laboratory has shown that ECD may be a
key regulator in the ER stress pathway through its interaction with PKR-like ER kinase (PERK). ER
stress is a stimulus for to initiate a defensive process called the unfolded protein response
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(UPR). UPR is comprised of several cellular mechanisms that are aimed to either assist in
cellular survival, or in cases of extreme stress, initiate mechanisms of cell death such as
autophagy or apoptosis (Ma & Hendershot, 2001; Welihinda, Tirasophon, & Kaufman, 1999).
ECD levels are downregulated in HMECs upon treatment of different endoplasmic reticulum
stress inducing compounds. We also observe ECD interaction with several UPR pathway
components, including PERK, indicating that ECD is an important regulator of UPR (This work will
be discussed in more detail in Chapter 3). We have also observed in PERK knockout mouse
embryonic fibroblast, ECD levels remain unchanged, indicating that ECD may play a role as a
negative regulator of stress.
ECD has been shown to interact with a protein, PIH1 domain-containing protein
1 (PIH1D1) and this interaction is Casein Kinase 2 (CK2) mediated phosphorylation dependent
(Hořejší et al., 2014). ECD binds to PIH1D1 on Serine residues 505 and 518 and PIH1D1
recognizes ECD as a substrate by the DpSDD motif on ECD (Hořejší et al., 2014). PIH1D1 is a
member of the co-chaperone complex named R2TP/Prefoldin complex. The R2TP complex
consists of four members: Rvb1, Rvb2, Phi1, and Tah1 in yeast and RUVBL1, RUVBL2, PIH1D1,
and RPAP3 in humans (Kakihara & Houry, 2012). These complex components are known by
different names as indicated in Table 1.2, however; for the purpose of this thesis, the gene
names of each component will consistently be used. The R2TP complex was first discovered in
yeast cells in 2005 by the Parsons lab (R. Zhao et al., 2005), as an heat shock protein 90, (HSP90)
associated chaperone complex. This complex is conserved from yeast to humans. Proteomic
analysis of HSP90 interacting partners in human samples identified RUVBL1, RUVBL2, PIH1D1,
and RPAP3 and GST-pulldown and yeast two hybrid experiments were conducted to reaffirm
these results (Boulon et al., 2008; Te, Jia, Rogers, Miller, & Hartson, 2007). Each component of
the R2TP is well characterized and has novel functions that are separate from the complex’s
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functions. The R2TP complex also interacts with the seven protein members of the Prefoldin-like
complex, which are Rpb5, PFDN2, PFDN6, URI, UXT, PDRG1, and WDR92 (Table 1.2) (Boulon,
Bertrand, & Pradet-Balade, 2012). The Prefoldin-like complex is present only in mammalian cells
and its main function is to increase the stability of the R2TP complex (Kakihara & Houry, 2012).
The R2TP/Prefoldin co-chaperone complex is composed of four proteins along with
HSP90. Two of these proteins are RUVBL1 and RUVBL2 and they are closely related, highly
conserved, AAA+ (ATPases associated with diverse cellular activities) super family ATPases.
ATPases are characterized by the AAA+ domain containing: Walker A and B motifs, sensor
domains 1 and 2, and an arginine finger (Jha & Dutta, 2009; Nano & Houry, 2013). These
proteins usually function as a hexamer to hydrolyze ATP to generate energy that can be utilized
in the conformation change of nucleic acids or proteins (Hanson & Whiteheart, 2005). Both of
these proteins are ATP-dependent helicases that function as scaffold protein that assist in the
formation of several protein complexes and are essential for their functions (Jha & Dutta, 2009).
The RUVBL1 and RUVBL2 proteins have been shown to be involved in several cellular processes
such as transcription, chromatin remodeling, DNA damage response, RNA polymerase II (RNAP
II) assembly, apoptosis, and mitotic spindle assembly (Boulon et al., 2012; Jha & Dutta, 2009).
Some of the specific complexes that RUVBL1 and RUVBL2 are known to assist in the formation of
include the INO80, TIP60, and SWR/SRCAP complexes (Nano & Houry, 2013). Both of the
proteins have been shown to be overexpressed in a variety of cancers including colon, lung, and
breast (Huber et al., 2008; S. G. Kim et al., 2013; Nano & Houry, 2013) Studies have shown that
decreasing the levels of RUVBL1 and RUVBL2 in vitro causes reduced tumor cell growth and an
increase of apoptosis (Huber et al., 2008). In cancers, the transcription of both of these proteins
is also deregulated, which is a contributing factor to the overexpression of these proteins (Nano
& Houry, 2013).

RUVBL1 and RUVBL2 have multiple roles in cancer including signaling,
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apoptosis, modulating cellular transformation, and DNA damage response and these roles are
mediated through their interaction with a number of proteins such as the tumor suppressor
Hint1, and transcription factors such as β-catenin, c-myc, and E2F (Huber et al., 2008; Nano &
Houry, 2013). Recently, our laboratory has published that ECD has a novel interaction with the
R2TP complex through the protein RUVBL1 (Mir et al., 2015). Our lab was able to show that ECD
interacts with RUVBL1 and this interaction is phosphorylation independent and also necessary
for cell cycle progression. We showed that phosphorylation deficient mutants of ECD failed to
bind to the PIH1D1 component of the R2TP complex, but were still able to interact with the
complex through RUVBL1. Also, phosphorylation deficient mutants were able to partially rescue
the cell cycle block observed in ecd flox/flox MEFs upon ecd deletion. We were able to conclude
that ECD interaction with the R2TP is through the phosphorylation dependent interaction with
PIH1D1 and the phosphorylation independent interaction with RUVBL1. We also showed that
ECD interaction with RUVBL1 is essential for cell cycle progression; however, ECD interaction
with PIH1D1 is not (Mir et al., 2015). I am an author in this work and the full paper can be seen
in Appendix A of this thesis.
PIH1D1 is the connector protein between RuvBL1/RuVBL2 and RPAP3, which binds to the Cterminal region (Hořejší et al., 2014). It is also the complex protein that usually interacts directly
with most of the known adaptor proteins. PIH1D1 has a phospho-peptide binding domain in the
N-terminal region that binds preferentially to highly acidic phosphorylated proteins, which
enables it to recognize specific substrates within the cell. PIH1D1 specific binding proteins, such
as TEL2 and ECD, contain a conserved phospho-peptide motif, DpSDD, that is recognized by the
phospho-peptide binding domain in PIH1D1 (Hořejší et al., 2014). PIH1D1, along with the R2TP
complex, interacts with TEL2 to help in the stability of phosphatidylinositol-3 kinase-related
protein kinases (PIKKs) and the formation of PIKKs functional complexes such as mTORC1,
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mTORC2, and ATRIP (Horejsí et al., 2010; Takai, Wang, Takai, Yang, & de Lange, 2007). PIH1D1
interacts with NUFIP and is necessary for the accumulation, assembly, and stability of small
nucleolar ribonucleoprotein (snoRNPs) and the core proteins of the snoRNP complex (Boulon et
al., 2012). PIH1D1 also interacts with box C/D snoRNP factors Nop1, Nop58, Nop56, which are
involved in snoRNP biogenesis (R. Zhao et al., 2008). PIH1D1 directly interacts with Raptor, a
component of the mTORC1 and has been shown to play an important role in its complex
assembly and S6 kinase activation in breast cancer cells (Kamano et al., 2013). Also, PIH1D1
binds to RPAP3 at its C-terminal domain and have been shown to be regulators of apoptosis in
ovarian cancer cells (Inoue, Saeki, Egusa, Niwa, & Kamisaki, 2010). PIH1D1 is an important
member of the R2TP complex and plays a role in a number of cell processes and also seems to
be playing a role in oncogenesis.
RPAP3 has been shown to be component that interacts directly with Hsp90 and is the
bridge protein between the R2TP complex and Hsp90 (Back et al., 2013). This protein seems to
helping to stabilize the R2TP complex in cells. RPAP3 contains two tetratricopeptide repeat
(TPR) motifs, which have been shown to a binding domain region where Hsp90 binds to and its
co-chaperones (Kakihara & Houry, 2012). This protein has been characterized as a cell death
enhancer for its role in apoptosis. RPAP3 interacts with Monad (WDR92), which is an apoptosis
regulating protein (Yoshida et al., 2013). This protein is expressed in three isoforms, isoform 1,
2, and 3. RPAP3 isoform 1 has been shown to interact with PIH1D1 and downregulation of this
isoform by small interfering RNA, causes downregulation of PIH1D1 protein levels (Yoshida et
al., 2013). RPAP3 isoform 2 does not interact with PIH1D1 and have a dominant negative effect
on the survival of the R2TP complex (Yoshida et al., 2013). RPAP3 also binds to WDR92, which is
member of the prefoldin-like chaperone complex and this interaction may mediate the R2TP
complex binding to the prefoldin-like chaperone complex (Back et al., 2013; Itsuki et al., 2008).
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Table 1.2: R2TP Complex
.
Yeast
Name

Human Name/

Rvb1

Protein Names

Gene Name

hRvb1

RuvB-like 1, Pontin 52, Pontin, TIP49A, 49
kDa, TBP-interacting protein (TIP49), ECP54, NMP238, TAP54-α, INO80H, TIH1

RUVBL1,
NMP238,
TIP49, TIP49A

Rvb2

hRvb2

RuvB-like 2, Reptin, TIP49B, 48 kDa, TBPinteracting protein (TIP48), ECP-51,
TAP54-β, INO80J, TIH2

RUVBL2,
TIP48, TIP49B

Tah1

Spagh

RNA polymerase II-associated protein,
hSpagh, FJL21908

RPAP3

Pih1,
Nop17

Pih1d1

PIH1 domain-containing protein 1, Nop17
homolog

PIH1D1,
Nop17

Rpb5

RNA polymerase I, II, and III subunit
ABC1, DNA-directed RNA polymerase
subunit E, XAP4

POLR2E

PFDN2

Prefoldin subunit 2

PFDN2, PFD2

PFDN6

Prefoldin subunit 6, protein Ke2

PFDN6, PFD6,
HKE2

URI

RPB5-mediating protein, unconventional
prefoldin RPB5 interactor

RMP, URI

UXT

Ubiquitously expressed transcript
protein, ART-27

UXT, PDRG

PDRG1

P53 and DNA damage-regulated protein 1

PDRG1, PDRG

WDR92

WD repeat-containing protein 92, Monad

WDR92

R2TP and
Prefoldin
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Table 1.2: The molecular components of the R2TP/Prefoldin Like complex with their common
designations in S. cerevisiae and in humans. The table includes the various protein and gene
names of the R2TP/ Prefoldin Like Complex in yeast and in humans. The black texts are
members of the R2TP complex and the red texts are components of the Prefoldin- like Complex.
The bolded names are the ones that are used ubiquitously throughout the dissertation. (Boulon
et al., 2010, 2012)
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Heat shock protein 90 (HSP90) is a molecular chaperone protein that interacts with the
R2TP complex by binding to RPAP3. It is highly conserved throughout eukaryotic cells and it is
essential for viability. HSP90 is a dimeric chaperone protein that contains three domains, the NTerminal Domain, the Middle Domain, and the C-terminal domain (Taipale, Jarosz, & Lindquist,
2010).

The N-Terminal domain contains the ATP binding site that is critical for Hsp90

conformational change. The Middle domain is thought to be involved in client recognition and
the C-Terminal Domain is used for dimerization (Taipale et al., 2010). Hsp90 is involved in the
folding, maintenance, and regulation of a variety of proteins, including ErbB2. Hsp90 is involved
in multiple steps in ErbB2 protein folding and maintenance. It binds to the nascent protein and is
involved in the final stage of protein folding (R. Zhao et al., 2005). At the plasma membrane,
HSP90 binds to the kinase domain of ErbB2, forming a stable complex and protecting it from
ubiquitin-dependent proteasomal degradation (W. Xu et al., 2005). Hsp90 also plays a role in the
maintenance and regulation of downstream targets of ErbB2 (Taipale et al., 2010; W. Xu et al.,
2005). HSP90 assist in the proper folding and has a role in degradation of misfolded protein by
the proteasome (Pratt, Morishima, Peng, & Osawa, 2010). HSP90 recognizes specific client
proteins through its different co-chaperone interactions indicating that co-chaperones assist in
the various roles of HSP90 (Taipale et al., 2010).
Chaperone proteins, including HSP90, have been seen to be overexpressed in a number
of different cancers. Hsp90 is overexpressed in breast cancer cell lines and also in breast
cancers samples. In microarray data obtained from over 600 breast cancer tumor samples,
higher expression of HSP90 has been correlated to ErbB2 overexpression, Estrogen Receptor
overexpression, larger tumors, lymph node involvement, and a poor overall survival (Pick et al.,
2007). Overexpression of chaperones has been a major contribution to oncogenesis and has
been linked to providing protection to tumor cells in a nutrient deprived, hypoxic,
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microenvornment (Whitesell & Lindquist, 2005). Also increased chaperone levels may allow
tumor cells to adapt to the imbalanced signaling that is associated with transformation and
thereby assist tumor cells in their evasion of apoptosis (Sangster, Queitsch, & Lindquist;
Takayama, Reed, & Homma, 2003; Whitesell & Lindquist, 2005). Since this discovery, Hsp90 has
become a new molecular therapy target in breast cancers. Currently, Hsp90 inhibitors, such as
17-allylamino-17-demethoxygeldanamycin (17-AAG), are in clinical trials for anticancer
therapeutic agents (Goetz et al., 2003). 17-AAG, which is a Geldanamycin derivative, is a small
molecule inhibitor that binds to the ATP pocket domain of HSP90 and inhibits its interactions
with its client proteins (Sausville et al., 2003). This inhibitor causes downregulation of ErbB2
levels in vitro and in vivo and is currently used in clinical trials in combination with Trastuzumab
((Basso, Solit, Munster, & Rosen, 2002; Modi et al., 2011; Sausville et al., 2003). Interestingly, I
have observed that treatment of ErbB2+ breast cancer cell lines with 17-AAG leads to
downregulation of ECD, as well as some components of the R2TP complex (This work is
explained more in Chapter 3).

This may suggest that downregulation of ErbB2 leads to

destabilization o ECD and of the R2TP complex. HSP90 inhibitors have been seen to be toxic to
some patients (Goetz et al., 2003). This concern drives scientists to discover other co-chaperone
complexes that interact with HSP90 and are involved in oncogenesis that could become future
therapy targets.
The R2TP complex assists with the assembly of multi-molecular protein complexes
involved in the following pathways: mRNA and tRNA transcription, telomerase complex
assembly, small nucleolar ribonucleoprotein (snoRNP) biogenesis, phosphatidylinositol-3 kinaserelated protein kinase (PIKK) stability and signaling, and translation (Boulon et al.,
2012)(Kakihara & Houry, 2012)(Boulon et al., 2010)(Kakihara, Makhnevych, Zhao, Tang, &
Houry, 2014)(Kamano et al., 2013)(Horejsí et al., 2010). This co-chaperone complex assists with
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transcription through the assembly of the RNA polymerase II complex (RNAPII). RNAPII is an
enzyme that is composed of twelve subunits, and one of these subunits, Rpb1 associates with
HSP90 and the R2TP complex (Boulon et al., 2010). HSP90 and the R2TP complex are necessary
to help stabilize unassembled RNAPII subunits before the assembly of the full enzyme (Boulon et
al., 2010). The R2TP complex has also been shown to be involved in the assembly of RNA
Polymerase I and RNA Polymerase III complexes (Boulon et al., 2012).

Small nucleolar

ribonucleoproteins (snoRNPs) are characterized into two families C/D and H/ACA and this
characterization is determined by an RNA motif associated with a specific set of proteins
(Boulon et al., 2004; Kiss, Fayet, Jády, Richard, & Weber, 2006). SnoRNPs are involved in prerRNA processing in the nucleolus (Kiss et al., 2006). HSP90 and the R2TP complex are required
for the accumulation of snoRNPs and this complex interacts with immature snoRNPs through an
adaptor protein called Nuclear Fragile X Mental Retardation Protein Interacting Protein (NUFIP)
(Bizarro et al., 2015; Boulon et al., 2008). The R2TP complex interacts with NUFIP through
PIH1D1, which binds to it and help in the proper folding and stabilization of snoRNP core
proteins before and during assembly (Boulon et al., 2012). NUFIP acts as an adaptor protein for
a larger family of RNPs named L7Ac RNPs, which include three core proteins that require HSP90
for their stability (Boulon et al., 2008). This could possibly broaden the scope of the R2TP
complex’s involved in snoRNPs biogenesis. The R2TP co-chaperone complex is also involved in
the stabilization and assembly of the phosphatidylinositol-3 kinase-related protein kinase (PIKK)
family of kinases. The PIKK family consists of six members; ATR, ATM, DNA-PKcs, mTOR, SMG1,
and TRRAP; that are structurally similar to one another (Boulon et al., 2012). Each component
requires the adaptor protein telomere elongation regulation protein (TEL2/TELO2) for their
stability (Takai et al., 2007). TEL2 recruits the R2TP complex, by binding to PIH1D1 in a
phosphorylation dependent manner, to the PIKKs to help stabilize them (Horejsí et al., 2010).
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TEL2, with HSP90, also assists in the complex formation of mTORC1, mTORC2, and ATRIP
(Kaizuka et al., 2010; Takai, Xie, de Lange, & Pavletich, 2010). The R2TP complex and HSP90 are
required in the stability and the functional complex formations of the PIKKs.
Recently, the R2TP complex members have been shown to be overexpressed in breast
cancer patients on the mRNA level and genetic level and this complex is involved in the
regulation of hyper-activity of the mTOR signaling pathway (S. G. Kim et al., 2013). The HSP90
and R2TP/Prefoldin-like complex are involved protein synthesis, cell growth, and telomere
elongation and thus could play an important role in oncogenesis. The complex also is a master
regulator of cell proliferation and helps to form and maintain different protein complexes that
are involved in cycle progression (Boulon et al., 2012). Since the members of the R2TP complex
and HSP90 are involved in the stabilization and assembly of multiple complexes that are
involved in protein synthesis and cell cycle, it is very likely that this complex is playing an
important role in oncogenesis.

Sustained signaling, uncontrolled cell proliferation, and

enhanced cell survival are all considered hallmarks of cancer (Hanahan & Weinberg, 2011).
Hsp90 and the R2TP/Prefoldin-like complex interact with a number of adaptor proteins in order
to perform the stabilization and assembly functions and these interactions may be important in
tumor development.

ECD interacts directly or is in close proximity to all four of these

components in the R2TP complex, and with HSP90, as indicated by (Figure 1.4). Currently, there
are some inhibitors that target specific HSP90 co-chaperone proteins and HSP90 itself, however
there is a need for new potential therapy targets for combinatorial therapy treatments. ECD
seems to be a novel adaptor protein of this complex and together, ECD and the R2TP complex
are involved in ErbB2 receptor stability in breast cancer. ECD, HSP90, and the R2TP complex
seem to be playing an instrumental role in the stabilization of ErbB2 and loss of ECD abrogates
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the ErbB2 and the R2TP complex interaction and eventually leads to destabilization of ErbB2.
(This work will be discussed in detail in Chapter 2).

1.5 ECD potential roles through different protein-protein interactions
ECD interacts with a number of proteins and with the HSP90 and R2TP complex and this
suggest that ECD may be playing a role in a number of cellular processes. The schematic in
Figure 1.5 shows our laboratory’s current knowledge of ECD and depicts the biological processes
ECD may potentially be involved in with the R2TP complex. The R2TP is involved in the assembly
and stability of several protein complexes and adaptor proteins are necessary to facilitate the
interaction between the R2TP complex and these protein complexes. ECD may be interacting
with the R2TP complex an adaptor protein. ECD interacts with this complex through PIH1D1 in a
phosphorylation dependent manner and domain specific manner (Mir et al., 2015; von Morgen
et al., 2015). ECD also interacts with the R2TP through its interaction with RUVBL1 and this
interaction is essential for ECD function as a cell cycle regulator (Mir et al., 2015). Through
ECD’s interaction with Retinoblastoma (RB), we know that ECD is important for cell cycle
progression and proliferation (J. H. Kim et al., 2009). Upon deletion of ECD, cells undergo G1
arrest and therefore cannot continue with mitosis, indicative of ECD playing an essential role
(Bele et al., 2015; J. H. Kim et al., 2009). Human ECD was first identified as a Human Papilloma
Virus 16 E6 (HPV16 E6) interacting protein. Our lab has found that HPV16 E6 binds to ECD at the
PEST domain and this interaction is helping to stabilize HPV16 E6, which indicates the potential
role of ECD in cervical cancer oncogenesis. The lab has also observed that ECD levels are high in
cervical cancer tumor samples; further strengthening the hypothesis that ECD is playing a role in
this cancer. ECD has also been found to interact with p53. It helps to stabilize p53 by binding to
MDM2 and inhibiting its function (Zhang, 2006). P53 is an important tumor suppressor that is
mutated in some cancers. Another previous graduate student has showed that ECD is playing a
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role in transformation in hTERT immortalized HMECs and in cell survival. When ECD is
overexpressed with the oncogene H-RAS, it leads to hTERT immortalized HMECs undergoing
transformation (Bele et al., 2015). ECD and RAS cells exhibited more migration, invasion and
acinar formation in 3D matrigel as compared to ECD only, RAS only, and vector expressing cells.
These cells also exhibited better survival, indicated by reduced autophagic response, under
extreme cellular stress conditions (Bele et al., 2015). These results indicate that ECD may be
playing a role in the cellular stress and cellular death pathways.
Further evidence confirming ECD role in a cell death pathway is the observation that
ECD interacts with TXNIP. TXNIP is a tumor suppressor that is involved in apoptosis. ECD
interacts with TXNIP to decrease ubiquitination of p53 leading to its stability (Suh et al., 2013). A
graduate student in Dr. Vimla Band’s lab has shown that ECD is involved in cellular stress. ECD
interacts with PERK. PERK is a mediator of the unfolded protein response (UPR) pathway, and it
is composed of several molecular mechanisms that are aimed to respond to cellular stress (Ma
& Hendershot, 2001). In cases of mild stress, mechanisms for cell survival are activated and in
cases of extreme stress, mechanisms for cellular death are activated (Ma & Hendershot, 2001;
Welihinda et al., 1999). Different stress inducing compounds, such as Thapsigargin and
Tunicamycin, cause downregulation of ECD levels in HMECs, indicating that ECD may be a
regulator of the UPR pathway.
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Figure 1.4: Endogenous association of ECD with HSP90, and the four R2TP components using
Proximity Ligation Assay.
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Figure 1.4: Endogenous association of ECD with HSP90, and the four R2TP components using
Proximity Ligation Assay:
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Figure 1.4: Endogenous association of ECD with HSP90, and the four R2TP components using
Proximity Ligation Assay: SKBR3 cells were plated on 18mm coverslips and were fixed in 3%
paraformaldehyde. Cells were then blocked in blocking buffer for 30 minutes and incubated
with primary antibody for 2 hours. Coverslips were then incubated in mouse (minus probe) and
rabbit (plus probe) probes for one hour, and then ligated for 30 minutes, and then probes
underwent amplification using a red fluorescent dye to indicate interactions for 2 hours.
Controls were ECD and HSP90 as positive control and single antibody controls as negative
controls. The scale bar is 10nm in length. All the pictures with ECD and the R2TP complex
members were taken on 63X objective lens. ECD and HSP90 positive control and single antibody
control pictures were taken on a 40X objective lens.
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Figure 1.5: Potential Functions of ECD with the HSP90 and the R2TP/Prefoldin-like Complex.
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Figure 1.5: Potential Functions of ECD with the R2TP Complex.
A schematic representation of Ecd as a part of R2TP/Prefoldin-like complex. Together ECD and
the R2TP complex interact with other proteins to perform various cellular functions. (Bele, 2015;
von Morgen et al., 2015)
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ECD also interacts with several molecular components of the UPR pathway, including PERK and
GRP78/BIP. (This work will be discussed in more detail in Appendix B). Interesting in PERK
knockout mouse embryonic fibroblast (MEFs) that are treated with ER stress inducers, ECD
levels remain unchanged. This observation is indicates that ECD may play a role as a negative
regulator of stress. Our lab has shown that Secretory Pathway Calcium ATPase (SPCA2)
expression levels are high in ECD+RAS HMECs as compared to ECD overexpressing and RAS
overexpressing HMECs alone (Bele, 2015). SPAC2 has been shown to be overexpressed in
breast cancer and it plays a role in oncogenesis by promoting calcium dependent signaling (Feng
et al., 2010). ECD may be regulating the expression of SPAC2 and when ECD is overexpressed, it
causes upregulation of SPAC2 in certain cell lines.
ECD may also be playing a role in ribosome biogenesis through its interactions with PIH1D1,
PRP8, and MYBBP1A. In Drosophila cells, ECD interacts with Pre-mRNA processing Factor 8
(PRP8), a member of the U5 snRNP spliceosomal complex (Claudius et al., 2014) and is necessary
for cell survival in larval imaginal discs. Deletion of ecd or prp8 prevents the splicing of an intron
from CYP307A2/spookier (spok) pre-mRNA. This spicing defect causes a block in entry to
metamorphosis (Claudius et al., 2014). Human ECD is able to rescue this phenotype which
indicates that ECD may have a similar function in this process in different species. ECD also
interacts with the nucleolar protein, Myb-Binding Protein 1A (MYBBP1A), which is a
transcription regulator that regulates several transcription factors (Díaz et al., 2007; Fan et al.,
2004; Favier & Gonda, 1994; Hara et al., 2009; Tavner et al., 1998). MYBBP1A also plays an
essential role in a number of cellular processes such as, mitosis, transcriptional regulation, rRNA
synthesis, and ribosome biogenesis (Akaogi et al., 2013; Bele, 2015; Mori et al., 2012; Ono et al.,
2013, 2014). A previous graduate student was able to observe that loss of ECD leads to a down
regulation of MYBBP1A (Bele, 2015). Upon overexpression, ECD also co-localizes with MYBBP1A
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in the nucleolus (Bele, 2015). ECD may be playing a role in MYBB1A stability and may also play
a role in the functions of MYBBP1A. Our laboratory has also shown that ECD interacts with p300
and may be playing an important role in chromosome integrity. Upon deletion of ecd in primary
mouse embryonic fibroblasts (MEFs), there were frequencies for chromosome aberrations (Bele,
2015). These chromosome aberrations include: chromosome breaks, fragments, deletions, and
translocations were observe. ECD is functionally important in the maintenance of chromosomes
through histone acetylation. Our laboratory has shown that ECD interacts with the histone
acetyltransferase, p300 and enhances its HAT activity (J. H. Kim, 2009). ECD may play a role in
transcription through its interaction with p300 since it does not have a DNA binding domain.
ECD seems to be playing multiple roles in mammalian cells and differential expression of ECD
causes several novel phenotypes. ECD is an important factor for cellular processes such as
development, cell cycle, cellular stress, stability, complex assembly, calcium signaling, ribosome
biogenesis, and possibly transcription and chromosome integrity. ECD also seems to be playing
an important role in oncogenesis as indicated with its ovexpression in a number of cancers as
well as its transformation potential in HMECs with overexpression of H-RAS (Bele, 2015; Bele et
al., 2015; Dey et al., 2012; X. Zhao et al., 2012). We have also observed that ECD is associated
with ErbB2 and ECD this interaction is facilitated by HSP90 (Ammons and Mirza et.al 2016
Chapter 2). Downregulation of ECD leads to downregulation of ErbB2 levels and downstream
molecular targets of ErbB2 signaling. ECD knockdown also depletes the number of ErbB2
receptors on the plasma membrane. This work will be fully discussed in Chapter 2 of this
dissertation. I have also observed that different chemotherapeutic agents affect ECD levels and
levels of the R2TP complex. Currently, Trastuzumab and Lapatinib are two chemotherapy drugs
that are used to treat patients with ErbB2 overexpressing breast cancer. 17-AAG is an HSP90
inhibitor that is currently in clinical trials for patients with ErbB2+ subtype of breast cancer.
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These three drugs downregulate ECD protein levels and levels of some of the R2TP complex
members indicating that ErbB2 signaling may be regulating the expression of these proteins.
This work will be fully discussed in Chapter 3 of this dissertation. I also observed using data
collected from the Cancer Genome Atlas, that ECD and several components of the R2TP complex
are overexpressed in different subtypes of breast cancer. This work will be fully discussed in
Chapter 3 of this dissertation. Lastly, using different inhibitors we have shown that ECD levels
are regulated by several different proteins, such as m-TOR and AKT. When I used Rapamycin, an
mTOR inhibitor, I observed downregulation of ECD and several members of the R2TP complex in
ErbB2+ cell lines. Since the R2TP complex has been observed to be involved in mTOR
stabilization and activity (Horejsí et al., 2010; S. G. Kim et al., 2013), it is plausible to hypothesize
that ECD may be part of a stabilization feedback loop with mTOR, however more experiments
need to be conducted before this can be proven. Again this work will be fully discussed in
Chapter 3 of this dissertation. When I treated ErbB2+ cell lines with MK-2206, a pan-AKT
inhibitor, I observed down regulation of ECD. Since knockdown of ECD leads to down regulation
of AKT levels and an AKT inhibitor leads to down regulation of ECD, it is plausible to hypothesize
that ECD and AKT are in a feedback loop that regulate one another’s levels perhaps through
different complex interactions. Interesting, ECD is not phosphorylated by AKT, according to the
potential kinases of ECD list created by a previous graduate student in the laboratory (Bele,
2015). This work will also be fully discussed in Chapter 3 of this dissertation.
Although there are several mechanisms of how ECD functions in cells that still need to fully
elucidated, our resources within the laboratory such as anti-ECD antibodies, in vitro and in vivo
models, and different ECD constructs and ECD mutant constructs, will help us uncover the
physiological and pathological role(s) of ECD in humans. Given the scope of the different
protein-protein interactions of ECD, its involvement in a number of cellular processes, and its
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differential expression of ECD in a number of different cancers, ECD should also be under
consideration as a new molecular biomarker as well as a new potential drug target.

1.6 Rationale, Hypothesis, and Specific Aims
The Human Epidermal Growth Factor Receptor 2 (ErbB2) overexpression accounts for 25%
of all breast cancers and is associated with a poor patient survival. A crucial component involved
in the regulation of ErbB2 signaling pathway is the chaperone component heat shock protein 90
(Hsp90) and interacting protein complex. Hsp90 participates in the folding, assembly, and
proteolytic turnover of many intracellular proteins, including ErbB2. Hsp90 also interacts with
other chaperone complexes in order to perform its protein regulation function. One such
complex that interacts with Hsp90 is the R2TP/Prefoldin-like Complex. In Eukaryotes, the R2TP
complex is comprised of four proteins, RuvBL1, RuvBL2, PIH1D1, and RPAP3 which interact in
concert with seven prefoldin-like proteins. Together, Hsp90 and the R2TP complex are involved
in several pathways, such as telomere elongation, splicing, ribosome biogenesis, and PIKK kinase
stability. The Hsp90 and the co-chaperone R2TP complex interact with an adaptor protein that
facilitates the assembly of this complex and determines which intracellular molecules of the
chaperone complex are regulated.
Ecdysoneless (Ecd) was first discovered in Drosophila melanogaster, which encodes a
protein whose orthologs are present in several other species including humans. My mentor’s
laboratory identified the mammalian ortholog of Drosophila Ecdysoneless from a yeast twohybrid screen of human mammary epithelial cells (hMECs). My mentor’s laboratory then
showed Ecd is a novel cell cycle regulator that is essential for embryogenesis and cell cycle
progression (34). Our preliminary studies demonstrate Ecd is a phosphoprotein Casein Kinase 2
(CK2) is a major kinase that phosphorylates Ecd. Phosphorylation of Ecd regulates its stability.

40
My studies have demonstrated Ecd has a strong interaction with Hsp90 chaperone protein and
with RuvBL1, a member of the R2TP/Prefoldin-like Complex. We and others have shown CK2mediated phosphorylation of Ecd, particularly at Serine residues 505 and 518, are required for
Ecd’s interaction with PIH1D1, an R2TP complex member. This phosphorylation dependent
interaction is known to determine the substrate specificity of this complex. Significantly, my
mentor’s laboratory has shown Ecd is overexpressed in breast cancers, specifically in ErbB2+
breast cancers, and its overexpression correlates with poor prognostic markers and poor
survival of patients. Importantly, my recent studies demonstrate treatment of ErbB2+/Ecd+
tumor cells with HSP90 inhibitors or tyrosine kinase inhibitors (Lapatinib and Trastuzumab)
dramatically down-regulated ErbB2 as well as Ecd, suggesting a link between these two proteins.
Based on our preliminary and published results, I hypothesize that ECD, as a cell cycle
regulator, could be functioning as a co-oncogene in ErbB2 driven oncogenesis.
SPECIFIC AIMS:
AIM I: Determine if Ecd is a co-oncogene in ErbB2 mediated oncogenesis. ECD associates with
ErbB2 and HSP90. Hsp90 is a chaperone protein that interacts with the R2TP/Prefoldin-like
complex and together is involved in the assembly and stabilization of a variety of proteins. I
hypothesize that in ErbB2+ breast cancer cells, ECD levels and association are playing a role in
ErbB2 stability. In order to test this hypothesis, I will a) Determine if ECD is a mediator protein
for Hsp90 and R2TP/Prefoldin-like chaperone complex in ErbB2+ breast cancer cells, b) Elucidate
the biological pathway that ECD and the R2TP/Prefoldin-like complex utilizes for ErbB2 mediated
breast oncogenesis.
AIM II: Elucidate the role of ECD as part of the Hsp90 and R2TP/Prefoldin-like chaperone
complex in ErbB2-mediated oncogenesis. Studies have shown that in breast cancers, Hsp90,
R2TP proteins, and Ecd are overexpressed. These components could potentially function in the

41
stability of other overexpressed or mutated signaling proteins that promote uncontrolled
proliferation and/or cell survival of cancer cells. I hypothesize that altering phosphorylated Ecd
levels within breast cancer cells will cause the complex to become hyper-active or destabilized
leading to a gain or loss of uncontrolled proliferation and/or cell survival.
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Chapter 2
ECD Positively Regulates ErbB2 Expression and
Function
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ABSTRACT:
ErbB2/HER2 overexpression accounts for approximately 25-30% of all breast cancer
patients and is associated with poor prognosis. Ecdysoneless (ECD), a novel cell cycle
regulator, is overexpressed in breast cancer and its overexpression is correlated with poor
survival outcome in ErbB2+ breast cancer patients. In this study, to assess if ECD
regulates ErbB2 protein, we first analyzed if ECD and ErbB2 proteins interact with each
other.

Using co-immunoprecipitation, as well as proximity ligation assays, we

demonstrate ECD, ErbB2 and HSP90 are present in the same complex. Furthermore,
silencing of ECD by siRNA-mediated knockdown led to the downregulation of total
ErbB2, phosho-ErbB2 and surface levels of ErbB2. Notably, downregulation of ErbB2
led to significant decrease in its downstream targets, ERK signaling. As expected,
knockdown of ECD resulted in significant decrease in ErbB2 association with HSP90.
We further demonstrate that ECD-mediated decrease in ErbB2 protein was due to a
significant decrease in ErbB2 mRNA stability and in part by protein stability.
Significantly, knockdown of ECD in ErbB2+ breast cancer cells resulted in decrease in
invasion and migration. These results demonstrate a novel interaction of Ecdysoneless
with ErbB2 and its functional consequence on ErbB2 levels and function. Future studies
should address if destabilization of ECD together with anti-ErbB2 therapy could provide
a better treatment strategy for ErbB2+ breast cancer patients.

Keywords: Breast cancer; HER2; ErbB2; Ecdysoneless; HSP90; R2TP
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INTRODUCTION:
Breast cancer is the second leading cause of cancer related deaths in women in the
United States with the highest number of new estimated cases in women than any other
cancer.1 Among different molecular subtypes of breast cancer, Epidermal Growth Factor
Receptor 2 (ErbB2/HER2) is one of the more aggressive subtypes, which accounts for
approximately 25-30% of all breast cancer cases.2 Although breast cancer patients with
ErbB2 overexpression are ideal candidates for anti-ErbB2 Trastuzumab (Herceptin)
antibody therapy3, not all patients benefit from this treatment. Approximately 15% of
patients relapse after therapy due to de novo or acquired resistance4 and progress into a
metastatic disease.5 Therefore, defining pathways that are connected to ErbB2 protein
stability may provide better treatment strategies. We have identified one such candidate,
called Ecdysoneless (ECD).
We identified the mammalian ortholog of Drosophila Ecdysoneless protein in a yeast
two-hybrid screen of human mammary epithelial cells (hMECs) cDNA library using
human papilloma virus 16 E6 (a highly efficient hMECs immortalizing gene in an in vitro
setting) as a bait and hMEC cDNA library. We previously identified Ecdysoneless (ECD)
as a p53 interacting protein.6 Subsequent studies from our laboratory, defined an
important role for ECD in cell cycle regulation. ECD interacts with retinoblastoma (RB)
protein and competes with E2F transcription factor to bind to RB.7 Further analyses from
our laboratory demonstrated ECD protein is overexpressed in breast cancers and its
overexpression is correlated with ErbB2+ breast cancers.8

ECD overexpression in

ErbB2+ patients correlated with poor survival of the patients, suggesting a co-oncogenic
role of ECD in ErbB2-mediated oncogenesis.8

Recent studies from our laboratory
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confirmed the co-oncogenic role of ECD in hMECs when ECD is co-overexpressed with
well-known oncogene mutant H-Ras.9 H-Ras, which is widely used for in vitro hMECs
transformation,

is

a

known

down-stream

mediator

of

ErbB2

signaling.10,11

Overexpression of ECD and mutant RAS in hMECs led to an oncogenic phenotype not
only in in vitro cell assays but also formed tumors upon implantation in to the mammary
gland of NOD/SCID mice.9 Additionally, we and others have recently identified ECD is a
component of a co-chaperone protein complex named R2TP-prefoldin complex.12,13 The
R2TP complex is comprised of four molecular components: two AAA+ ATPases
RUVBL1 and RUVBL2, an adaptor protein PIH1D1, and an HSP90 interacting protein
RPAP3.14 We have shown that ECD interacts with two components of R2TP complex,
PIH1D1and RUVBL1, and ECD’s interaction with RUVBL1 is critical for

ECD’s

function in cell cycle progression.13
In the present study, we examined the association and potential mechanistic link
between ECD and ErbB2 proteins. Using co-immunoprecipitation, as well as proximity
ligation assay, we demonstrate ECD associates with ErbB2, as well as ErbB2 stabilizing
protein HSP90. Furthermore, siRNA mediated knockdown of ECD downregulated total
ErbB2 protein levels, surface levels of ErbB2, as well as phospho-ErbB2 protein. The
association of ErbB2 with HSP90 was significantly reduced upon ECD knockdown.
Significantly, ECD knockdown significantly decreased ErbB2 mRNA stability but also
partly decreased turnover of the protein. Lastly, knockdown of ECD in ErbB2+ breast
cancer cells resulted in a decrease in invasion and migration of cells. Thus, we present
evidence that ECD associates with ErbB2 and regulates its mRNA stability, and we
suggest knockdown of ECD together with Trastuzumab may provide a better treatment
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strategy for ErbB2+ /ECD+ breast cancer patients.
RESULTS:
ECD associates with ErbB2 protein
Given our previous findings that elevated levels of ECD protein strongly correlates with
overexpression of ErbB2, we speculated that ECD may directly interact with ErbB2. For
this purpose, we performed two sets of experiments, in one set of experiments,
endogenous ECD was immunoprecipitated using anti-ECD antibodies in ErbB2+ breast
cancer cell lines, followed by immunoblotting with anti-ECD or anti-ErbB2 antibodies.
These results clearly demonstrated an association between ECD and ErbB2 proteins. We
also performed reciprocal experiments with immunoprecipitation with anti-ErbB2
antibodies followed by immunoblotting with anti-ECD antibodies and obtained similar
association (Figure 1A and 1B). It has been shown that Heat shock protein 90 (HSP90)
regulates ErbB2 stability, as it is involved in the folding, maintenance, and regulation of
ErbB2.15 Therefore, we assessed if ECD interacts with HSP90. Immunoprecipitation
with anti-HSP90 antibody followed by western blotting with anti-HSP90 showed ErbB2
was associated with HSP90, as expected. Significantly, ECD was also associated with
HSP90 (Figure 1C), suggesting that all three proteins are in a complex in ErbB2+ cells.
In the second approach we used proximity ligation assay16 to examine direct interaction
of ECD with ErbB2 or ECD with HSP90. In these experiments ErbB2 interaction with
HSP90 served as a positive control. In this assay, each dot represents one molecule of
each protein interactions. As indicated by the red fluorescent dot signals (Supplementary
Figure 1) and in Figure 1D, endogenous ECD is in close proximity to ErbB2, as well as
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to HSP90. The Y-axis indicates the total number of signals counted per five random
fields with ten cells per field. The X-axis indicates two protein interactions. Taken
together, our results clearly demonstrate association of ECD with ErbB2, as well as
HSP90, suggesting a tri-complex of ECD-ErbB2-HSP90 in ErbB2+ cells.
ECD regulates levels of ErbB2 protein
To investigate the function of ECD and ErbB2 interaction, we knocked down ECD in
ErbB2+ cell lines using two independent siRNAs against ECD, a scrambled siRNA was
used as control. Significantly, knockdown of ECD showed a dramatic reduction in the
phosphorylated (at residue 1248) as well as total ErbB2 protein (Figure 2A). As expected,
decreased levels of ErbB2 led to decreased phosphorylated ERK levels. Notably the
levels of total ERK, AKT other downstream target of ErbB2 remained unchanged
indicating that the effects of ECD downregulation on ErbB2 and ERK are specific.
Next, we assessed if down regulation of ECD changes surface levels of ErbB2.
For this purpose, we treated two ErbB2+ cell lines with scrambled or two different
siRNA against ECD, as described before. After 48 hours, live cells were collected and
incubated with Alexa Fluor 647-conjugated mouse anti-human ErbB2 or IgG and
analyzed using FACS analysis. As shown in Figure 2B and 2E, there was a clear
reduction in surface levels of ErbB2, indicated by the shift towards left of the two siRNA
ECD peaks, as compared to the control scrambled siRNA peak. In order to quantify
these shifts, the mean fluorescence intensity of ErbB2 peak was calculated (Figure 2C
and 2F). Western blotting confirmed knocked down of ECD in these cells (Figure 2D and
2G). Taken together, these results suggested ECD regulates ErbB2 protein levels.
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Knockdown of ECD decreases interaction of ErbB2 with HSP90 protein
ErbB2 protein stability is strongly modulated by its interaction with HSP90 chaperone
protein complex.10,15 This interaction is essential in preventing ErbB2 ubiquitnation and
degradation.17,18 Dissociation of this interaction is an important therapeutic approach.19
To examine if ECD down regulation influences interaction of HSP90 and ErbB2 protein,
we performed again proximity ligation assays as well as co-immunoprecipitation assays
in ECD knockdown cells. Notably, PLA experiment (Figure3A), as well as coimmunoprecipitation experiment (Figure 3B) showed a significant decrease in interaction
of HSP90 with ErbB2 protein upon ECD knockdown, underscoring that ECD regulates
ErbB2 protein.
ECD regulates ErbB2 mRNA and protein stability
To ascertain whether ECD mediated decreased in ErbB2 levels is a mechanism at the
transcriptional level or at the protein level, ECD siRNA expressing cells were treated
with cycloheximide (CHX), a known nascent translation blocking agent at 0 time point
and then harvested cells at various time points followed by western blotting of cell
lysates. To start with (0 time point) the ErbB2 protein levels were low as compared to
control cells. As time progress, in ECD knock down cells the ErbB2 protein turnover was
faster. A clear decrease at later time points 12-24 hours of CHX treatment (Figure 3C).
These experiments showed ErbB2 protein is highly stable in control cells, but has a faster
turnover in ECD knockdown cells (Figure 3C). However, considering the dramatic
decrease in ErbB2 protein level upon ECD knockdown and this slight increase in protein
turn over may not be the entire mechanism how ECD regulates ErbB2 protein levels.
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Therefore, we explored if ECD-mediated decrease in ErbB2 is due to transcriptional
regulation.
ECD knockdown downregulates ErbB2 mRNA by altering its stability
To assess if ECD downregulates ErbB2 at a transcriptional level, we knockdown ECD
from two ErbB2+ cell lines, SKBR3 and BT474, isolated mRNA and performed realtime PCR (RT-PCR) to assess the effect on ErbB2 mRNA levels. Significantly, we
observed a dramatic decrease in ErbB2 mRNA levels upon ECD knock down in both cell
lines (Figure 4 A and 4 B). DHFR, a known E2F target gene and known to be decreased
upon ECD KD, served as a positive control and EGFR, another family member of ErbB2
served as a negative control in these experiments.
Next, we asked if decrease in ErbB2 mRNA levels upon ECD knockdown is due
to mRNA stability. For this purpose, two breast cancer cell lines, SKBR3 and BT474
were treated with actinomycin D, a transcriptional blocker agent after ECD knock down.
Total RNA was isolated at indicated time points after actinomycin D treatment. qRTPCR was performed to analyze ErbB2 mRNA levels. In ECD downregulated cells, at 0
time point the ErbB2 mRNA levels were low as compared to control cells. As time
progress, the mRNA from control cells was more stable. Notably, ErbB2 mRNA half life
is approximately 7 to 8 hrs in scrambled siRNA expressing SKBR3 and BT474 cells, in
keeping with previously published data.20,21 Significantly, ECD knockdown reduced the
ErbB2 mRNA stability to approximately 4 to5 hours (Figure 4C and 4D). Thus, the major
mechanism of ECD mediated decrease in ErbB2 is transcriptional effect, however protein
stability may also contribute.
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ECD Knockdown dramatically inhibits invasion and migration of ErbB2+ breast
cancer cell lines
To demonstrate the functional role of ECD in ErbB2-driven tumorigenic phenotype, we
used scrambled or ECD siRNA expressing BT474 cells and then performed commonly
used cell migration and invasion assays using Boyden Chambers, as described in Material
and Methods. As shown in (Figure 5A) knockdown of ECD significantly inhibited
invasion of BT474 cells in both siRNAs expressing cells when compared to the control
siRNA (p=0.002 and p=0.009). Silencing of ECD also resulted in reduced cell migration
capacity (p=0.004 and p=0.042) (Figure 5C). Western blotting confirmed ECD
knockdown in BT474 cells. These results suggest a role of ECD in ErbB2-driven
oncogenesis.
Taken together, ECD associates with ErbB2 and HSP90 and regulates ErbB2
mRNA as well as protein stability. Furthermore, ECD contributes to ErbB2-mediated
tumorigenic phenotype.
Discussion:

Recent molecular profiling has helped classify the ErbB2+ breast cancers as a
distinct subtype of breast cancer accounting for 20 to 30% of all cases.22,23 Targeting of
ErbB2 with humanized anti-ErbB2 monoclonal antibodies is now an important
therapeutic strategy for ErbB2-overexpressing breast cancers3,24, but therapeutic
resistance has emerged as a key issue

4,5

, providing impetus for identification of

molecular pathways that regulate ErbB2 at the mRNA and protein levels, as such
mechanisms may offer alternate avenues for targeting. Both physiological (e.g. via EGF-

52

induced heterodimerization with EGFR) and pharmacological (using anti-ErbB2
antibodies and HSP90 inhibitors) down-regulation of ErbB2 have been linked to
induction of receptor ubiquitinylation, which apparently targets the modified receptor for
lysosomal and proteasomal degradation.10,19,25–28 While most of the studies focus on
protein degradation, downregulation of ErbB2 mRNA which can eventually translate into
lower protein levels is an area that has received less attention. Knowledge of the mRNA
level control of ErbB2 expression could facilitate the development of newer targeted
strategies to achieve receptor down-regulation as well as combinatorial therapeutic
strategies with agents that target ErbB2 signaling.

In this study, we describe a novel interaction of ErbB2 with ECD, a positive cell
cycle regulatory protein whose expression is increased in ErbB2+ breast cancers,
predicting poor survival in such patients. We previously identified ECD in a yeast twohybrid screen as a binding partner of the oncoprotein HPV16 E6, which is a highly
efficient human mammary epithelial cell immortalizing protein even though HPVs are
not in general linked to breast cancer. Our subsequent analyses demonstrated that ECD is
required for mammalian cell cycle progression.7 Furthermore, ECD interacts with
RUVBL1, a component of R2TP complex13, and this interaction and serinephosphorylation of ECD are required for its cell cycle regulatory function. The R2TP
complex, composed of RUVBL1, RUVBL2, PIH1D1, and RPAP3, is an HSP90associated co-chaperone complex.14 By interacting with distinct adaptor proteins through
its PIH1D1 component, the HSP90/R2TP chaperone complex facilitates the assembly of
protein complexes involved in many basic biological pathways including the mRNA and
tRNA synthesis, telomerase complex assembly, small nucleolar ribonucleoprotein
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(snoRNP) biogenesis, phosphatidylinositol-3 kinase-related protein kinase (PIKK)
signaling, and translation.14,29–35 Recently, phosphorylated ECD was shown to interact
with PIH1D112 suggesting that ECD may also help target the R2TP/HSP90 complex to
other targets. Notably, the levels of ECD, HSP90 and components of the R2TP complex
have been shown to be overexpressed in several cancers.8,36–42 these published studies
from others and our laboratory prompted us to investigate if mechanistic links exist
between ECD and ErbB2.
As HSP90 is a molecular chaperone that assists in the proper folding and
maintenance of the mature, folded states a variety of client proteins, including ErbB2, and
HSP90 overexpression in breast cancers is correlated with a poor overall survival
outcome36, we speculated that ECD may be part of a complex with HSP90 and that this
complex may help stabilize the ErbB2 protein. Co-immunoprecipitation and proximity
ligation assays clearly demonstrated that ECD is in a complex with ErbB2, as well as
with HSP90 proteins in ErbB2+ breast cancer cell lines (Figure 1). Using well established
ECD specific siRNA, we demonstrate that ECD knockdown decreases the levels of total
as well as phospho-ErbB2 protein, as well as surface ErbB2 levels (Figure 2). As the
reduction in ErbB2 levels upon ErbB2 knockdown was seen under conditions of
cycloheximide block of new proteins synthesis, these results suggests that ECD functions
in part by promoting ErbB2 protein stability (Figure 3C and D). ECD knockdown was
associated with a decrease in the association between ErbB2 and HSP90 (Figure 3A and
B), suggesting that ErbB2 stabilizing function of ECD may be mediated through HSP90.
Notably, the reduction in total ErbB2 levels upon ECD knockdown was
considerably more robust than the modest decrease in ErbB2 protein half-life, suggesting
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that additional mechanisms were involved in how ECD regulates ErbB2. Analysis of
ErbB2 mRNA levels demonstrated a significant reduction in ECD knockdown cells
(Figure 4 A and B), suggesting a second mechanism by which ECD regulates ErbB2
protein expression. Furthermore, treatment of control or ECD knockdown cells with
Actinomycin D to block new mRNA synthesis demonstrated a reduction in the half-life
of ErbB2 mRNA (Figure 4 C and D); supporting the idea that ECD promotes ErbB2
mRNA stability.
How ECD promotes the ErbB2 mRNA stability will be of great interest to dissect
through future analyses. In this regard, several recent studies have shown the regulation
of ErbB2 mRNA levels to be a key component of ErbB2 protein expression in tumor
cells. Heregulin was reported to negatively regulate the transcription of ErbB2/3 without
influencing EGF receptor transcription.21 An ErbB3-interacting protein EBP1 has been
shown to reduce the expression of ErbB2 by affecting mRNA stability.43 ErbB2 mRNA
stability has also been shown to be regulated negatively by the binding of microRNAs,
such as miR-125a and miR-125b in the 3’-UTR

44–46

, and positively by binding to

adjacent sequences of HuR protein.47,48 Some studies have reported a counter-regulatory
relationship

between

microRNA-dependent

destabilization

and

HuR-mediated

stabilization.47ErbB2 expression is also under active transcriptional control and has been
linked to positive regulation by breast cancer-overexpressed coactivator SRC-3
transcription factor ERRα

51,52

49,50

and

as well as negative regulation by PAX2 or FOXP3.53–56

Future studies should help delineate the roles of these known pathways or other
mechanism of mRNA stability and/or transcription of ErbB2 in how ECD functions
positively in the maintenance of ErbB2 levels in breast cancer cells.
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Given our prior work establishing ECD as a positive regulator of cell cycle
progression 7, its overexpression in ErbB2+ breast cancers 8, and promotion of an
oncogenic phenotype in human mammary epithelial cells by overexpression of ECD
together with mutant H-Ras 9, we assessed if ErbB2-driven oncogenic phenotype requires
the presence of ECD. Indeed, we observed a dramatic downregulation of invasion and
migration of ErbB2+ breast cancer cells when ECD was downregulated, underscoring a
functional role for ECD in ErbB2-driven oncogenesis.
In conclusion, the present study demonstrates a novel interaction of ECD with
ErbB2 and HSP90 which appears to positively regulate ErbB2 stability and in addition
reveal a novel role of ECD in the stability of ErbB2 mRNA. Future studies of in vivo
cooperation of ErbB2 and ECD in oncogenesis, using ECD plus ErbB2 transgenic mouse
models currently being engineered in our laboratory, will be of great interest to extend
our current findings that clearly support an important role of ECD in ErbB2-driven
oncogenesis. Furthermore, targeting ECD in ErbB2+ cells along with anti-ErbB2 therapy,
trastuzumab may provide a better treatment strategy.
Materials and methods:
Cell Culture, Regents, and Transfections:
SKBR3 and BT474 cells were cultured and maintained in RPMI mediun supplemented
with 10% fetal bovine serum. For proximity ligation assays, SKBR3 cells were grown to
30% confluence on glass cover slips in 12-well plates. Cells were transfected with either
50 nM of control, ECD siRNA1, ECD siRNA2 described previously 6, using the
DharmaFECT 1 Transfection Reagent (T-2001-03, Dharmacon, Pittsburgh, PA). CHX
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(Sigma, St. Louis, MO) Actinomycin D (Sigma, St. Louis, MO) is commercially
available.
Duolink in situ proximity ligation assay
Anti-mouse PLA probe plus, anti-rabbit PLA probe minus, and detection kit Res 563
were purchased from OLink Bioscience (Uppsala, Sweden). 3% Paraformaldehyde fixed
cells were blocked with Blocking buffer received from the kit for 30 minutes, and
incubated with primary antibodies for ECD and ErbB2 (c-8) (sc-284), ErbB2 (c-8) (sc284), and HSP90 (H-114) (sc-7947), ErbB2 and Ada3, and IgG mouse (sc-2025) and IgG
rabbit(sc-2763) for 2 hours at 37oC, as previously from Santa Cruz Biotechnology
(Dallas, TX) described in detail

16

. PLA probes were diluted 1:5 in antibody diluent

solution. Ligation and Amplification steps were followed from the Duolink Proximity
Ligation Assay Protocol. Detection of the PLA signals was carried out with LSM 510
META and LSM 710 META Confocal fluorescence microscope (Zeiss).
FACS Analysis
For live-cell surface ErbB2 staining, cells trypsinized using Trypsin from Sigma (St.
Louis, MO). After the trypsin was inactivated, the cells were then spun down at 1000
RPM at 4 oC. Cells were washed three times with FACS buffer and incubated for 1 h on
ice in the dark with Alexa Fluor 647-conjugated mouse anti-human ErbB2 monoclonal
antibodies (mAb) (cat no,3244412) from Biolegend (San Dieago, CA) Inc or mouse IgG
(control) diluted in FACS buffer. Following the incubation, the cells were washed three
times using the same buffer. Cells were fixed at room temperature in 4% PFA for 10 min,

57

run on a BD FACScalibur flow cytometer and analyzed with CellQuest software as done
previously.57
Immunoprecipitation and Western Blotting
For immunoprecipitation cells were washed in 1X PBS and lysed in CHAPS buffer
{[0.3% CHAPS, 20 mM Tris-HCl (pH 7.4), 120 mM NaCl, 10% glycerol, 5mM EDTA]
supplemented with protease and phosphatase inhibitor (Roche, Indianapolis, IN). Lysates
equivalent to 2mg of total protein were subjected to immunoprecipitation, as described in
figure legends. For western blotting, cell extracts were prepared in RIPA buffer (Cat#
89901, ThermoFisher Scientific, Waltham, MA) supplemented with protease inhibitor
(Roche, Indianapolis, IN). Lysate equivalent to 15-25µg of protein was resolved on SDSPAGE gel followed by western blotting with indicated antibodies. Antibody against ECD
was described previously

7,8

. Rabbit anti-ErbB2 pAb (c-8) (sc-284) from Santa Cruz

Biotechnology (Dallas, TX) and rabbit anti-HSP90 α/β pAb (H-114) (sc-7947), from
Santa Cruz Biotechnology (Dallas, TX). Conjugated secondary antibodies for Western
blotting are from Invitrogen (Grand Island, NY).
Transwell Migration and Invasion Assays
The migration assay was done using BD BioCoatTranswell chambers (#354578) (San
Jose, CA). In BT474 cells ECD was knockdown using specific siRNA as described
above. Before plating cells were starved in 0.1% serum. 10,000 cells were plated in the
top chambers. After 2 h, 10% fetal calf serum containing medium was added to the lower
chamber and then incubation was carried out for 24 h. Cells were fixed with ice-cold
methanol and stained with propidium iodide. Similar protocol was followed as
described.9 The migrated cells on the bottom surface of filters were then mounted on
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coverslips and observed at 20X magnification under rhodamine filter using 710 LSM at
confocal microscopy. Five random fields were counted from each well of triplicates.
Invasion assay was performed using BD Matrigel invasion chambers (#354480) (San
Jose, CA). Cells were plated, processed and counted similar to migration assay.
RNA Isolation and Quantitative Real Time PCR
Total RNA was isolated from SKBR3 and BT474, control and siRNA treated samples
using TRIzol reagent, according to the manufacturer’s protocol. 1 μg RNA was reverse
transcribed using SuperScriptTM II reverse transcriptase (Invitrogen, ThermoFisher
Scientific, Waltham, MA) and oligo-dT primers (18MER) and quantitative real-time PCR
6

(qRT-PCR) analyses with specific primer sets for ECD
and

ACTTTGAAACACACGAACCTGGCG-3’
TGATGCAGGTGTGTGCTAGTTCCT-3’,
TAAACTGCATCGTCGCTGTGT-3’

Reverse:

and

5’

–

Forward:

DHFR

AGGTTGTGGTCATTCTCTGGAAA-3’,

Forward: 5’ -

Reverse:
ErbB2

5’-

5’

–
5’-

Forward:

AGCCTTGCCCCATCAACTG-3’ and Reverse: 5’–AATGCCAACCACCGCAGA-3’,
EGFR

Forward:

5’-TGCCATCCAAACTGCACCTA-3’

CTGTGTTGAGGGCAATGAG-3’.

GAPDH,

and

Human

Reverse:
Forward:

5’

–
5’-

GTCATCCATGACAAGTTTGG-3’ and Reverse: 5’ – TGCCAGTGAGCTTCCCGTTC3’, were ordered from (Sigma, St. Louis, MO).qRT PCR were carried out in an Applied
Biosystems 7500 Real Time PCR system using Power SYBR Green master mix from
Applied Biosystems (ThermoFisher Scientific, Waltham, MA).

mRNA Stability Assays
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Cells were seeded in 6 well plates (200,000 cells per well). After 48 hrs of ECD
knockdown, followed by addition of Actinomycin D (5μg/ml) (Sigma, St. Louis, MO) at
time zero time point. Total RNA was isolated at indicated time point, 0, 2, 4, 6, 8 and 12
hours of Actinomycin D with Trizol as per the manufacture’s protocol. First-strand
cDNA was synthesized using SuperScript III reverse transcriptase, followed by qPCR
with ErbB2, ECD, and GAPDH primers, as described above.
Figure Legends:
Figure1. ECD associates with ErbB2: Co-immunoprecipitation shows association of
endogenous ErbB2, ECD and HSP90 (A, B & C). Two ErbB2+ cell lines, SKBR3 or
BT474, cell lines were lysed in CHAPS buffer and 2 mg of lysates were
immunoprecipitated (IP) with anti-ErbB2, anti-ECD or anti-HSP90 specific antibodies.
Mouse (Ms) and Rabbit (Rb) IgG served as negative controls. HSP90 interaction was
used as a positive control. The bound proteins were subjected to Western blotting
analysis with indicated antibodies in A, B & C. (D) Proximity ligation assays were
performed between ECD and HSP90 or ECD and ErbB2(as described in materials and
methods). Quantification was performed by Duolink Image tool. This tool is able to
detect the number of signals per cell. We took 5 distinctive jpeg images of the cells
under 63X magnification. These images are uploaded and checked for quality using the
Duolink ImageTool. The nuclei channel is automatically labeled blue and the user selects
the signal channel, and in this case it is red). The tool then counts approximately 10
individual cells per image, therefore we have about 50 cells that we counted. The
histograms represent the total number of signals of each image.
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Figure 2. ECD regulates levels of ErbB2 protein. (A) ErbB2+ cell lines, SKBR3 and
BT474 were transfected with either 40 nM of control or two different ECD siRNA, using
the DharmaFECT 1 Transfection Reagent. Lysates were harvested after 48 hours of
transfection and immunoblotted with indicated antibodies. Β-actin was used as a loading
control. Data shown here are mean of ± S.E.(error bars ) from three independent
experiments and p values were calculated using student´s t test p≤ 0.05 is considered
significant *. (B) ECD knockdown reduces the surface levels of ErbB2. SKBR3 and
BT474 cells were treated with scrambled or two different siRNA specific for ECD, as
discussed previously. After 48 hours of transfection these cells were labeled with Alexa
flour 488- conjugated anti-ErbB2 antibody for 1 hour at 4C. Anti- mouse IgG alone
served as a negative control (B & E). Cell surface levels of ErbB2 were quantified using
flow cytometry and then analyzed with BD cellquestTM software. (C & F) The Y axis
represents MFI (mean fluorescence intensity) (C & F) Lysates were harvested after 48
hours of transfection and then immunoblotted with indicated antibodies. β-actin was
used as a loading control (D and G).
Figure 3. Knockdown of ECD decreases interaction of ErbB2 with HSP90 (A)
Proximity Ligation Assay depicting interactions between ErbB2 and HSP90 upon ECD
knockdown. Proximity ligation assay was carried out, as described above. Quantification
of proximity signals was carried out using Duolink Image Tool Software. Analysis of
>50 cells per interaction is shown here. These figures and graphs are representative
images. (B) SKBR3 cell line was transfected with scrambled and siRNA against ECD, as
discussed previously. After 48 hours of transfection these cells were lysed in CHAPS
buffer and 2 mg of lysates were immunoprecipitated (IP) with anti-HSP90 antibody. The
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bound proteins were subjected to Western blotting analysis first with anti-ErbB2 antibody
and after stripping blotted again with anti-HSP90 antibody. (C) SKBR3 cell line was
transfected with scrambled or siRNA against ECD, 48 hours later cells were treated with
cycloheximide (CHX) at 100 (μg/ml) (0 time point), and then cell lysates were collected
at indicated time periods for Western blotting. Down regulation of ECD was confirmed
by western blotting and α-tubulin was used as a loading control. (D) ErbB2 protein
degradation in SKBR3 was measured by using Image J software after normalizing with
corresponding α-tubulin band intensities. The values were converted as percentages; log
value was calculated and plotted on Y axis. X-axis represents times after CHX treatment.
Figure 4: ECD knockdown decreases ErbB2 mRNA levels by enhancing its turn
over
ECD knockdown was performed using specific siRNA against ECD in ErbB2 positive,
BT474 and SKBR3 cell lines. Total RNA was isolated after 48 hour of transfection and
cDNA was made. Levels of ECD and ErbB2 mRNA were detected by quantitative realtime RT–qPCR; DHFR was used as a positive control and GAPDH as an internal control.
Fold change over GAPDH was calculated and plotted (A) BT474 and (B) SKBR3 cells.
ECD down regulation decreases ErbB2 mRNA stability. The stability of mRNA was
analyzed in SKBR3 (C) and BT474 cells (D). After ECD down regulation by siRNA,
cells were treated with actinomycin D (5 μg/ml) at 0 time point, and then total RNA was
isolated at various time points (0, 2, 4, 6, 8 and 12 hours) after actinomycin D treatment.
cDNAs were made and levels of ErbB2 were measured by RT-qPCR. GAPDH was used
as normalization control.

62

Figure 5: Knockdown of ECD decreases invasion and migration ability of ErbB2
positive breast cancer cell lines. Western blotting shows downregulation of ECD
protein upon siRNA knockdown (B & D), these cells when plated on Boyden chambers
show decrease in their ability to invade (A) and migrate (C). The bar diagrams represent
number of cells migrated or invaded. Data shown here are mean ± S.E. (standard error
bars) from three independent experiments, and p values were calculated using student´s t
test, p≤ 0.05 is considered significant *.
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Supplementary Figure Legends
Supplementary Figure 1: A-B) Proximity Ligation Assay depicting Interaction between
ECD and ErbB2, and ECD and HSP90. SKBR3 cells were plated on 18mm coverslips
and were fixed in 3% paraformaldehyde. Cells were then blocked in blocking buffer for
30 minutes and incubated with primary antibody for 2 hours. Coverslips were then
incubated in mouse (minus probe) and rabbit (plus probe) probes for one hour, then
ligated for 30 minutes, then probes underwent amplification using a red fluorescent dye
to indicate interactions for 2 hours. Each red fluorescent signal indicates one proteinprotein interaction. Controls were C) HSP90 and ErbB2 as positive control, D) ErbB2
and ADA3 and E) IgG antibodies used as as negative controls. Pictures were taken at 63x
magnification and 40X magnification for controls on the Zeiss 510 and 710 Confocol
Microscopes. Scale bars represent 10μm. Insersts are of representative cell taken from
the image.
Supplementary Figure 2: A-B) Proximity Ligation Assay depicting Interaction between
ErbB2 and HSP90 when ECD knockdown and control samples. BT474 cells were plated
on 18mm coverslips and were transfected with either 40 nM of control or ECD siRNA 2,
using the DharmaFECT 1 Transfection Reagent. After 48 hours of transfection cells
were fixed in 3% paraformaldehyde. Cells were then blocked in blocking buffer for 30
minutes and incubated with primary antibody for 2 hours. Coverslips were then incubated
in mouse (minus probe) and rabbit (plus probe) probes for one hour, then ligated for 30
minutes, then probes underwent amplification using a red fluorescent dye to indicate
interactions for 2 hours. Each red fluorescent signal indicates one protein-protein
interaction. C-D) IgG antibodies controls as negative controls in C) control siRNA cells
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and D) siRNA ECD cells. Scale bars represent 10μm. Pictures were taken at 63x
magnification on the Zeiss 510 and 710 Confocol Microscopes. Insersts are of
representative cell taken from the image.
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Chapter 3
Ongoing Studies and Future Directions
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3.1 ECD localization and expression in ERBB2 exogenous overexpressed
cell lines.
In order to explore the role of ECD assisting in the stabilization of ERBB2 in vitro, we
wanted to observe if ECD localization differed in ERBB2+ breast cancer cell lines. Our
laboratory has shown that ECD is mainly localized in the cytoplasm; however ECD has
the ability to shuttle to the nucleus. ECD does not have a nuclear localization signal, but
it does have a fast nuclear export (J. H. Kim et al., 2010). ERBB2 is mainly localized at the
plasma membrane and is stabilized by HSP90 and other co-chaperones (Yarden &
Sliwkowski, 2001). HSP90, in complex with other co-chaperones, bind to the tyrosine
kinase domain of ERBB2 in the cytoplasm and protects the receptor from ubiquitination
and degradation (Ehrlich et al., 2009; W. Xu et al., 2005). ERBB2 also undergoes a
recycling process called endocytosis; however the pathway has not been fully
elucidated. Endocytosis is an active transport pathway that transports molecules into
the cell by engulfing them and there are several pathways the cell can utilize to
complete this function (Marsh, 1999). Interestingly, in some cell lines the ERBB
receptors have been shown to activate several biochemical signaling pathways, such as
ERK and AKT, during endocytosis (Liu, Tao, Woo, Xiong, & Mei, 2007; Yang, Huang,
Xiong, & Mei, 2005). Since ERBB2 and ECD both may have functions in the cytoplasm, I
wanted to see if ECD and ERBB2 colocalized in any compartment of the cell when ERBB2
is overexpressed. In order to test this question, I performed several immunofluorence
experiments in several different ERBB2+ cell lines. I used human anti-ECD antibody that
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the lab has generated and human anti-ERBB2 antibody from Santa Cruz. As shown in
Figure 3.1, ECD does not colocalize with ERBB2 at the plasma membrane. However, it is
difficult to determine if ECD and ERBB2 colocalize in the cytoplasm upon ERBB2
overexpression and further test will need to be performed to confirm this phenomenon.
Since we have previously published that ECD overexpression correlates with ERBB2
overexpression in breast cancer patients (X. Zhao et al., 2012), we wanted to see if we
can recapitulate this correlation in vitro. We first observed localization of these two
proteins in ERBB2+ cell lines, and we were not able to see distinctive colocalization in
any cell compartment. I then wanted to observe how exogenous ERBB2 effected
protein and mRNA levels in immortalized human mammary epithelial cell lines (HMECs)
and in MCF7 breast cancer cells which are ER+. All these cell lines have basal levels of
ERBB2, so I transfected either pMSCV-vector puromycin or pMSCV-ERBB2 puromycin
into these cells using retroviral infection and treated cells with puromycin selection.
After selection, I harvested protein lysates and mRNA from these cells and observed
levels or ECD and ERBB2. Interestingly, ECD protein levels, compared to vector control,
increased after exogenous ERBB2 transfection (Figure 3.2) in all three cell lines. This
result in conjunction with ECD overexpression observed in breast cancer cell lines shown
in Figure 1.1, indicate that ECD levels are regulated by ERBB2 and elevated ECD is
necessary in ERBB2 overexpressed cell lines. ECD mRNA however, does not seem to be
significantly changed in vector or ERBB2 overexpressing cells (Figure 3.3). From these
results, we are able to conclude that ECD is overexpressed in ERBB2 overexpressed cell
lines on protein level and not mRNA level, indicating that ECD is becoming more
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Figure 3.1: ECD and ERBB2 Localization in ERBB2+ Breast Cancer Cell Lines.
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Figure 3.1: ECD and ERBB2 Localization in ERBB2+ Breast Cancer Cell Lines (continued).
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Figure 3.1: ECD and ERBB2 Localization in ERBB2+ Breast Cancer Cell Lines (continued)
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Figure 3.1: ECD and ERBB2 Localization in ERBB2+ Breast Cancer Cell Lines. Different
ERBB2+ breast cancer cell lines, SKBR3 (A-B), BT474 (C-D), UACC 812 (E-F), HCC 1419 (GH), HCC 202 (I-J), and UACC 893 (K-L) were plated on cover slips were fixed in 4%
paraformaldehyde for 20 minutes. The primary antibodies used were human anti-ERBB2
antibody, and anti-ECD antibody. Secondary antibodies used were Alexa fluor 488 and
Alexa fluor 594 from Life Technologies. Nuclei were counterstained with DAPI. The cover
slips were then placed on slides using the mounting medium. Fluorescent images were
captured using LSM 510 META Confocal fluorescence microscope at 40X magnification
(Zeiss).
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Figure 3.2: ECD is overexpressed in overexpressed ERBB2 transfected cell lines.
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Figure 3.2: ECD is overexpressed in overexpressed ERBB2 transfected cell lines. A)
76NTERT, MCF10A, and MCF 7 cell lines were transfected with either vector plasmid or
ErbB2 plasmid. Cell lines were treated with puromycin and were harvested using RIPA
Buffer and ECD expression was determined by western blotting using anti-ECD, antiERBB2, anti-PIH1D1, and anti-β-actin (as loading control). B) The graph below is the
densitometry analysis of ECD levels as compared to β-ACTIN. Densitometry performed
using ImageJ.
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Figure 3.3: ECD mRNA is unaffected in overexpressed ERBB2 transfected cell lines.
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Figure 3.3: ECD mRNA is unaffected in overexpressed ERBB2 transfected cell lines. A-B)
76NTERT and MCF10A cell lines were transfected with either vector plasmid or ErbB2
plasmid and mRNA was harvested using Trizol. Real Time PCR analysis was performed
and the data is represented in the bar graphs above for A) ECD or B) ERBB2.
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stabilized in these cell lines and this stabilization in turn is helping in the stabilization of
the ERBB2 receptor.

3.2 Potential role of ECD and the R2TP complex in ErbB2 signaling
pathway.
As a continuation of the work discussed in Chapter 2, we wanted to see how different
chemotherapeutic agents targeting ErbB2 affected ECD and members of the HSP90/R2TP cochaperone complex. The R2TP complex is comprised of four molecules: PIH1D1, RUVBL1,
RUVBL2, and RPAP3 and the complex interact with the chaperone protein, HSP90. HSP90 is a
chaperone protein that assist in the folding, maintenance, and assembly of many proteins and
many protein complexes in cells (R. Zhao et al., 2005). Interestingly, we have shown that ECD
and HSP90 interact with one another through immunoprecipitation and proximity ligation assay.
We have also seen that ECD and HSP90 co-localize with one another in SKBR3 cells, an ERBB2
overexpressing breast cancer cell line (Figure 3.4). HSP90 has been shown to be overexpressed
in breast cancer and it is an important chaperone that helps to stabilize ERBB2 at the plasma
membrane, we wanted to see how ECD and HSP90 are interacting with the R2TP complex in
ERBB2+ breast cancer cells.
The HSP90/ R2TP complex has been shown to be involved in the assembly and stabilization
of a number of protein complexes such as RNA polymerase II assembly, PIKKs, box C/D small
nucleolar ribonucleoprotein (snoRNP) biogenesis, telomere activity, apoptosis, and chromatin
remodeling (Kakihara & Houry, 2012). Recent reports have shown overexpression of the R2TP
components in different cancers, such as breast and colon(S. G. Kim et al., 2013). We then
wanted to observe the levels of the R2TP complex and ECD in different breast cancer cell lines.
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Figure 3.4: ECD and HSP90 Co-localization in SKBR3 cells.
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Figure 3.4: ECD and HSP90 Co-localization in SKBR3 cells. A) SKBR3 cells were plated on cover
slips were fixed in 4% paraformaldehyde for 20 minutes. The primary antibodies used were
human anti-HSP90 antibody, and anti-ECD antibody. Secondary antibodies used were Alexa
fluor 488 and Alexa fluor 594 from Life Technologies. Nuclei were counterstained with DAPI. The
cover slips were then placed on slides using the mounting medium. Fluorescent images were
captured using LSM 510 META Confocal fluorescence microscope at 40X magnification (Zeiss).
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Figure 3.5: ECD, HSP90, and members of the R2TP complex is overexpressed in various breast
cancer cell lines.
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Figure 3.5: ECD, HSP90, and members of the R2TP complex is overexpressed in various breast
cancer cell lines. A) Various breast cancer cell lines were harvested using RIPA Buffer and ECD
expression was determined by western blotting using anti-ECD, anti-ERBB2, anti-HSP90, antiPIH1D1, anti-RUBVL1, anti-RUVBL2, and anti-β-ACTIN (as loading control). 76NTERT and MCF10A
serve as normal immortalized breast epithelial cell lines. Cell lines are separated via subtype. B)
The graph below is the densitometry analysis of ECD levels as compared to β-ACTIN.
Densitometry performed using ImageJ.
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As shown in Figure 3.5, ECD and different members of the R2TP are overexpressed in different
breast cancer cell lines. There are some cell lines that have more expression of the R2TP
components, and the overexpression seems to correlate with ECD overexpression. This
observation needs to be explored further though to see if ECD overexpression correlates with
R2TP complex members’ overexpression in cancers.
There have been several speculations about the role of the HSP90/R2TP complex in
oncogenesis. The HSP90/R2TP complex plays important role in several cellular functions such as
proliferation, division, and survival. The complex is involved with the assembly of the human
telomerase RNP complex, which in necessary for telomere elongation and cellular division
(Boulon et al., 2008; Venteicher, Meng, Mason, Veenstra, & Artandi, 2008). The HSP90/R2TP
complex is also involved in the stability of the mTOR kinase, which is involved in cellular survival.
Over-activation of the mTOR kinase and upregulation of telomerase have been observed in a
number of cancers and it is hypothesized that the HSP90/R2TP complex is helping to stabilize or
assembly these complexes in cancer cells (Zoncu, Efeyan, & Sabatini, 2011). In Chapter 2, we
observed that knockdown of ECD leads to downregulation of ERBB2 and downstream targets of
ERBB2; we wanted to see if knockdown of ECD had any effect on the levels of HSP90 or the R2TP
complex. We treated three breast cancer cell lines with siRNA scrambled control, siRNA ECD 1,
or siRNA ECD 2 for 48 hours. We collected lysates and ran them on an SDS-PAGE gel. As shown
in Figure 3.6, knock down of ECD does not seem to have any effect on levels of HSP90 or
members of the R2TP complex.
Since knock down of ECD did not have any effect on levels of HSP90/R2TP complex, I
wanted to observe if downregulation of ERBB2, either by downregulation of ERBB2 protein
levels or inhibition of ERBB2 signaling pathway, had any effect on the complex. In order to

88
Figure 3.6: ECD siRNA mediated knockdown does not downregulate members HSP90/R2TP
complex in various breast cancer cell lines.
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Figure 3.6: ECD siRNA mediated knockdown does not downregulate members HSP90/R2TP
complex in various breast cancer cell lines. A) Various breast cancer cell lines were transfected
with siRNA scrambled control or siRNA ECD 1 or 2 and incubated for 48 hours. Cells were
harvested using RIPA Buffer and ECD expression was determined by western blotting using antiECD, anti-ERBB2, anti-HSP90, anti-PIH1D1, anti-RUBVL1, anti-RUVBL2, and anti-β-ACTIN (as
loading control). 76NTERT and MCF10A serve as normal immortalized breast epithelial cell lines.
Cell lines are separated via subtype. B-D) Quantitative density analysis of ECD, HSP90, RUVBL1,
RUVBL2, and PIH1D1 normalized to β-ACTIN in SKBR3, MDA-MB 361, and MDA-MB 175 breast
cancer cell lines where ECD was knockdown with two different siRNAs. Densitometry performed
using ImageJ.
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achieve this, we treated ERBB2+ cell lines with different chemotherapy agents that target
ERBB2. The most common chemotherapy drug used in cancer patients with ERBB2
overexpression is Trastuzumab (Herceptin). Trastuzumab is a human monoclonal antibody that
has two specific antigen sites that bind to the extracellular juxtamemberane of the ERBB2
receptor and prevents activation of the intracellular tyrosine kinase domain (Hudis, 2007).
There are several mechanisms of action of Trastuzumab may utilize to decrease signaling. These
mechanisms include decreasing ERBB2 receptor dimerization, activation of the immune system,
increasing the degradation of the ERBB2 receptor by increasing the endocytic recycling pathway,
and inhibiting the shedding of the extracellular domain (Hudis, 2007; Vu & Claret, 2012).
Trastuzumab has a high efficacy rate in breast cancer patients and it is the most common
form of therapy in ERBB2+ breast cancers. However, increasing instances of acquired and
primary resistance proves to be quite a challenge for clinicians. The mechanism of Trastuzumab
resistance has not been fully elucidated. One potential mechanism of resistance is the
disruption between Trastuzumab with ERBB2 leading to steric hindrance. MUC4 is a
glycoprotein that has been shown to interact with ERBB2 and it is also overexpressed in breast
cancers. MUC4 binding to ERBB2 does not allow Trastuzumab to interact with the receptor and
shut down ERBB2 signaling (Nahta & Esteva, 2006). It is also hypothesized that overlapping
signaling pathways such as SRC or PI3K/AKT pathway become overactive in patients with
Trastuzumab resistance (Vu & Claret, 2012). Since Trastuzumab resistance is a growing concern
for clinicians and scientists alike, there is a need for new biomolecules that can be used as
potential therapy targets. Therefore, in order to explore the possibility of ECD becoming a new
potential biomarker, we wanted to see how levels of ECD and the HSP90/R2TP complex
members are affected when cells are treated with Trastuzumab. ERBB2+ cell lines, SKBR3 and
BT474, were treated with different dosages of Trastuzumab for 72 hours. After 72 hours, lysates
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were collected and run on an SDS-page gel. As shown in Figure 3.7, Trastuzumab causes down
regulation of phosphorylated ERBB2 and total ERBB2, which has previously been shown.
Interestingly, Trastuzumab also causes the down regulation of ECD and the four components of
the R2TP complex. This indicates that downregulation of ERBB2 leads to the destabilization of
ECD and the R2TP complex. In conjunction, we treated two Trastuzumab resistant cell lines,
SKBR3 TR and BT474 TR, with different dosages of Trastuzumab for 72 hours. In Figure 3.8 we
observed that Trastuzumab had no effect on ECD levels or levels of the four R2TP components.
These results indicate that abrogation of ERBB2 signaling and levels leads to the destabilization
of the R2TP complex and ECD. Since the R2TP complex is emerging as an important cochaperone scaffolding complex in cells and in cancers, it is important to understand how the
complex is regulated in oncogenesis. In the future, ECD and the R2TP complex may potentially
be used as new chemotherapy targets. By combining Trastuzumab and inhibitors to ECD and
the R2TP complex may help increase the efficacy of Trastuzumab and become new treatments
for patients with Trastuzumab resistance.
In order to determine if downregulation of ECD was a cause of ERBB2 signaling abrogation
or downregulation of ERBB2 protein levels, we decided to use another chemotherapy agent that
targets the ERBB2 signaling pathway. Lapatinib (GW572016) is a chemotherapy agent that
targets the intracellular tyrosine kinase domain of Epidermal Growth Factor Receptor 1 (EGFR)
and ERBB2. It is a dual kinase inhibitor that binds to the tyrosine kinase domain of these
receptors and inhibits phosphorylation and down regulates their signaling pathways (Wood et
al., 2004). Research has shown that combination of Trastuzumab and Lapatinib treatment to
patients with ERBB2 overexpressing subtype of breast cancer, improved rates of pathological
response as compared to single agent treatments (de Azambuja et al., 2014). Lapatinib
however, has some cytotoxic effects on patients and some patients acquire resistance, thus
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Figure 3.7: ERBB2+ cell lines treated with Trastuzumab causes downregulation of ECD and
members of the R2TP complex.
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Figure 3.7: ERBB2+ cell lines treated with Trastuzumab causes downregulation of ECD and
members of the R2TP complex (continued).
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Figure 3.7: ERBB2+ cell lines treated with Trastuzumab causes downregulation of ECD and
members of the R2TP complex. A-B) BT474 and SKBR3 cells were treated with different dosages
of Trastuzumab (Herceptin) in μg/mL and lysates were collected after 72 hours of treatment.
Cells were hours of treatment. Cells were harvested using RIPA Buffer and ECD expression was
determined by western blotting using anti-ECD, anti-ERBB2,anti-PIH1D1, anti-RUBVL1, antiRUVBL2, anti-RPAP3, and anti-β-ACTIN (as loading control). C-D) Quantitative density analysis of
ECD, RUVBL1, RUVBL2, and PIH1D1 normalized to β-ACTIN in BT474 and SKBRR3breast cancer
cell lines. Densitometry performed using ImageJ.
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Figure 3.8: ERBB2+ Trastuzumab resistant cell lines treated with Trastuzumab does not change
ECD and members of the R2TP complex levels.
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Figure 3.8: ERBB2+ Trastuzumab resistant cell lines treated with Trastuzumab does not change
ECD and members of the R2TP complex levels (continued).
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Figure 3.8: ERBB2+ Trastuzumab resistant cell lines treated with Trastuzumab does not change
ECD and members of the R2TP complex levels. A-B) BT474 and SKBR3 Trastuzumab resistant
cells were treated with different dosages of Trastuzumab (Herceptin) in μg/mL and lysates were
collected after 72 hours of treatment. Cells were harvested using RIPA Buffer and ECD
expression was determined by western blotting using anti-ECD, anti-ERBB2, anti-PIH1D1, antiRUBVL1, anti-RUVBL2, anti-RPAP3, and anti-β-ACTIN (as loading control). C-D) Quantitative
density analysis of ECD, RUVBL1, RUVBL2, RPAP3, and PIH1D1 normalized to β-ACTIN in BT474
and SKBRR3breast cancer cell lines. Densitometry performed using ImageJ
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indicating the need other molecular targets (D’Amato et al., 2015). We treated SKBR3 and
BT474 cells with Lapatinib and collected lysates at different time points, and observed the effect
of the chemotherapeutic agent on ECD levels and levels of different R2TP components. As
shown in Figure 3.9, Lapatinib strongly downregulates the phosphorylation of ERBB2, which we
used as a positive control. Levels of ECD and levels of different R2TP components were down
regulated upon Lapatinib treatment in both ERBB2+ cell lines. Since Lapatinib is a dual kinase
inhibitor that affects EGFR as well as ERBB2, we wanted to determine if the downregulation was
specific to ERBB2 signaling. Therefore, we treated MCF7 cells which are Estrogen Receptor
positive breast cancer cells that have a basal level of ERBB2 and EGFR and MDA MB 231 cells,
which is a triple negative (ER-/PR-/HER2-) EGFR+ breast cancer cell line. Interestingly, upon
treatment of Lapatinib in these cell lines did not alter the levels of ECD or members of the R2TP
complex (Figure 3.10). These results indicate that deregulation of ECD and the R2TP complex is
specifically tied to the downregulation of the ERBB2 receptor.
After observing these results, we wanted to see how downregulation of protein levels of
ERBB2 would affect ECD and members of the R2TP components. We therefore treated cells
with a chemotherapeutic agent that targets HSP90 and leads to ERBB2 degradation. The Hsp90
inhibitor, 17-AAG has been shown to cause the rapid degradation of ErbB2 (Maloney &
Workman, 2002; Pick et al., 2007; Taipale et al., 2010; Whitesell & Lindquist, 2005; Workman et
al., 2007). 17-AAG, which is a derivative of Geldanamycin, is 17-AAG is a small molecule inhibitor
that binds to the ATPase activity domain of the Hsp90 dimeric protein, inhibiting its ATP activity
and prevents its interaction with client proteins (Workman et al., 2007). This inhibitor has a
certain sensitivity to mature ErbB2 receptors that is not seen in other Epidermal Growth Factor
Receptor family members. Even though 17-AAG has been shown to be more promising than its
predecessor, some clinicians fear the potential of
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FIGURE 3.9: ERBB2+ cell lines treated with Lapatinib causes downregulation of ECD and
members of the R2TP complex
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FIGURE 3.9: ERBB2+ cell lines treated with Lapatinib causes downregulation of ECD and
members of the R2TP complex (continued)
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FIGURE 3.9: ERBB2+ cell lines treated with Lapatinib causes downregulation of ECD and
members of the R2TP complex A-B) BT474 and SKBR3 cells were treated with 1μm of Lapatinib
and lysates were collected a the specified time points. Cells were harvested using RIPA Buffer
and ECD expression was determined by western blotting using anti-ECD, anti-phosphoERBB2,anti-PIH1D1, anti-RUBVL1, anti-RUVBL2, and anti-β-ACTIN (as loading control). C-D)
Quantitative density analysis of ECD, RUVBL1, RUVBL2, and PIH1D1 normalized to β-ACTIN in
BT474 and SKBRR3breast cancer cell lines. Densitometry performed using ImageJ.
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Figure 3.10: MCF7 and MDA MB 231 cell lines treated with Lapatinib causes no
downregulation of ECD and members of the R2TP complex
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FIGURE 3.10 MCF7 and MDA MB 231 cell lines treated with Lapatinib causes no
downregulation of ECD and members of the R2TP complex A) MCF7 (ER+) and MDA-MB-231
(ER-/ERBB2-/PR-) breast cancer cells were treated with 1μm of Lapatinib and lysates were
collected a the specified time points. Cells were harvested using RIPA Buffer and ECD expression
was determined by western blotting using anti-ECD, anti-PIH1D1, anti-RUBVL1, anti-RUVBL2,
and anti-β-ACTIN (as loading control). B) Quantitative density analysis of ECD, RUVBL1, RUVBL2,
and PIH1D1 normalized to β-ACTIN in BT474 and SKBRR3breast cancer cell lines. Densitometry
performed using ImageJ.
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hepatotoxicity (Workman et al., 2007). Geldanamycin proved to be highly toxic and caused
hepatotoxicity, and although 17-AAG has been shown to be less toxic (Whitesell & Lindquist,
2005; Workman et al., 2007), there is still a possibility that this drug will not be suitable for some
patients. We therefore wanted to see how 17-AAG affects ECD levels in ERBB2+ cell lines. I took
BT474 and MDA 361 cells and treated them with different dosages of 17-AAG. As shown in
Figure 3.11, ECD levels are decreased upon introduction of 17-AAG in both breast cancer cell
lines. To reconfirm this result, I performed a time dependent experiment on BT474 and blotted
the western with PIH1D1, which is a member of the R2TP complex. I observed a gradual down
regulation of ECD and PIH1D1 in this experiment (Figure 3.12). I also performed another time
dependent experiment on BT474 and a dose dependent experiment on 21MT2 cells, which is
another ERBB2+ breast cancer cell line. I observed down regulation of ECD, ERBB2, as well as
down regulation of RUVBL1, another member of the R2TP complex (Figure 3.13). However,
HSP90 levels were unchanged in 21MT2 cells. In conclusion, 17-AAG treatment leads to
downregulation of ECD and two components of the R2TP complex. This downregulation seems
to be caused by the downregulation of ERBB2 levels in ERBB2+ breast cancer cell lines. This
indicates that ECD and the R2TP complex become destabilized when ERBB2 is downregulated
indicating that this complex may be acting downstream of this receptor. By understanding how
ECD and the R2TP complex is stabilized In vitro could eventually help design small molecule
inhibitors that target these protein and destabilize them in ERBB2+ breast cancers and in
chemotherapy resistant tumors.
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Figure 3.11: ERBB2+ cell lines treated with 17-AAG leads to downregulation of ECD.
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Figure 3.11: ERBB2+ cell lines treated with 17-AAG leads to downregulation of ECD. A-B)
BT474 and MDA 361 cells were treated with different dosages of 17-AAG and lysates were
collected after 9 hours of treatment. Cells were harvested using RIPA Buffer and ECD expression
was determined by western blotting using anti-ECD, anti-ERBB2, and anti-β-ACTIN (as loading
control).
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Figure 3.12: BT474 ERBB2+ breast cancer cell line treated with 17-AAG lead to downregulation
of ECD and members of the R2TP complex
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Figure 3.12: BT474 ERBB2+ breast cancer cell line treated with 17-AAG leads to
downregulation of ECD and members of the R2TP complex. A) BT474 were treated with
100nm of 17-AAG and lysates were collected after 9 hours of treatment. Cells were harvested
using RIPA Buffer and ECD expression was determined by western blotting using anti-ECD, antiERBB2, anti-PIH1D1, and anti-β-ACTIN (as loading control). B-D) Quantitative density analysis of
B) phospho-ERBB2, C) ECD, and D) PIH1D1 was normalized to β-ACTIN. Densitometry performed
using ImageJ.
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Figure 3.13: ERBB2+ cell lines treated with 17-AAG leads to downregulation of ECD and
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Figure 3.13: ERBB2+ cell lines treated with 17-AAG leads to downregulation of ECD and
members of the R2TP complex. A) BT474 were treated with 100nm of 17-AAG and lysates were
collected after 9 hours of treatment. B) 21MT2 cells were treated with different dosages of 17AAG and lysates were collected after 9 hours of treatment. Cells were harvested using RIPA
Buffer and ECD expression was determined by western blotting using anti-ECD, anti-ERBB2, antiHSP90, anti-RUBVL1, and anti-β-ACTIN (as loading control). C-D) Quantitative density analysis of
ECD, RUVBL1, and HSP90 was normalized to β-ACTIN. Densitometry performed using ImageJ.
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3.3 Role of ECD in downstream ErbB2 Signaling Pathway
In Chapter 2, we observed that siRNA mediated knock down of ECD caused down regulation
of downstream components of ERBB2 signaling pathway. In order to assess the role ECD may be
playing in different signaling pathways, we used a panel of inhibitors against specific kinases and
observed if ECD levels were altered. We first looked at the effect Rapamycin, an mTOR inhibitor
in ERBB2+ breast cancer cell lines. Mammalian target of rapamycin (mTOR) is a member of the
phosphoinositide-kinase-related kinase (PIKK) family, and is a master regulator of cellular
growth and proliferation (Bjornsti & Houghton, 2004; Hay & Sonenberg, 2004). Two
downstream effectors of mTOR that regulates protein synthesis by phosphorylation and
inactivation of the repressor of mRNA translation, eukaryotic initiation factor 4E-binding protein
(4E-BP1), and through the phosphorylation and activation of S6 kinase (S6K1) (Hay & Sonenberg,
2004). The mTOR kinase also responds to environmental stimuli and nutrient conditions which
help the kinase to regulate several cellular processes such as protein turnover, transcription,
actin cytoskeleton organization, repress autophagy, and initiate translation (Bjornsti &
Houghton, 2004). mTOR signaling is regulated by growth factors, amino acids, ATP and oxygen
levels, and possibly by mitochondrial stress. Two of the upstream effectors of mTOR are the
P13K/AKT kinases, which are downstream of the ERBB family of receptors (Hay & Sonenberg,
2004). Since mTOR is involved in a number of cellular processes and since it is deregulated in
cancer, it began to gain interest as a cancer therapy target. Rapamycin, which is an mTORC1
and mTORC2 inhibitor, is a macrolide antibiotic that was first discovered to be a potent
immunosuppressive (Bjornsti & Houghton, 2004; Pohanka, 2001; Saunders, Metcalfe, &
Nicholson, 2001). Developing Rapamycin for a cancer therapy has been slow due to fears about
formulation and stability of these inhibitors in patients. The mechanism of action for Rapamycin
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is that the inhibitor first binds to immunophilin FK506-binding protein (FKBP12) and together,
the complex inhibits the autophosphorylation of mTOR (Bjornsti & Houghton, 2004). Since
mTOR is downstream of the ERBB receptor tyrosine kinases, I wanted to determine the effect
Rapamycin had on ECD levels as well as levels for the R2TP complex. As shown in Figure 3.14,
treatment of ERBB2+ cell lines with different dosages of Rapamycin for 72 hours caused
downregulation of ECD and the R2TP components. The R2TP complex is involved in the stability
of mTOR and other family members of the PIKK family (Horejsí et al., 2010). This data indicates
that the R2TP complex perhaps in conjunction with ECD become destabilized when mTOR is
inhibited.
An immediate downstream signaling pathway that is activated by ERBB2 is the P13K/AKT
pathway. The phosphatidylinositol 3 –kinase (PI3K)-Akt signaling pathway is activated by
receptors with protein tyrosine kinase activity and by G protein-coupled receptors. Once PI3K is
activated it converts the plasma membrane lipid PI (4,5)P2 to PI(3,4,5)P3 (Osaki, Oshimura, &
Ito, 2004). AKT is a serine/ threonine kinase that preferentially binds PI (3, 4, and 5) P3 over
other PIs. Once PI (3, 4, and 5) P3 is produced by PI3K, it begins to accumulate at the plasma
membrane. AKT then translocates to the plasma membrane and binds to the phospholipids.
Once bound to PI(3,4,5)P3, AKT undergoes a conformational change to expose its two
phosphorylation sites and allows it to be phosphorylated (Osaki et al., 2004). The P13K/AKT
pathway regulates fundamental cellular functions such as transcription, translation,
proliferation, growth, and survival (Osaki et al., 2004). This pathway is also highly deregulated in
cancer through over-activation. PI3K/AKT leads to the activation of a number of signaling
cascades that lead to cell growth, proliferation, survival, and motility that is necessary to drive
tumor progression (Vivanco & Sawyers, 2002). By understanding molecules that affect the levels
of P13K or AKT in cells will help in the development of novel chemotherapy agents that will be

112
effective in combating these cancers. In order to understand the role of ECD in this pathway, I
treated two ERBB2+ breast cancer cell lines with MK-2206 HCl. MK-2206 HCl is an AKT 1, AKT 2,
and AKT 3 inhibitor. As shown in Figure 3.15, upon treatment of MK-2206 HCl, ECD levels were
downregulated. The effect seemed more dramatic in BT474 cells which are ER+/ERBB2+ as
compared to SKBR3 cells which are ER-/ERBB2+. This may be caused by the expression of ER in
these cells, but this hypothesis needs to be explored at a later time.

3.4 Potential Role of ECD in Different Subtypes of Breast of Cancer
Our laboratory has shown that ECD is overexpressed in ERBB2+ tumors and this
overexpression is correlated with ERBB2 overexpression (X. Zhao et al., 2012). HSP90 has also
been shown to be overexpressed in breast cancers and this overexpression is correlated with
poor survival outcome (Pick et al., 2007). Recent studies have shown that the R2TP
components, and TEL2 which is a known adapter protein in the complex, are overexpressed in
breast and colon cancer patient samples (S. G. Kim et al., 2013). However, no one has shown if
overexpression of ECD and the four R2TP components correlate with one another in different
breast cancer subtypes. Therefore, I collaborated with another graduate student, Kristin
Wipfler, in the bioinformatics laboratory of Dr. Babu Guda to observe the levels of ECD and the
R2TP complex are overexpressed in similar breast cancer subtypes. In order to achieve this she
first downloaded RNASeqV2 mRNA expression data from the Cancer Genome Atlas (TCGA) for
712 breast invasive carcinoma patients. The sequencing to generate this data was performed
with the Illumina HiSeq 2000 platform and was analyzed with the version 2 pipeline, which uses
MapSplice for the alignment and RSEM for quantitation. She then divided the samples into ER+,
HER2+, ER+/HER2+, and triple negative subtypes. The expression data was then filtered to
examine six genes, ECD, RUVBL1, RUVBL2, PIH1D1, RPAP3, and TELO2. Table 3.1 is a compilation
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Figure 3.14: ERBB2+ cell lines treated with Rapamycin causes downregulation of ECD and
members of the R2TP complex.
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Figure 3.14: ERBB2+ cell lines treated with Rapamycin causes downregulation of ECD and
members of the R2TP complex. A-B) SKBR3 and BT474 cells were treated with different
dosages of Rapamycin and lysates were collected after 72 hours of treatment. Cells were
harvested using RIPA Buffer and ECD expression was determined by western blotting using antiECD, anti-phospho-mTOR, anti-PIH1D1, anti-RUBVL1, anti-RUVBL2, anti-RPAP3, and anti-βACTIN (as loading control).
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Figure 3.15: ERBB2+ cell lines treated with MK-2206 HCl causes downregulation of ECD.

A

B
SKBR3

BT474

MK-2206 HCl
(72Hours)

P-AKT
ECD
β-ACTIN

Figure 3.15: ERBB2+ cell lines treated with MK-2206 HCl causes downregulation of ECD. A-B)
SKBR3 and BT474 cells were treated with different dosages of MK-2206 HCl and lysates were
collected after 72 hours of treatment. Cells were harvested using RIPA Buffer and ECD
expression was determined by western blotting using anti-ECD, anti-phosphorylated AKT, and
anti-β-ACTIN (as loading control).
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of the summary results that are common for each group among the six genes. Kristin then
performed ANOVA tests comparing the expression between the four subtypes for each of the six
genes: ECD (Table 3.2), RUVBL1 (Table 3.4), RUVBL2 (Table 3.6), PIH1D1 (Table 3.7), RPAP3
(Table 3.9), and TELO2 (Table 3.11). Five of the ANOVA tests were significant, indicating that at
least one of the four groups was significantly different from the others for five of the six genes.
For the five genes with significant ANOVA results, she then performed student's t-tests for each
possible combination of subtypes to identify which subtypes had significantly different
expression levels from the others (ECD (Table 3.3), RUVBL1 (Table 3.5), PIH1D1 (Table 3.8),
RPAP3 (Table 3.10), and TELO2 (Table 3.12)). Remarkably, ECD, RUVBL1, PIH1D1, RPAP3, and
TELO2 all have the same two groups of subtypes where there is a significant difference between
the groups. One group is a comparison between ER+ and Triple Negative subtypes and the
second group is ER+/HER2+ and Triple Negative. By observing the Transcripts per million (TPM)
number on the charts, we are able to determine if there are more transcripts or less transcripts
in one subtype compared to the other. We can also add or subtract the variance to see the
range of transcript differences between the subtypes. There are also other subtype groups that
are significant between each of the six genes that we looked at, but the ones highlighted above
are trending patterns for all genes. This data indicates that there may be a correlation of ECD
mRNA expression and the four R2TP components mRNA expression in different subtypes of
breast cancer. This data is very interesting and needs to be explored further.

3.5 Role of ECD in Endoplasmic Reticulum Stress Pathway
Recently, another graduate student in my mentor’s laboratory has shown that ECD may be
a key regulator in the ER stress pathway through its interaction with PERK. ER stress is a
stimulus; such as hypoxia, nutrient deprivation, or misfolded proteins; for the cell to initiate a
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Table 3.1: Summary of experimental results for TCGA samples for ECD, TEL2, and R2TP
components.

Transcripts per

3.32147E-05

2.84927E-10

2.50368E-10

29.09105854

31.13821112

33.21466841

Variance

435

3.11382E-05

1.83211E-10

25.48980237

Average

ER+

121

2.90911 E-05

1.27466E-10

Count

ER+/HER2+

40

2.54898E-05

Groups

HER2+

116

Million (TPM)

ER-/PR-/HER2-
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Table 3.1: Summary of experimental results for TCGA samples for ECD, TEL2, and R2TP
components. MRNA expression data from different breast cancer patients was collected from
The Cancer Genome Atlas. The patient samples were separated based on molecularly classified
subtypes, such as ER+, HER2+, ER+/HER2+, and ER-/PR-/HER2- (triple negative). Each patient
sample in each subtype was then filtered for six genes: A) ECD, B) RUVBL1, C) RUVBL2, D)
PIH1D1, E) RPAP3, and F) TELO2. The summary data includes the counts (the number of patient
samples taken from each group), the averages, the variances, and transcripts per million.
 This work and statistical analysis was performed by Kristin Wipfler, B.S. from Dr. Babu
Guda laboratory, in collaboration with myself.
 The dataset was provided by ©The Cancer Genome Atlas
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Table 3.2: An ANOVA test was then performed on each gene, starting with ECD, between each
subtype group to determine if there was any significant change in mRNA expression for ECD.

Source of
Variation

SS

df

MS

F

P-Value

Significance

Between
groups

5.70536E09

3

1.90179E09

8.177497092

2.34214E05

YES

Within
Groups

1.64655E07

708

2.32563E10

Table 3.3: Student T-Test was then performed for each gene between each subtype to
determine if there was a significant change in mRNA expression for ECD.
GROUP1 compared to GROUP
2

P-Value

Significance

ER+ To ER+/HER2+

0.208863782441418

NO

ER+ To HER2+

0.111370684530581

NO

ER+ To ER-/PR-/HER2-

0.0000010779541448405

YES

ER+/HER2+ to HER2+

0.487362470329568

NO

ER+/HER2+ to ER-/PR-/HER2-

0.00285254895147712

YES

HER2+ to ER-/PR-/HER2-

0.100855856548926

NO
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Table 3.4: An ANOVA test was then performed on each gene between each subtype group to
determine if there was any significant change in mRNA expression for RUVBL1.
Source of
Variation

SS

df

MS

F

P-Value

Significance

Between
groups

2.40731456
553593E-08

3

8.024381
88511978
E-09

11.041378
4479648

4.319641727811
68E-07

YES

Within
Groups

5.14542853
633642E-07

708

7.267554
4298537E
-10

Table 3.5: Student T-Test was then performed for each gene between each subtype to
determine if there was a significant change in mRNA expression for RUVBL1.
GROUP1 compared to GROUP 2

P-Value

Significance

ER+ To ER+/HER2+

0.151587657479842

NO

ER+ To HER2+

0.966167060065643

NO

ER+ To ER-/PR-/HER2-

3.41243885161866E-08

YES

ER+/HER2+ to HER2+

0.415493285299253

NO

ER+/HER2+ to ER-/PR-/HER2-

0.00265785411576765

YES

HER2+ to ER-/PR-/HER2-

0.0119944935269851

YES
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Table 3.6: An ANOVA test was then performed on each gene between each subtype group to
determine if there was any significant change in mRNA expression for RUVBL2.

Source of
Variation

SS

df

MS

F

P-Value

Between
groups

Significance

YES

8.08644E-09

3

1.28485E-06

708

2.69548E-09 1.485313521 0.217238877

Within
Groups
1.81475E-09
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Table 3.7: An ANOVA test was then performed on each gene between each subtype group to
determine if there was any significant change in mRNA expression for PIH1D1.
Source of
Variation

SS

df

Between
groups
2.41692E-08

3

6.78152E-07

708

MS

F

P-Value

1.69093E8.05642E-09 8.411006568
05

Significance

YES

Within
Groups
9.57842E-10

Table 3.8: Student T-Test was then performed for each gene between each subtype to
determine if there was a significant change in mRNA expression for PIH1D1.
GROUP1 compared to GROUP
2

P-Value

Significance

ER+ To ER+/HER2+

0.016332892251614

YES

ER+ To HER2+

0.165896496198448

NO

ER+ To ER-/PR-/HER2-

0.0000114492940005427

YES

ER+/HER2+ to HER2+

0.0997459616333197

NO

ER+/HER2+ to ER-/PR-/HER2-

0.000189602787837004

YES

HER2+ to ER-/PR-/HER2-

0.209932151716371

NO
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Table 3.9: An ANOVA test was then performed on each gene between each subtype group to
determine if there was any significant change in mRNA expression for RPAP3.
Source of
Variation

SS

df

MS

F

P-Value

Between
groups

Significance

YES

1.28564E-09 3

4.28548E-10

3.31193E-08 708

4.67786E-11

9.161193948 5.93721E-06

Within
Groups

Table 3.10: Student T-Test was then performed for each gene between each subtype to
determine if there was a significant change in mRNA expression for RPAP3.
GROUP1 compared to GROUP
2

P-Value

Significance

ER+ To ER+/HER2+

0.336966676998174

NO

ER+ To HER2+

0.0192161582183761

YES

ER+ To ER-/PR-/HER2-

0.0000116854768042364

YES

ER+/HER2+ to HER2+

0.0080458484175475

YES

ER+/HER2+ to ER-/PR-/HER2-

0.0000147519103811155

YES

HER2+ to ER-/PR-/HER2-

0.699636362488147

NO
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Table 3.11: An ANOVA test was then performed on each gene between each subtype group to
determine if there was any significant change in mRNA expression for TEL02.
Source of
Variation

SS

df

MS

F

P-Value

Significance

Between
groups

YES

3.54096E-09

3

9.13838E-08

708

6.07634E1.18032E-09 9.144590003
06

Within
Groups
1.29073E-10

Table 3.12: Student T-Test was then performed for each gene between each subtype to
determine if there was a significant change in mRNA expression for TEL02.
GROUP1 compared to GROUP
2

P-Value

Significance

ER+ To ER+/HER2+

0.946889582010066

NO

ER+ To HER2+

0.0000315307342747369

YES

ER+ To ER-/PR-/HER2-

0.000991791813725305

YES

ER+/HER2+ to HER2+

0.000172951485415618

YES

ER+/HER2+ to ER-/PR-/HER2-

0.00518486999426572

NO

HER2+ to ER-/PR-/HER2-

0.0063119727470464

YES
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Table 3.1-3.12: mRNA expression data from different breast cancer patients was collected from
The Cancer Genome Atlas. The patient samples were separated based on molecularly classified
subtypes, such as ER+, HER2+, ER+/HER2+, and ER-/PR-/HER2- (triple negative). Each patient
sample in each subtype was then filtered for six genes: A) ECD, B) RUVBL1, C) RUVBL2, D)
PIH1D1, E) RPAP3, and F) TELO2. An ANOVA test was then performed on each gene between
each subtype group to determine if there was any significant change in mRNA expression. Upon
a significant change in the p-value from the ANOVA test, a student T-Test was then performed
for each gene between each subtype to determine if there was a significant change in mRNA
expression.
 This work and statistical analysis was performed by Kristin Wipfler, B.S. from Dr. Babu
Guda laboratory in collaboration with myself.
 The dataset was provided by ©The Cancer Genome Atlas
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defensive process called the unfolded protein response (UPR). UPR is comprised of several
cellular mechanisms that are aimed to either assist in cellular survival, or in cases of extreme
stress, initiate mechanisms of cell death such as autophagy or apoptosis (Ma & Hendershot,
2001; Welihinda et al., 1999). The UPR involves three stress sensors: activating transcription
factor 6 (ATF6), PKR-like ER kinase (PERK) and inositol-requiring kinase 1 alpha (IRE1α), that are
kept in an inactive state through their interaction ER chaperone GRP78 (also known as Bip)
(Walter & Ron, 2011). Misfolded proteins accumulate in the ER lumen during ER stress, and then
these proteins bind to GRP78. This interaction promotes the ER-Golgi transport of ATF6, where
its cleavage releases the transcription factor domain for translocation to the nucleus to induce
the transcription of specific genes, such as GRP78, to promote ER protein folding (Walter & Ron,
2011; Welihinda et al., 1999). Then PERK is activated by phosphorylation and this in turn
inactivates the eukaryotic initiation factor 2 alpha (eIF2α). The inactivation of eIF2α causes a
repression in general protein synthesis in order to decrease the amount of proteins entering the
ER lumen while selectively inducing the translation of specific mRNAs such as ATF4. ATF4
induces the expression of CCAAT/enhancer-binding protein-homologous protein (CHOP) (Walter
& Ron, 2011). The multiple arms of UPR mediate a coordinated program of cellular protection
and mitigation of stress and under some conditions such as prolonged ER stress, promotes
apoptosis downstream of UPR (Ma & Hendershot, 2001; Walter & Ron, 2011; Welihinda et al.,
1999).
Cancer tumors exhibit increased ER stress with activation of UPR pathways and cause different
cellular responses to help survive harsh environments. The responses to ER stress includes
suppression of new protein synthesis, exit from cell cycle and apoptosis, processes that are not
pro-oncogenic (Lee & Hendershot, 2006; Moenner, Pluquet, Bouchecareilh, & Chevet, 2007).
Cancer cells must enact adaptive mechanisms to eliminate the inhibitory outcomes of the UPR
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while in turn rely on the pathway’s protective aspects, such as increased antioxidant defenses
and increased anti-apoptotic and autophagic mechanisms (Moenner et al., 2007). Current
experiments in the lab have shown that ECD levels are downregulated in HMECs upon treatment
of different endoplasmic reticulum stress inducing compounds, such as Thapsigargin and
Tunicamycin. I have performed a proximity ligation assay where I observed ECD interaction with
several UPR pathway components, including PERK, GRP78, and ATF6 (Figure 3.16 and Figure
3.17). These results indicate that ECD is an important regulator of UPR. Interestingly, in PERK
knockout mouse embryonic fibroblast (MEFs) that are treated with ER stress inducers, ECD
levels remain unchanged. This observation is indicates that ECD may play a role as a negative
regulator of stress.
Since the UPR pathway is dysregulated in cancer, we wanted to observe how an ER stress
inducer, Bortezomib, effects ECD levels in ERBB2+ breast cancer cell lines. Bortezomib (PS-341,
Velcade), is a potent proteasome inhibitor (Nawrocki, Carew, Dunner, et al., 2005; Nawrocki,
Carew, Pino, et al., 2005). The proteasome is an organelle that is responsible the degradation
for most proteins within the cell. Bortezomib is a proteasome inhibitor that induces ER stress by
preventing the passage of misfolded proteins from the ER (Nawrocki, Carew, Dunner, et al.,
2005). Bortezomib is also currently in clinical trials as a chemotherapy agent that targets solid
tumors (Nawrocki, Carew, Dunner, et al., 2005; Nawrocki, Carew, Pino, et al., 2005).
Remarkably, when BT474 and SKBR3; two ERBB2+ breast cancer cell lines; ECD levels are
upregulated in a time dependent manner (Figure 3.18). Our laboratory has shown that ECD is
degraded through the proteasome, but we have not been able to show a compound that
increases ECD levels in vitro. Combinational treatment of cells with Bortezomib and other ER
stress inducers could possible elucidate the role ECD is playing in ER Stress.
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Figure 3.16: Proximity Ligation Assay depicting Interaction between ECD and ER Stress
Components.
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Figure 3.16: Proximity Ligation Assay depicting Interaction between ECD and ER Stress
Components (continued).
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Figure 3.16: Proximity Ligation Assay depicting Interaction between ECD and ER Stress
Components. MCF10A cells were plated on 18mm coverslips and were fixed in 3%
paraformaldehyde. Cells were then blocked in blocking buffer for 30 minutes and incubated
with primary antibody for 2 hours. Coverslips were then incubated in mouse (minus probe) and
rabbit (plus probe) probes for one hour, and then ligated for 30 minutes, then probes
underwent amplification using a red fluorescent dye to indicate interactions for 2 hours.
Controls were ECD and PIH1D1 as positive control; ECD and ADA3 interaction, IgG, and single
antibody controls as negative controls. Quantification of proximity signals was completed using
Duolink Image Tool Software. Analysis of >50 cells per interaction. These figures and graph are
representative images of three independent experiments. Scale bars represent 10μm.
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Figure 3.17: Proximity Ligation Assay depicting Interaction between ECD and ER Stress
Component ATF6.
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Figure 3.17: Proximity Ligation Assay depicting Interaction between ECD and ER Stress
Component ATF6.

SKBR3 cells were plated on 18mm coverslips and were fixed in 3%

paraformaldehyde. Cells were then blocked in blocking buffer for 30 minutes and incubated
with primary antibody for 2 hours. Coverslips were then incubated in mouse (minus probe) and
rabbit (plus probe) probes for one hour, then ligated for 30 minutes, then probes underwent
amplification using a red fluorescent dye to indicate interactions for 2 hours. Control was ATF6
alone as negative controls.
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Figure 3.18: ERBB2+ cell lines treated with Bortezomib causes upregulation of ECD.
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Figure 3.18: ERBB2+ cell lines treated with Bortezomib causes upregulation of ECD. A-B) BT474
and SKBR3 cells were treated with 1μM of Bortezomib and lysates were collected at different
time points. Cells were harvested using RIPA Buffer and ECD expression was determined by
western blotting using anti-ECD and anti-β-ACTIN (as loading control). C-D) Quantitative density
analysis of ECD was normalized to β-ACTIN. Densitometry performed using ImageJ.
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3.6 ECD potential role as a therapy target in cervical cancer
Previously, we have shown that ECD is overexpressed in breast cancer and in pancreatic
cancer (Dey et al., 2012; X. Zhao et al., 2012). Dr. Band’s laboratory also identified that ECD is an

HPV 16 E6 binding protein. Therefore, we wanted to examine the expression in HPV
positive cancers such as cervical cancer. Cervical cancer is a malignant neoplasm arising
from the uterine cervix. About 80% of all cervical cancers are of the squamous subtype;
and the remainder are either areadenocarcinomas, adenosquamous carcinomas, or other
rare types (Waggoner, 2003). Two laboratory members in Dr. Band’s lab, Dr. Aditya
Bele and Dr. Sameer Mirza, have shown that ECD is overexpressed in both squamous
cell carcinoma as well as adenocarcinoma of cervix and that ECD knockdown in cervical
cancer cell lines leads to decrease in invasion and migration (Bele, 2015). After these
results, I wanted to test how a chemotherapy agent that has already been proven to cause
down regulation of ECD affected two cervical cancer cell lines. Hela and Siha cells that
are both HPV E6 positive, were treated with different dosages of 17-AAG. As shown in
Figure 3.19, treatment of 17-AAG causes down regulation of ECD in cervical cancer cell
lines. These observations suggest that ECD overexpression is specifically linked to
certain oncogenes and that ECD may be part of an unknown pathway that is critical for
cellular functions. This makes ECD an excellent therapy target which can be applicable
for a wide variety of cancers.
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Figure 3.19: Cervical cancer cell lines treated with 17-AAG causes
downregulation of ECD in a dose dependent and time dependent manner.
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Figure 3.19: Cervical cancer cell lines treated with 17-AAG causes downregulation of
ECD in a dose dependent and time dependent manner. A-B) Hela and Siha cells were
treated with different dosages of 17-AAG and lysates were collected after 9 hours of
treatment. Cells were harvested using RIPA Buffer and ECD expression was determined
by western blotting using anti-ECD, anti-ERBB2, and anti-β-ACTIN (as loading control).
C-D) Quantitative density analyses of ECD and ERBB2 were normalized to β-ACTIN.
Densitometry performed using ImageJ. E-F) Hela and Siha cells were treated with 100
nm of 17-AAG and lysates were collected after different time points indicated. Cells were
harvested using RIPA Buffer and ECD expression was determined by western blotting
using anti-ECD, anti-ERBB2, and anti-β-ACTIN (as loading control). G-H) Quantitative
density analyses of ECD and ERBB2 were normalized to β-ACTIN. Densitometry
performed using ImageJ.
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Summary and Conclusions
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Breast cancer is a heterogeneous disease that has been responsible for the deaths of
over two hundred thousand women in the past year in the United States (Siegel et al., 2015).
There are six subtypes of breast cancer that is categorized based on the gene expression profile
and the molecular properties of the tumor (Prat et al., 2010, 2014; Sorlie et al., 2003). Cancer
patients with overexpressing ERBB2 have a poorer overall survival rate compared to patients
that overexpress the Estrogen Receptor and/or the Progesterone Receptor (Prat et al., 2014;
Sorlie et al., 2003). ERBB2 is a member of the ERBB family of tyrosine kinase receptors are
involved in multiple cellular pathways and have a number of downstream targets (Hynes &
MacDonald, 2009). Since ERBB2 has the ability to homodimerize with itself and heterodimerize
with other receptor family members, the signaling potential increases exponentially in cancers
where ErbB2 is overexpressed (Bertucci et al., 2004; Hynes & MacDonald, 2009; Onitilo et al.,
2009). Current therapy utilizes the monoclonal antibody Trastuzumab, which specifically targets
and inhibits the signaling of the ErbB2 receptor (Hudis, 2007; Prat et al., 2014; Yarden &
Sliwkowski, 2001). In some ErbB2 positive breast cancer patients, there is a chance of relapse
and metastasis. These patients usually develop acquired resistance to Trastuzumab as well, but
the mechanism behind this is not yet fully understood (Nahta & Esteva, 2006; Vu & Claret,
2012). There is a strong need to find novel chemotherapy targets that cause downregulation of
ERBB2 in resistant patients.
Our laboratory has previously shown that ECD is an essential regulator of cell cycle
progression through its function as a regulator of the RB-E2F interaction (J. H. Kim et al., 2009).
We have also previously shown that ECD interacts with p53 and regulates its expression (Zhang,
2006). We have also shown that complete knockout of ECD leads to embryonic lethality in mice
and deletion of ECD in ECDflox/flox mouse embryonic fibroblast causes G1/S cell cycle arrest; but
exogenous expression of ECD has the ability to rescue this phenotype (J. H. Kim et al., 2009).
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Our laboratory has also shown that ECD is overexpressed in breast cancer and this
overexpression is correlated with ERBB2 overexpression.

We have also shown that

overexpression of ECD and ERBB2 is correlated with a poor overall survival outcome (X. Zhao et
al., 2012).
In my thesis, I wanted to explore the relationship between ERBB2 and ECD in vitro and
uncover the mechanism of how ECD is working in these cells. First, we (a joint collaboration
between myself and Dr. Sameer Mirza) performed immunoprecipitation and proximity ligation
assays to determine the interaction between ECD and ERBB2. We were able to see some
interaction, but we hypothesized that perhaps this is not a direct interaction and ECD may be
interacting with ERBB2 through another protein interaction. Therefore, we decided to use this
assays to assess ECD and HSP90 interaction and we were able to see a more direct interaction
(Chapter 2). This result allowed us to conclude that ECD and ERBB2 have a proximity interaction
that is mediated through both proteins interaction to HSP90. Interestingly, we have observed
that exogenous overexpression of ERBB2 in HMECs leads to protein overexpression of ECD
(Chapter 3). This indicates that cells with ERBB2 overexpression require higher levels of ECD,
perhaps to help stabilize these receptors.

In order to test this, we downregulated ECD

expression by siRNA in ERBB2+ breast cancer cells and we saw that ERBB2 levels were
decreased. We also observed that ECD knockdown downregulates some downstream effectors
of ERBB2 signaling (Chapter 2). ECD is assisting in the stabilization of ERBB2 and downregulation
of ECD causes a decrease in ERBB2, AKT, and ERK levels. ECD downregulation decreases the
surface level of ERBB2 on ERBB2+ breast cancer cells and this downregulation leads to increase
of ubiquitination of ERBB2. Interesting, we have also seen that downregulation of ECD leads to
decrease in the number of interactions between ERBB2 and HSP90 (Chapter 2) possibly leading
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to the destabilization of ERBB2. All of these results validate the potential of Ecd as a novel
molecular therapy target in ErbB2 positive breast cancer.
Recently, it was discovered that ECD is a substrate of a protein called, PIH1D1 which is
one of the members of a co-chaperone protein complex named R2TP (Hořejší et al., 2014). The
R2TP complex is comprised of four molecular components: two AAA+ ATPases RUVBL1 and
RUVBL2, an adaptor protein PIH1D1, and an HSP90 interacting protein RPAP3 (Boulon et al.,
2012).

We have shown that outside of ECD interaction with PIH1D1,

interaction with RUVBL1 and this interaction is critical for

ECD has a novel

ECD’s function in cell cycle

progression (Mir et al., 2015). In my thesis, I have shown that ECD is in close proximity of all
four of the components in the R2TP complex (Chapter 1). Chaperone complexes, particularly
Hsp90 and the R2TP/ Prefoldin-like, have been exciting new topics of research due to promising
evidence of their involvement in number of molecular pathways. Hsp90 directly stabilizes ErbB2
and protects the receptors from proteasomal degradation (Maloney & Workman, 2002; W. Xu
et al., 2005). Hsp90 also works in tandem with the R2TP/Prefoldin-like complex in stabilizing
PIKKs, ribosome biogenesis, mRNA transcription, tRNA transcription, and translation (Boulon et
al., 2010, 2012; Horejsí et al., 2010; Kakihara & Houry, 2012; Prieto et al., 2015; Yoshida et al.,
2013). In breast cancer samples, Hsp90 and the components of the R2TP/Prefoldin-like complex
have been shown to be overexpressed (S. G. Kim et al., 2013; Maloney & Workman, 2002). To
date, the field of determining the mechanisms chaperone complexes is involved in and
discovering adaptor proteins that are facilitating these interactions and mechanisms, is still
relatively new. In my research I have shown direct correlations between ERBB2 and the R2TP
complex in cells (Chapter 3) and in the future, it would be beneficial to explore the mechanism
this complex is playing in ERBB2+ breast cancer.
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In order to explore how ERBB2 affects levels of HSP90, ECD, and R2TP complex, I used
three different chemotherapy drugs that target ERBB2 to see their effect on ECD and the R2TP
complex. I used Trastuzumab; a humanized monoclonal antibody against ERBB2; Lapatinib; a
dual intracellular tyrosine kinase inhibitor that blocks the downstream signaling pathway of
ERBB2 and EGFR; and 17-AAG. 17-AAG is a small molecule inhibitor that binds to the ATPase
activity domain of the Hsp90 dimeric protein, inhibiting its ATP activity. This mechanism of
action causes the rapid degradation of ErbB2 (Maloney & Workman, 2002; Modi et al., 2011;
Sausville et al., 2003). Each of these drugs has their own drawbacks that have made the need to
discover new molecular therapy targets critical for scientist. Trastuzumab and Lapatinib, both
have had patients whose tumor cells have acquired resistance against these agents (D’Amato et
al., 2015; Nahta & Esteva, 2006). Resistance is becoming a major problem for clinicians and
patients. Scientists have been working on elucidating the mechanisms of resistance but it has
still been a work in progress. 17-AAG has been shown to be more promising than its
predecessor; Geldanamycin; some clinicians fear the potential of hepatotoxicity (Workman et
al., 2007). Geldanamycin proved to be highly toxic and caused hepatotoxicity, and although 17AAG has been shown to be less toxic, there is still a possibility that this drug will not be suitable
for some patients (Whitesell & Lindquist, 2005; Workman et al., 2007). Therefore is an
increasing the need for other molecular therapy targets that cause less toxicity to patients. By
elucidating the mechanisms of resistance and toxicity, we would be able to develop novel
chemotherapeutic targets that will be effective in cancer patients and with fewer side effects.
In Chapter 3, I have shown that ECD and R2TP complex members are down regulated in
ERBB2+ cell lines upon treatment of Trastuzumab, Lapatinib, and 17-AAG (Chapter 3).
Interestingly, there is no effect on HSP90 levels, in resistant cell lines, and in non-ERBB2+ cell
lines. When ERBB2+ cell lines are treated with phosphorylate AKT inhibitor and mTOR kinase
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inhibitor, leads to downregulation in ECD and the four members of the R2TP complex (Chapter
3). Taken together, we can infer that ECD, along with the R2TP complex, may be working
downstream of these signaling pathways and that destabilization of these kinases leads to
destabilization of ECD and this complex. When we downregulated ECD, we did not see any
change in members of the R2TP complex. We did observe downregulation of ERBB2 and AKT,
indicating that ECD may be part of a feedback loop with these kinases that help stabilize one
another. In Chapter 3, in collaboration with another graduate student Kristin Wipfler, showed
using data obtained from The Cancer Genome Network, that ECD and members of the R2TP
complex have mRNA expression that correlates with one another in different subtypes of breast
cancer. This will need to be explored further to see if these components are upregulated or
downregulated in these subtypes of breast cancer. ECD, HSP90, and the R2TP complex are
involved in multiple cellular processes and assist in the stabilization and assembly of a number
of proteins and protein complexes. The data collected indicates that ECD is playing an
important role in the stabilization of ERBB2, but ERBB2 is also playing an important role in
stabilizing ECD and the R2TP complex. By understanding the role ECD and the R2TP complex is
playing in ERBB2+ breast cancers, can help provide scientists with new potential therapy targets
that are not just effective in breast cancer, but in other ERBB2+ cancers such as ovarian. I have
shown that ECD is also in close proximity to a number of ER stress markers. ER stress is a
defensive process cells undergo when they are exposed to a stimulus; such as hypoxia, nutrient
deprivation, or misfolded proteins (Welihinda et al., 1999). Cancer tumors exhibit increased ER
stress with activation of UPR pathways and cause different cellular responses to help survive
harsh environments. ECD seems to be a novel regulator of ER stress and could potentially be a
novel therapy target.
CONCLUSIONS:
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ECD is overexpressed in a number of cancers including breast and prostate.



ECD interacts directly or is in close proximity with the four members of the R2TP
complex: RUVBL1, RUVBL2, PIH1D1, and RPAP3. Downregulation of ECD does not affect
levels of the R2TP complex.



ECD has a novel interaction with ERBB2/HER2 in breast cancer cells and this interaction
may be mediated through HSP90.



SiRNA mediated downregulation of ECD leads to downregulation of ERBB2 protein
levels, but not mRNA levels in endogenous ERBB2 overexpressing cell lines and
exogenous ERBB2 overexpressing cell lines.



ECD knockdown also leads to a decrease in levels of downstream signaling targets such
as AKT and phosphorylated ERK.



ECD knockdown reduces the surface levels of ERBB2 in ERBB2 positive cell lines.



ECD downregulation leads to destabilization of ERBB2 and increases the ubiquitination
of ERBB2.



ECD does not co-localize with ERBB2 in ERBB2+ cell lines, but exogenous overexpression
of ERBB2 in human immortalized mammary epithelial cells increases endogenous levels
of ECD protein but not ECD mRNA.



Different chemotherapy agents against ERBB2 receptor, such as Trastuzumab, Lapatinib,
and 17-AAG leads to downregulation of ECD, RUVBL1, RUVBL2, PIH1D1, and RPAP3.



Different inhibitors that target the ERBB2 signaling pathway, such as AKT and mTOR,
leads to downregulation of ECD, RUVBL1, RUVBL2, PIH1D1, and RPAP3.



ECD interacts or is in close proximity with several members of the UPR pathway, such as
PERK, ATF6, and GRP78
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Summary:

Breast cancer is the second most frequent type of cancer occurring in women in the
United States. Approximately 25-30% of breast cancer patients have overexpression of ErbB2,
which is associated with a poor prognosis. In 20-25% of ErbB2+ breast cancers, ErbB2
overexpression is caused by gene amplification of chromosome 17 regions q 12-21 and by
enhanced transcription. Therefore understanding the molecular mechanisms of transcriptional
regulation of erbb2 is a significant area of research. A number of transcription factors are
known to positively regulate erbb2 gene transcription, such as SRC-3 or ERRα that are discussed
in detail in this review article. These transcriptional factors themselves are overexpressed in
certain cases of breast cancers and are potential therapy targets. In addition a group of
transcription factors, such as PAX2 or FOXP3 negatively regulate erbb2 gene. This review will
present a comprehensive literature summary of transcriptional regulation of the erbb2 gene in
normal and cancer mammary cells followed by discussion on current views. Understanding the
transcriptional regulation of erbb2 may provide other therapy options for ErbB2+ breast cancer
patients in addition to Trastuzumab, particularly in Trastuzumab resistance cases of metastatic
disease.

Introduction:
Breast cancer is the second most prevalent cause of cancer related deaths in women in
the United States (1). Currently, based on expression profiling, breast cancer is categorized into
six molecular subtypes; luminal subtype A which is Estrogen Receptor (ER)/ Progesterone
Receptor (PR) positive and Epidermal Growth Factor Receptor 2 (ErbB2/HER2) negative, luminal
subtype B which is ER+/PR+ and ErbB2+, ErbB2+ positive , basal-like or triple negative which is
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ER-, PR-, and ErbB2-, claudin-low, and normal-like (2-5). Each subtype is classified according to
particular set of gene expression, as well as based upon the receptor expression profile (1 - 6).

The current knowledge on subtype of a breast cancer patient helps to determine the
prognosis, as well as the treatment options (2-7). Currently, Trastuzumab (Herceptin) is
a humanized monoclonal antibody that is most prevalently used for ErbB2+ subtype of
breast cancer patients, a portion of these patients may present with more aggressive
tumor and later develop resistance to the therapy (8).
ErbB2 is a member of the receptor tyrosine kinase superfamily and is involved in various
signaling transduction pathways (9, 10). The RTK members all have three regions, an
extracellular ligand-binding region, a single membrane-spanning region, and a cytoplasmic
tyrosine kinase containing domain. ERBB2 does not have a known ligand, but, like the other
receptors, can heterodimerize or homodimerize with other receptors to activate the intrinsic
tyrosine kinase domain. Once activated, ERBB2 can activate the PI3K-AKT and MAPK pathways
(10). Previous studies demonstrated ErbB2 is amplified in about 20-25% of breast cancers and
this amplification of chromosome 17 regions q12-21 leads to overexpression of the receptor
(11). Patients with ErbB2+ tumors have shown worse prognosis than patients with ER+/PR+
tumors (12). A more recent study of approximately 500 breast tumors conducted by The Cancer
Genome Atlas (TCGA) Network has shown the biological heterogeneity of clinical ErbB2overexpressing cancers (HER2+), as defined by gene amplification. This group further
characterized these cancers by gene expression into two subtypes, HER2-enriched (HER2E) and
luminal (13). HER2E and HER2+ tumors exhibited higher frequencies of aneuploidy, somatic
mutations, and TP53 mutation (13). These patients also exhibited genetic amplification of
FGFRs, EGFR, CDK4, and Cyclin D1. Luminal- ErbB2-overexpressing breast cancers displayed a
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higher expression of a luminal gene cluster which included GATA3, BCL2, and ESR1. Although,
not all tumors of the HER2-enriched gene expression subtype are erbb2 amplified, it is thought
that some breast cancers with a single copy of erbb2 gene harbor an expression signature of
ErbB2 dependence and may benefit from anti-ErbB2 therapy (13). ErbB2 overexpression in
tumors leads to enhanced proliferation and an increase in cell survival (14). ErbB2
overexpression, however, is not only caused by gene amplification, but also by an upregulation
of erbb2 transcription. Aaronson’s lab has shown that on the erbb2 promoter there is an
acquired H3K4me3 mark and in ErbB2 overexpressing tumors, shown an enrichment of this
mark. By using ErbB2 overexpressing and ErbB2 amplified cell lines and ChiP analyses, they
were able to show that in H3K9 is acetylated in ErbB2 amplified cells but not in Erbb2
overexpressing cells. This indicates that epigenetic changes that are acquired effect the
activation of ErbB2 transcription (15).
The erbb2 promoter was initially characterized by Ishii et al. and Tal et al. (16, 17) erbb2
gene transcription is controlled by at least two known promoters, the distal and the proximal
which are separated from one another by 12 kilo bases (kb) (16). Although the distal promoter
remains poorly defined, several regulatory elements have been characterized within the
proximal promoter and its 5’-flanking sequence up to the 6 kb upstream of the major
transcription start site (9, 11-13, 16; Fig. 1).
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Figure 1: A schematic representation of part of the proximal promoter of the ErbB2 gene spanning +1
base pairs to -2000 base pairs. The colored boxes represent the binding sites of the regulatory factors of
transcription discussed in this review. The ERE section represents the Estrogen Response Elements that is
sporadically spaced in the region of +1 base pairs to -500 base pairs. ERE is where SRC-3 and PAX2 bind
with ERα. EBS is the Ets Binding Site where Ets transcription factors bind.

Studies suggest that several associated trans-activators or trans-repressors are involved in the
increased transcription of the erbb2 gene in breast cancer cells. These factors include: the E26
transformation-specific ( ETS) transcription Factors (18-27), Activator Protein -2 (AP-2) (28-38),
Estrogen Related Receptor α (ERR α) (39-45), Y-Box binding protein-1 (YB-1) (46-51), Ying Yang 1
(YY1) (52-56), Specificity Protein 1 (Sp1) (19, 57-61), ERα with amplified in breast cancer-1 (SRC3/AIB-1)(35, 62-65), which all positively regulate erbb2 transcription. In addition several
negative regulators, such as ERα with paired box 2 gene product (PAX2)(14, 68-70), Myc
Promoter-Binding Protein Factor (MYB-1) with Histone Deacetylase 1 (HDAC1)(71-77), forkhead
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box P3 (FOXP3) (78-79), and GATA Binding Protein 4 (GATA4) (79-80) downregulate erbb2 gene
expression. These factors along with recruitment of co-activators or co-repressors successfully
turn on or off transcription of erbb2 gene, respectively. By understanding the components that
regulate erbb2 transcription could pave the way for novel therapeutic targets and prognostic
markers. Below we describe in details each factor that regulates erbb2 gene expression.

Transcriptional factors/coregulators that positively regulate ErbB2 transcription
ETS Family of Transcription Factors (ETS) proteins are a group of evolutionary related
Transcription factors that have a conserved 85 amino acid long DNA binding domain and they
regulate gene expression by binding to promoter and/or enhancer regions. ETS proteins are
involved in the transcriptional activation or repression of genes that are involved in cellular
processes such as proliferation, differentiation, development, transformation, and apoptosis
(23). ETS transcription factors are downstream components of the RAS-MAPK pathway (24). In
most ETS proteins there is a highly conserved regulator domain in the N-Terminal and a CTerminal DNA binding domain (19). In order to activate the transcription factor, a conserved
threonine residue in the regulatory domain is phosphorylated by MAPK (24). Once activated,
these proteins facilitate the assembly of transcriptional complexes (19, 24).These proteins also
play a critical role in the regulation of the transcription of receptor tyrosine kinases (18). There
is an ETS binding domain located in the proximal promoter region of erbb2 where an ETS
transcription factor can bind and upregulate the expression of ErbB2 (18). The ETS binding site
on the erbb2 promoter is located close to the TATA major start site and when an ETS
transcription factor is bound, it causes a severe bend in the DNA and creates a transcription
start site at -69bp (25).

177
An ETS transcription factor that plays an important role in erbb2 transcription and
tumorgenesis is Polyoma Enhancer Activator 3 (PEA3). PEA3 overexpression in seen in ErbB2+
tumors and was first observed by In situ hybridization in paraffin embedded tumor samples (20).
This overexpression correlated with ErbB2+ overexpression Immunoprecipitation studies
showed that PEA3 directly interacts with ErbB2 in cells when both are exogenously expressed
(20)
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Figure 2: This schematic depicts the ETS transcription factor, ER81, and its positive regulation

of the ErbB2 gene (18-27).
ETS transcription factors have been shown to be involved in a variety of cancers such as breast,
prostate, thyroid, and leukemia (21-23). In ErbB2 overexpressing breast cancers, ETS
transcription factors have been shown to be overexpressed and activated through
phosphorylation (24). Some ETS transcription factors, particularly ETS-1, Fli-1, ER81, and other
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family members, are overexpressed in breast cancer and are involved in invasion and metastasis
(21, 22). Some of these positive regulators such as, ER81 (as shown in Figure 2) are downstream
targets of the ErbB2 receptor tyrosine activity (18). ER81 interacts with the ETS binding site on
the erbb2/neu promoter and activates erbb2/neu transcription with help of co-activators like
p300 and CBP (18). This activity is enhanced by stimulation of MAPK pathways and by the
ErbB2/Neu protein itself. ErbB2 activates ER81 indirectly by modulating the activity of signaling
pathways that regulate ER81 phosphorylation (25, 26). Thus, ER81 forms a part of a positive
regulatory feedback mechanism where oncogenic ErbB2/Neu activates ER81, and ER81 along
with p300/CBP as well as activated MAPK pathway further enhances the erbb2/neu gene
expression (26). Also, ER81 regulates transcription of matrix metallo proteases like MMP-1
which may play a role in tumor metastasis (27).

Activator Protein-2 Family (AP-2) is composed of three highly homologous transcription
factor members, AP-2α, AP-2β, and AP-2γ. All three members can bind to the proximal
promoter, 218bp upstream of the major transcriptional start site, of the erbb2 gene and activate
its transcription (28). AP-2 has two binding sites on the erbb2 proximal promoter located 213bp
(29) and 495bp upstream from the transcription start site (30-32). These sites are however not
conserved on the Neu promoter (33, 34). The Estrogen Receptor α (ERα) is a ligand dependent
receptor and can only perform its function when it is bound to a ligand. In the presence of
estrogen, ERα can bind to estrogen and then bind to the same binding site as AP-2 proteins on
the erbb2 gene and repress erbb2 transcription (35). This binding creates a competition
between ERα and the AP-2 transcription factors (35). It has been shown that in ErbB2
overexpressing tumors show relatively high levels of AP-2α and AP-2β (34). The high expression
of AP-2α and AP-2β leads to increase of erbb2 transcripts within a cell because the AP-2 proteins
are able to compete out ER α for binding to the erbb2 gene (35, 36). In the presence of
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Tamoxifen and other anti-estrogens, this competition is abolished and both AP-2 and ER bound
to Tamoxifen or an anti-estrogen can upregulate erbb2 transcription (37).
AP-2α has a higher binding affinity to the erbb2 promoter region than its other two
family members, AP-2β, and AP-2γ (28). AP-2 proteins can also recruit cAMP binding element
proteins to the promoter region (28, 37). AP-2 has been shown to be a functionally critical
transcription factor involved in the transcriptional regulation of the proto-oncogene, ErbB2 (35,
38). Some studies demonstrate AP-2 is overexpressed in breast cancers and the high expression
of nuclear AP-2 and ErbB2 over expression correlates with worse prognosis in patients
compared to patients with low nuclear AP-2 levels despite of ErbB2 overexpression (35, 38).
Consistently, suppression of AP-2 transcription factors downregulates the erbb2 transcript levels
in ErbB2+ breast cancer cell lines, thus further, underscoring an important role of AP-2 in
positively regulating erbb2 transcription.

Estrogen Related Receptor Alpha (ERRα) is a gene that is related to the ERα and is a nuclear
orphan receptor. It binds to the estrogen response element and is involved in estrogenic actions
within a cell (39). It shares features from ERα, including its structure and function. ERRα
expression inversely correlates with the expression of ERα in breast cancer (40). Studies have
shown that ERRα binds to the erbb2 amplicon and regulates its transcription at different sites
within the 17q12-21 chromosomal region (41). The erbb2 amplicon is a genomic region of
amplified genes that is composed of over 50 genes and some of these are thought to be driver
genes of oncogenesis (42). When ERRα binds to the erbb2 amplicon, it recruits its coactivator
Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β) (41). PGC-1β is a
coactivator of nuclear receptors and other transcription factors. It has been shown to function
in the regulation of different components in the energy metabolism pathway (43). After ERRα
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binds to the erbb2 promoter, it recruits its coactivator to the erbb2 amplicon and together these
components recruit RNA polymerase II to the promoter region of the gene. RNA polymerase II
then transcribes the erbb2 gene, as well as the neighboring genes (41).
ERRα signaling is shown to be involved in cancer progression in ErbB2+ and ER+ breast
cancers (40, 41). ERRα levels are higher in ER- tumors and in ErbB2+ tumors, indicating a more
aggressive prognosis. When ERRα expression is ablated, erbb2 amplicon transcripts are reduced
(41). ERRα has been identified as an important contributor in the development and/or
progression of breast cancer, ovarian cancer and osteopenic disorders (44-45). In ovarian cancer
patients, high levels of ERRα correlates to a poorer survival rate (44). In breast cancer, a study
has shown that ERRα levels are higher in ER negative tumors and in ErbB2+ tumors, indicating a
more aggressive prognosis. It has also been shown that ERRα is the most abundant nuclear
receptor in a subset of tumors which lack ERα (40, 41). In addition, it has been observed that
ErbB2 driven tumorigenesis was delayed upon silencing of ERRα in ErbB2+ mice (40).

Y-Box binding protein-1 (YB-1) is an oncogenic transcription factor that binds to the erbb2
promoter region. It was first discovered through a screening of an expression profile library for
DNA binding proteins that interact with the erbb2 gene (46). YB-1 can regulate ErbB2
expression by binding to potential YREs (YB-1 Response Elements) located about 2 Kbs from the
start site. YB-1 may also regulate erbb2 transcription by binding to other transcription factors,
such as AP-2 (47). Using a transgenic mouse model, YB-1 was discovered to create genomic
instability through centrosome amplification and mitotic failure in different breast carcinomas
(48). YB-1 has little to no expression in normal cells but is highly expressed in a variety of
cancers, including breast (49). YB-1 has also been speculated to be involved in acquired
chemotherapy resistance in a number of cancers such as breast (50) and multiple myeloma (51).
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In a clinical study where postoperative patients that received chemotherapy for breast cancer,
but relapsed; the tumors of these patients showed a higher expression of YB-1. These patients
also acquired therapy resistance. However, the tumors that showed low expression of YB-1;
these patients did not relapse and therefore did not acquire resistance (50).

Ying Yang 1 (YY1) is a conserved zinc-finger DNA binding transcriptional factor that
regulates the transcription for a number of genes that are involved in cellular processes such as
cell growth, differentiation, and development. (52-53). YY1 a nuclear cofactor that interacts with
the AP-2 factors, especially with AP-2α (54). A clinical study using tissue arrays of different
breast carcinomas were characterized by staining them using YY1, AP-2α, AP-2β, ErbB2, and
other biomarkers in order to observe possible correlations and prognostic markers. This group
showed a correlation between AP-2α and YY1 with ErbB2 protein expression. YY1 also
correlated with ErbB2 gene expression and there were several cases that showed a difference
between ErbB2 gene and protein expression (54). YY1 has the ability to interact with a number
of proteins indicating that its function is dependent on its protein-protein interactions. It
interacts with the AP-2 factors through a highly conserved domain and enhances the
transcriptional activity at the erbb2 promoter in cells (52-56).

Specificity Protein 1 (Sp1) is yet another transcription factor that has been shown to regulate
ERRB2 expression. Sp1 is a transcription factor that is highly conserved in eukaryotic cells and
binds to a variety of promoters to regulate transcription (19). Sp1 are known for their affinity to
bind to GC-rich promoter regions (57). The erbb2 promoter has two GC-rich sequence elements
that have been determined as distinct Sp1 binding sites approximately 50 to 130 bp upstream
from the transcription start site (58). Sp1 is ubiquitously expressed in cells and it regulates
different house -keeping genes that involved in cell cycle, receptor signaling, cellular growth
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(59). Sp1 activation is tightly regulated through phosphorylation, glycosylation, and
SUMOYlation (60). A study has shown that Betulinic acid, which induces apoptosis and inhibits
cell growth in ErbB2-overexpressing cells, was able to decrease levels of Sp1, Sp2, Sp3, and Sp4,
causing a downregulation of ErbB2 through YY1 repression (61).

Amplified in Breast Cancer-1 Transcription Factor SRC-3 (AIB-1) is a member of the SRC
family, which are nuclear receptor coactivators. SRC-3 binds to ERα at a conserved LXXLL motif
at the nuclear receptor interaction domain (62). When ERα is bound to estrogen at its ligand
binding domain, the receptor dimerizes with another Estrogen Receptor and changes its
conformation to recruit coactivators such as SRC-3 to bind to the estrogen response element in
the erbb2 gene promoter region (35, 63). The overexpression of AIB1/SRC-3 was found to be
correlated with increased HER2/neu expression and resistance to tamoxifen in ER+ breast cancer
patients (62, 63). These findings suggest that the biological roles of AIB1/SRC-3 and
HER2/neu are linked in breast cancer and that AIB1/SRC-3 may increase the sensitivity of breast
cancer cells to HER2/neu–driven tumorigenesis (64). Cross talks between the Estrogen Receptor
and ErbB2 pathways have been implicated to play important roles in Tamoxifen resistance (65,
66). However, a molecular mechanism linking estrogen receptor signaling, erbb2 expression and
tamoxifen resistance has remained elusive. Carroll and colleagues first reported that erbb2
expression is controlled by the balance between the estrogen receptor co-activator AIB-1 and
the co-repressor transcription factor PAX2 (67). Both factors competitively bind to the
same ebb2 regulatory element (67).

Transcription Factor Negatively Regulates ErbB2 Transcription
Paired Box 2 Gene Product (PAX2) was originally discovered to regulate Wilms tumor
suppressor gene, WT1, a gene that regulates the development of fetal urogenital system,
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spleen, and mesothelium (68). In normal breast cell, PAX2 works in tandem with ERα to bind to
the cis-regulatory region of the erbb2 gene to down-regulate its transcription (14, 69).
Mutations or siRNA knockdown of PAX2 has been shown to prevent estrogen mediated
transcriptional inhibition of erbb2, indicating a role for PAX2 in the transcriptional repression
(69). PAX2 has also been shown to be a critical regulator in cell proliferation in the mammary
gland (70). It has been shown that the response of breast cancer cells to Tamoxifen is regulated
by competition between AIB-1 and PAX2 binding to cis-regulatory elements in erbb2. Indeed, a
decrease in PAX2 expression in Tamoxifen-resistant (Tam-R) cells correlated with an increase
in erbb2 expression (69). The ER was still recruited to erbb2 gene, but the PAX2 binding
decreased, making Tam-R cells as responsive to Tamoxifen as tamoxifen-sensitive cells (69).
Conversely, AIB-1 binding increased in Tam-R cells in response to Tamoxifen treatment.
Overexpression of PAX2 reduced AIB-1 binding to the erbb2 gene and restored Tamoxifenmediated repression of ErbB2 and inhibited cellular proliferation (14, 69, and 70)

Myc Promoter-Binding Protein Factor (MBP-1) is a 48 kDA protein that binds to the c- MYC
P2 promoter region and negatively regulates its transcription (71). Nuclear MBP-1 protein is
correlated with breast cell transformation, since loss of its nuclear expression seems to be
correlated with a worsened prognosis in patients with invasive ductal breast carcinoma (72).
MBP-1 binds to the erbb2 gene at a region that is located in its proximal promoter and recruits
Histone Deacetylase 1, HDAC1, (72, 73). HDAC1 then deacetylates Histone H4 causing a
repression of erbb2 gene transcription. When ErbB2 is overexpressed, MBP-1 and HDAC1
expression decrease significantly (73).
Histone Deacetylase inhibitors are promising new therapy options for a variety of
cancers. HDACs have been shown to be responsible for modifying a number of proteins such as
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histones, transcription factors, and signal transduction mediators (74). HDACs are also
differentially expressed in breast tumors and have been considered as therapeutic targets as
well as potential prognostic markers (75). Earlier studies using a promoter-reporting cell screen,
in ErbB2 overexpressing breast cancer cells, HDAC inhibitors have been shown to repress ErbB2
gene transcription by two mechanisms; direct transcriptional repression by inhibiting synthesis
of ErbB2 mRNA and by accelerating the decay mature ErbB2 transcripts (76). In a recent
publication using copy number and RNA transcript data, it was found that HDAC1 are able to
repress highly amplified genes including ErbB2 by targeting RNA polymerase II elongation (77).

Forkhead Box P3 (FOXP3), a member of the forkhead/winged helix transcription factor family,
is an X-linked gene whose expression has been shown to negatively correlate with ErbB2
overexpressing mammary tumors (78). FOXP3 is a breast cancer suppressor gene and it is
important for the regulation of the erbb2 gene. FOXP3 is the first X-linked breast cancer
transcription factor that binds to a consensus sequence in the 5’ erbb2 gene promoter region
and represses transcription (78, 79).

GATA Binding Protein 4 (GATA4) is a member of the zinc finger transcription factors and is
known to play a role in the regulation of several genes involved in embryogenesis and
myocardium differentiation and function (80). In cardiomyocytes, GATA4 is activated via the
mitogen-activated protein kinase pathway, which in turn is activated in the ErbB2 signaling
pathway (80). GATA4 recognizes and binds to the GATA motif, several of these motifs are
located in the erbb2 proximal promoter region. GATA4 becomes activated through the MAPK
pathway and once it is activated, it binds to the GATA motif of the erbb2 gene repressing its
transcription (80). When GATA4 is overexpressed in ErbB2 overexpressing cells, ErbB2 protein
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levels are decreased and when GATA4 is silenced by siRNAs in cells, ErbB2 mRNA and protein
levels increases (79, 80).

Discussion:
In this comprehensive review we focused on various transcriptional factors or coregulators that are associated with ErbB2 by directly or indirectly binding to its promoter and
thus regulating its expression. The mechanism behind ErbB2 overexpression has been
extensively studied and previously only attributed to the amplification of the erbb2 gene (81).
However, it is now documented that ErbB2 overexpression occurs without the erbb2 gene being
amplified (82). As outlined above there are multiple transcription factors that positively or
negatively regulate erbb2 transcription. ETS transcription factors have been shown to positively
regulate the ERBB2 gene by binding to the ETS Response Element located in the ERBB2
promoter region (18, 25). ETS transcription factor, ER81 has been shown to positively regulate
the ERBB2 gene through a positive feedback loop in the MAPK pathway. Activation of this
pathway leads to phosphorylation of ER81, which in turn binds to the ERBB2 gene and activates
its transcription (18). This feedback loop opens the door for a possible therapy target for
patients who are ERBB2+. The ER81 transcription factor has been shown to be overexpressed or
constitutively active in ERBB2+ tumors (83).
AP-2 is a transcription factor that competes with estrogen to bind to an enhancer on the
erbb2 promoter region to turn on transcription (29). AP-2 is a well-studied regulator oferbb2
transcription and has potential as a new prognosis factor in ErbB2+ patients (32). High nuclear
expression of AP-2 has been correlated with a worsened prognosis in ErbB2+ overexpressed
breast cancer patients (33). ERRα is a nuclear orphan receptor that binds to the estrogen
response element on the erbb2 amplicon and recruits PGC-1β to upregulate ErbB2’s
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transcription (41). ERRα has recently been shown a role in tumorgenesis because knockdown of
ERRα shows a reduction of tumor progression in ErbB2+ mice (40). YB-1, YY1, and Sp1, all have
binding sites located on the proximal promoter of the erbb2 gene (46-61). YB-1 has been shown
to have higher expression in breast cancer cells, particularly in ErbB2 overexpressing cells as
compared to normal (46). The erbb2 gene is also involved in another positive feedback loop
with ERα and its coactivator, SRC-3 (62-67). SRC-3 overexpression has been seen in ErbB2
overexpressing cells and studies have shown that overexpression of SRC-3 and ErbB2 in ER+
tumor patients, leads to a poorer prognosis and a poorer survival outcome in those patients
even when treated with Tamoxifen (67). In Tamoxifen treated tumor cells, SRC-3 still has the
ability to bind to ERα and activate the erbb2 gene transcription leading scientists to think of
alternative strategies when treating patients with ErbB2+ and ER+ tumors (14, 66, 67, and 68).
The erbb2 gene is also regulated in a negative fashion by various factors. Some of
which, are PAX-2, MBP-1 and HDAC1, GATA4 and FOXP3. PAX2 competes with SRC-3 for binding
of the ERα receptor when it is bound to its ligand and the complex binds to the cis-regulatory
region of the erbb2 gene and causes a repressive effect on its transcription (14). In ErbB2
overexpression tumors where SRC-3 expression is high, PAX-2 expression is low (14, 66, 67, and
68). In a study to test the ability of PAX-2 to increase or decrease sensitivity to tamoxifen, MCF 7
a breast cancer ER+/ErbB2- cells were treated in the presence of tamoxifen or estrogen where
PAX-2 was silenced by siRNA. It was observed that the PAX-2 siRNA cells showed an increase in
ErbB2 mRNA expression (68).
MBP-1 and HDAC1 also negatively regulate erbb2 expression by binding to its proximal promoter
region (71-77). MBP-1 recruits HDAC1 to the proximal promoter region of the erbb2 gene
causing the deacetylation of histone H4 and transcriptional repression of erbb2 (73). Recent
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studies have shown that ErbB2 expression levels have an inverse correlation to MBP-1 and
HDAC expression levels in ErbB2+ tumor samples (72). Interestingly, inverse correlations of
repressor factors of the erbb2 gene to upregulation factors has been seen in a number of ErbB2+
tumor samples (68, 72, 78, and 80). This could lead to new possible therapy ideas where
exogenous expression of these repressive factors may help to decrease tumor progression of
these ErbB2+ tumors. FOXP3 is an X-linked gene that binds to a consensus sequence in the 5’
erbb2 gene promoter region and represses transcription (78). FOXP3 expression has been
shown to negatively correlate with ErbB2 overexpressing mammary tumors (78, 79). GATA4 is a
member of the zinc finger transcription factors and it binds to the GATA motif (s) located in the
erbb2 proximal promoter region and downregulates erbb2 transcription (80). GATA4 gene
expression was also shown to be negatively correlated with ErbB2 overexpression (79). By
understanding the transcriptional regulation of ErbB2, can pave the way for thinking about
possible new therapy targets and prognosis markers in ErbB2+ breast cancers.
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Running title: ECD-RUVBL1 interaction regulates cell cycle progression.
Abstract
Ecdysoneless (ECD) is an evolutionarily-conserved protein whose germline deletion
is embryonic lethal. Deletion of Ecd in cells causes cell cycle arrest which is rescued
by exogenous ECD, demonstrating a requirement of ECD for normal mammalian
cell cycle progression. However, the exact mechanism by which ECD regulates cell
cycle is unknown. Here, we demonstrate that ECD protein levels and subcellular
localization are invariant during cell cycle progression, suggesting a potential role of
post-translational modifications or protein-protein interactions. As phosphorylated
ECD was recently shown to interact with the PIH1D1 adaptor component of the
R2TP

co-chaperone

complex,

we

examined

the

requirement

of

ECD

phosphorylation in cell cycle progression. Notably phosphorylation-deficient ECD
mutants that failed to bind to PIH1D1 in vitro, fully retained the ability to interact
with the R2TP complex, yet exhibited a reduced ability to rescue Ecd-deficient cells
from cell cycle arrest. Further biochemical analyses demonstrated that an
additional phosphorylation-independent interaction of ECD with the RUVBL1
component of the R2TP complex, and this interaction is essential for ECD’s cell
cycle progression function. These studies demonstrate that interaction of ECD with
RUVBL1, and its CK2-mediated phosphorylation, independent of its interaction
with PIH1D1, are important for its cell cycle regulatory function.
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Introduction
Precisely regulated cell proliferation is essential for embryonic development as
well as homeostasis in adult organs and tissues, whereas uncontrolled cell proliferation is
a hallmark of cancer (1). A more in-depth understanding of the regulatory controls of cell
cycle progression is therefore of great interest.
The Ecd gene was originally inferred from studies of Drosophila melanogaster
ecdysoneless (or ecd) mutants that exhibit defective development due to reduced
production of the steroid hormone ecdysone (2). Subsequent cloning of drosophila ecd
helped identify a cell-autonomous role of ECD protein in cell survival aside from its noncell autonomous role in ecdysis (molting) (3). However, the molecular basis of how ECD
functions remains unknown (3). The human ECD homologue was initially identified in a
screen of human open reading frames that complemented the S. cerevisiae mutants
lacking Gcr2 (Glycolysis regulation 2) gene, and it rescued the growth defect caused by
reduced glycolytic enzyme activity in Gcr2 mutants. The human gene was initially
designated as HSGT1 (human suppressor of Gcr2), and was suggested to function as a coactivator of glycolytic gene transcription (4). However, ECD protein bears no structural
homology to Gcr2 and a true ECD orthologue is absent in S. cerevisiae, suggesting that
ECD likely functions by distinct mechanisms.
We identified human ECD in a yeast two-hybrid screen of human mammary
epithelial cell cDNA-encoded proteins for novel binding partners of the Human
Papilloma Virus 16 (HPV16) E6 oncogene (5). We showed that deletion of Ecd gene in
mice causes embryonic lethality, identifying an essential role of ECD during early
embryonic development (6). Notably, Cre-mediated conditional deletion of Ecd in Ecdfl/fl
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mouse embryonic fibroblasts (MEFs) led to a G1/S cell cycle arrest, and this phenotype
was rescued by ectopic expression of human ECD (6), indicating an essential role of
ECD in promoting cell cycle progression. We showed that ECD can interact with the
retinoblastoma (RB) protein and reduces the repression of RB on E2F transcription
factors, providing a novel mechanism by which ECD functions as a positive factor of
mammalian cell cycle progression (6). Recently, ECD was shown to play a vital role in
pre mRNA splicing by interacting with the splicing factor Pre-mRNA-processingsplicing factor 8 (PRPF8) (7). We and others have shown that ECD shuttles between
nucleus and the cytoplasm, with a predominantly cytoplasmic steady-state localization
due to rapid nuclear export (7, 8). Consistent with these key cellular roles of ECD, we
found that ECD is significantly overexpressed in breast and pancreatic cancers, and its
overexpression correlates positively with poor prognostic factors and poor patient
survival (9, 10).
A pull-down screen using the phospho-peptide-binding domain of PIH1D1, the
adaptor component of the evolutionarily-conserved prefoldin-like co-chaperone complex
R2TP, recently identified ECD as one of the binding partners (11). This interaction was
shown to require dual phosphorylation of Ser-505 and Ser-518 on ECD (11), suggesting
that ECD phosphorylation may mediate its interaction with the R2TP complex. To date,
this interaction has not been demonstrated in the context of endogenous ECD nor has a
functional role of this interaction been determined. The core R2TP complex is composed
of four proteins, PIH1D1, RPAP3, RUVBL1, and RUVBL2 (each with a number of other
names) (12).

The R2TP complex is involved in the assembly of multi-subunit

complexes, including the small nucleolar ribonucleoproteins (snoRNPs), RNA
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polymerase II, and phosphatidylinositol 3-kinase-related kinases (PIKKs) and their
complexes (13-15). As such, the R2TP complex is involved in a number of essential
cellular processes. The closely-related RUVBL1 and RUVBL2 proteins are
AAA+ (ATPases associated with diverse cellular activities) that are essential for R2TP
function (16). Recent studies have shown that RUVBL1 (Pontin) plays an important role
in cell cycle regulation (17, 18). Germline deletion of Ruvbl1 was shown to be early
embryonic lethal (18, 19). Depletion of RUVBL1 in AML1-ETO fusion oncogeneexpressing leukemic cells was shown to cause cell cycle arrest (17) and Cre mediated
deletion of Ruvbl1 in Ruvbl1fl/fl cells also led to G1/S cell cycle arrest (18). The apparent
similarities in the embryonic lethality and cell cycle arrest phenotypes imparted by the
loss of ECD or RUVBL1 expression suggested the likelihood that the recently described
interaction with the R2TP complex (11) may underlie the functional requirement of ECD
in cell cycle progression.
In this study, we extensively analyzed the mechanism of ECD-R2TP interaction
and how disabling this interaction by mutations in ECD affects the latter’s role in cell
cycle progression. We demonstrate that ECD levels and localization do not vary during
cell cycle progression. We show that Casein Kinase 2 (CK2) phosphorylates ECD in cells
at 6 major sites and a mutant ECD (6S/A) disabled for CK2-mediated phosphorylation
exhibits reduced ability to rescue the cell cycle arrest caused by Ecd gene deletion.
Notably, while ECD can interact with PIH1D1, loss of this interaction by mutating CK2
phosphorylation sites did not impact the ECD-R2TP association in cells. We identified a
novel interaction of ECD with RUVBL1, independent of ECD’s interaction with
PIH1D1, which we show to be essential for ECD’s cell cycle progression function.
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Notably, a phospho-mimetic mutant (6S/D) of ECD failed to bind PIH1D1 and was
incompetent at rescuing the cell cycle arrest caused by Ecd gene deletion, suggesting a
potential accessory role for PIH1D1-ECD interaction. Taken together, our results
demonstrate that while CK2-mediated phosphorylation of ECD is important for its role in
cell cycle progression, ECD’s interaction with PIH1D1 is dispensable, suggesting that the
novel RUVBL1-ECD interaction that we identified is particularly critical for ECD’s
function in cell cycle.
Materials and Methods
Reagents
λ protein phosphatase (# P9614) was purchased from Sigma Aldrich USA and the
treatment was given according to manufacturers’ instruction. 12.5% SuperSep Phostag™ (50 μmol/L) was purchased from Wako Laboratory Chemicals (catlog # 19516391). Electrophoresis was performed according to manufacturer’s protocol.
PreScission protease was purchased from GE health care life sciences.

Cells culture

HEK-293T, MEFs and T98G glioblastoma cell lines were grown in DMEM (Life
Technologies, Grand Island, N.Y.) supplemented with 10% fetal calf serum. Immortal
mammary epithelial cell line 76NTERT was cultured in DFCI-1 medium, as described
previously (20). U2OS cell line was cultured in α-MEM medium. CK2 inhibitor TBB
was dissolved in DMSO and used at 50 µM concentration.

Plasmid constructs, site-directed mutagenesis and transfection
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Generation of the pMSCV-puro (Clontech)-based expression constructs for
FLAG-ECD and its truncated versions has been described previously (6, 8).

The

pMSCV-puro construct expressing ECD with deletion of amino acids 499-527 was
generated using a thee-fragment ligation into BglII and HpaI sites. C-terminally His6tagged ECD truncations (1-567, 1-534, 1-432) were generated though PCR amplification,
cloning into Xba1 and Sal1 sites of pET-28b+ vector (Invitrogen) and recombinant
proteins were purified after expression in E. coli BL21DE3 strain using Nickel affinity
column (GE Healthcare). C-terminally His6-tagged full-length ECD was generated by
cloning ECD coding sequence into SalI and NotI sites of the pFastBac1 vector
(Invitrogen), expressed in Sf21 insect cells and purified using Nickle affinity column.
The PIH1D1-specific and control siRNAs (Santa Cruz. Sc-97385) were transfected into
sub-confluent cells using DharmaFECT®1 transfection reagent (Thermo Scientific). GFP
tagged full-length or truncated ECD expression constructs in the pGEn2 vector were
generated by replacing the ST6-Gal1 insert in the ST6-Gal1-pGEn2 construct
(ST6GAL1-pXLG-NtermTCMhisStrep-DEST) (21) with PCR-amplified ECD coding
sequences at the EcoRI and HindIII sites by infusion cloning kit (Clonetech). The primer
sequences used for cloning are indicated in Table S2. Human PIH1D1 cDNA sequences
(Origene, clone SC321317) were subcloned into BamHI and XhoI sites of pGEX-6p-1
for expression as a GST fusion protein in E. coli BL21 strain. A recombinant GST-PERK
kinase domain was expressed in BL21DE3 cells purified as GST-fusion protein.
Point mutants of ECD were generated using a PCR-based commercial kit
(GENEART Site-Directed mutagenesis

system,

Invitrogen), according to

the

manufacturer’s instructions, cloned into the pET28b+ vector for His-tagged recombinant
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protein expression and purifed using Nickel affinity column. The PCR primer sequences
are listed in table S2. All constructs were verified by sequencing.
DNA constructs were transfected in HEK-293T cells using the X-tremeGENE
transfection reagent (Roche). Retroviral infection was carried out as described previously
(6).
Flow Cytometry for Cell cycle Analysis and Biochemical Fractionation
76NTERT cells were plated at 5 X 105 cells per 100-mm dish for 12 hours,
subjected to growth factor deprivation by culturing in growth factor-free DFCI-3 medium
for 72 hours (20) and released from synchony using growth factor-containing DFCI-1
medium (20). Half of the cells were fixed for fluorescence-activated cell sorter (FACS)
analysis after fixation in chilled 70% ethanol and staining with propidium iodide; the
remaining cells were used for western blotting. G2/M to G1 progression in MEFs was
similarly assessed using FACS analysis following Nocodazole (100 ng/ml)-dependent
arrest in early G2/M phase of cell cycle (22). Nuclear and cytoplasmic fractions were
prepared from cells at various times points during cell cycle progression using the NEPERTM kit (Thermo Scientific, cat# 78833). To assess the mitotic index of Ecdflox/flox
MEFs, infected with adeno-Cre-GFP or control Adeno-GFP. Cells were collected and
fixed as described above. Cell pellet was resuspended in 100 µl of PBS containing 1%
BSA and 0.25 µg of phospho-H3-S10 (abcam cat # ab14955) and then incubated for 1 h
at room temp. Cells were washed in 150 µl of PBS and resuspended in Alexa Fluor® 647
(A212235, Life Technologies) conjugated goat anti-mouse antibody diluted at a ratio of
1:300 in 100 μl of PBS containing 1% BSA and incubated at room temperature in the
dark for 30 min, followed by FACS analysis. The Median Fluorescence Intensity (MFI)

209

of GFP-positive cells at 488 and 633 nm wavelengths was recorded as an indicator of
mitosis in the control and Ecd-null cells.
Immunoblotting and Immunoprecipitation
Cells were lysed in radio-immunoprecipitation assay (RIPA) buffer (20 mM Tris, pH 7.2,
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate
[SDS]) and protein concentration was measured using the BCA protein assay reagent
(Pierce). Immunoblotting was performed with primary antibodies against ECD (9), RB
(554136,

Pharmingen),

anti-phospho-Ser

(05-1000,

Millipore),

anti-phospho-Th

(AB1607, Millipore), PIH1D1 (sc-101000 or sc-390810, Santa Cruz), RUVBL1 (12300S,
Cell Signaling or SAB4200194, SIGMA) RUVBL2 (ab36569, Abcam), RPAP3
(HPA038311, SIGMA), PARP (sc-8007, Santa Cruz), Histone H3 (06-755, Millipore),
PRPF8 (ab137694, Abcam), β-actin (A5441, SIGMA) or α-tubulin (T6199, SIGMA), as
indicated. For immunoprecipitations, cells were lysed in NP-40 lysis buffer (20 mM TrisHCl (pH 7.5), 200 mM NaCl, 0.5% Nonidet P-40 [NP-40], 1 mM NaF, 0.1 mM Na3VO4
and protease inhibitor mixture (Roche Applied Science)) and then immunoprecipitated
with 3 μg of antibodies against ECD or 35 µl of Ezview red anti FLAG M2 affinity gel,
(SIGMA) for 2 h to overnight at 4 °C. The immune complexes were captured with
protein A/G-agarose (sc-2003, Santa Cruz Biotechnology). To elute FLAG-tagged
proteins from anti-FLAG beads before analysis, immune complexes were incubated with
150 ng/µl of 3X FLAG peptide (SIGMA) for 15 min at room temp and supernatants were
collected for SDS-PAGE. For PIH1D1 interaction with ECD, cell lysates were prepared
in CHAPS lysis buffer (0.3% CHAPS, 0.20 mM Tris-HCl (pH 7.4), 120 mM NaCl, 10%
glycerol, 5 mM EDTA) supplemented with protease and phosphatase inhibitor (Roche).

210

RUVBL1 immunoprecipitation to assess association with ECD was carried out using a
monoclonal anti-RUVBL1 antibody (cat# SAB4200194-200UL SIGMA, 2 g).
Immunoprecipitated RUVBL1 (close to IgG heavy chain) was detected by western
blotting with an anti-RUVBL1 antibody (cat#12300s, cell signaling) that was conjugated
to HP using the Lightning-Link® HP Conjugation Kit (NOVUS BIOLOGICALS).
In vitro kinase assay

500 ng of purified recombinant ECD proteins or its mutants were incubated with
0.2 mM ATP, 1µCi of [γ-32P]ATP (PerkinElmer) and 0.2 µl (10 units) human
recombinant CK2 (NEB, Beverly, MA) at 30°C for 30 min, or as indicated. The reaction
was stopped by adding SDS-PAGE sample buffer. The [32P] labeled proteins were
detected by autoradiography following SDS-PAGE and then transfer to PVDF
membranes (Millipore). Once the radioactive signals had decayed, the membranes were
blotted with anti-p-Ser antibodies. 10 ng of recombinant GST-PERK kinase domain was
autophosphorylated in kinase assay buffer (50 mM HEPES [pH 8.0], 10 mM MgCl2, 2.5
mM EGTA ) supplemented with 20 μM cold ATP (NEB).5 ng were loaded on SDS page
and subjected to western blotting with anti-p-Ser and anti-p-Thr antibodies.
[32P] metabolic labeling and immunoprecipitation
Exponentially-growing or serum-deprived T98G cells were washed with
phosphate-free DMEM supplemented with 10% dialyzed fetal bovine serum, and
incubated in the same medium for 1 hour before adding 0.1 mCi [32P] orthophosphate
(NEN) per 10-cm plate. Cells were labeled for 4 hours at 37°C (or for 2, 5 or 16 hours for
cell cycle analyses), rinsed once in ice-cold PBS and lysed in ice-cold lysis buffer (250
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mM NaCl, 1% NP-40, 20 mM Tris-HCl at pH 7.4, 1 mM EDTA, 2 μg/ml of aprotinin, 2
μg/ml of leupeptin, 1 μg/ml of pepstatin, 2.5 μg/ml of antipain, 1 μg/ml of chymostatin, 1
mM Na3VO4, 10 mMNaF, 1 mM sodium molybdate, and 0.5 mM PMSF). Labeled ECD
was immunoprecipitated with affinity-purified mouse anti-Ecd monoclonal antibody or
anti-FLAG beads overnight at 4°C and Protein-G Plus/Protein-A agarose beads added for
1 h. The beads were washed thee times with ice-cold wash buffer (150 mM NaCl, 1%
NP-40, 20 mM Tris-HCl at pH 7.4, 1 mM EDTA, and protease inhibitors). The
immunoprecipitated proteins were resolved on 7.5 % SDS–polyacrylamide gels,
transferred to PVDF membrane and visualized by autoradiography.
In vitro binding assays
GST-or His-tagged protein pull-downs were performed as described previously
(6). FLAG-tagged WT ECD or its mutants (3S/A and 6S/A) were expressed by transient
transfection in 293T cells and lysed in CHAPS Lysis buffer as described above. 1000 µg
of lysate protein was incubated with 2 µg bead-bound purified GST-PIH1D1 for 2 hours
at room temperature, washed five times, and then bound proteins were detected by
western blotting with anti-FLAG antibody. Membranes were stained with Ponceau S to
visualize GST fusion proteins. In-vitro TAP was performed as described (23) using
purified recombinant ECD with a C-terminal FLAG tag.
Cell proliferation and colony formation assays
The cell proliferation was analyzed as described (6). Briefly, Ecdflox/flox MEFs were
infected with adenoviruses encoding GFP-Cre or GFP (control) (University of Iowa Gene
Transfer Vector Core) and plated at 104 cells/well in 6-well plates, followed by counting
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of cells at the indicated time points. For colony-formation assay, infected cells were
plated at 5,000 or 1,000 per well in 6-well plates for 10 days, the colonies were stained
with crystal violet (0.5% crystal violet in 25% methanol), solubilized in 10% acetic acid,
and then quantitative measure of colony formation was measured by absorbance at 590
nm.
Statistical analysis
A generalized estimating equation method was used to assess the differences among

cell types accounting for the correlated measurement within a sample. Comparisons
between WT and other cell types at a given time were made with Simulation’s correction.
Some results were analyzed using paired two-tailed student's-t test. p values of ≤0.05
were considered statistically significant.
Results
ECD levels and localization do not change during cell cycle progression
Given the requirement of ECD for cell cycle progression and its direct association with
RB (6), we assessed if ECD levels or localization are altered during cell cycle
progression. For this purpose, an immortal mammary epithelial cell line, 76NTERT, was
arrested in the G1 cell cycle phase by growth factor deprivation and the cells were then
allowed to proceed synchonously though cell cycle phases by culture in regular growth
factor-containing medium. FACS analyses showed that a majority of growth factordeprived cells were growth arrested, with 98% cells in the G1 phase, and only 0.75%
cells in the S and 1.25% cells in the G2/M phases (Fig. 1A). Western blotting of lysates
showed no significant differences in the levels of ECD protein in cells at various times
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during cell cycle progression (Fig. 1B). Analysis of nuclear and cytoplasmic fractions
prepared at various times during cell cycle progression showed that ECD localizes
primarily in the cytoplasm (Fig. 1C), consistent with its rapid nuclear export, as
previously reported (8). Overall, our results indicate that ECD levels and its subcellular
localization do not change significantly during cell cycle progression.
ECD is phosphorylated on serine residues but overall phosphorylation does not
change during cell cycle progression
Given the known roles of phosphorylation in regulating the cell cycle machinery (24),
we asked if ECD is a phosphoprotein and whether its phosphorylation varies with cell
cycle progression. For these analyses, T98G cells (a human brain glioblastoma cell line
that expresses a wild-type RB) (25) were cultured in low serum medium for 48 hours to
induce growth arrest and then allowed to progress though cell cycle by adding serumcontaining medium with [32P] labelled sodium orthophosphate. Autoradiography of antiECD immunoprecipitates showed that ECD is indeed a phosphoprotein; however, the
levels of phosphorylation were comparable at various time points during cell cycle
progression (Fig. 2A). As a control, RB showed an expected cell cycle related increase in
phosphorylation at the 16 h and 20 h time points (Fig. 2A). Further analyses using antiFLAG IPs from [32P]orthophosphate-labeled cells expressing an exogenous FLAGtagged ECD protein confirmed the phosphorylation of ECD in cells (Fig. 2B). These
analyses demonstrate that ECD is a phosphoprotein, however the phosphorylation levels
do not change during cell cycle progression.
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It was reported that a peptide sequence derived from ECD was phosphorylated by
casein kinase 2 (CK2) in vitro (11).To assess if the phosphorylation of ECD corresponds
to

phsospho-serine (p-Ser) or phospho-theonine (p-Th) residues, anti-FLAG

immunoprecipitates of T98G cells expressing a FLAG-tagged ECD were blotted with
anti-p-Ser or anti-p-Thr antibodies. A recombinant GST-PERK kinase domain, known to
undergo auto phosphorylation on serine and theonine residues during an in in vitro kinase
reaction (26), was used as a positive control for serine and theonine phosphorylation.
Indeed, both p-Ser and p-Th signals were detected by blotting of autophosphorylated
GST-PERK kinase domain (Fig. 2C). While no signals were detected with anti-p-Thr
antibody blotting of anti-ECD immunoprecipitation, even after long exposures, a specific
band was observed with the anti-p-Ser antibody (Fig. 2C). These results suggested that
cellular ECD is predominantly phosphorylated on serine residues.
CK2-mediated phosphorylation of ECD is important for its cell cycle regulation
function
In view of our results presented above, and a recent study that used an array of spotted
peptides to identify CK2 phosphorylation of an ECD peptide on Ser-505 and Ser-518
(11), we performed a detailed analysis of potential phosphorylation sites on ECD using
the publically available KinasePhos 2.0 tool (http://kinasephos2.mbc.nctu.edu.tw/). This
analysis identified multiple sites on ECD that could be phosphorylated by various Ser/Th
kinases. Among these, CK2 was predicted to preferentially phosphorylate multiple serine
residues, and this was of obvious interest in view of our results that cellular ECD is
primarily phosphorylated on Ser residues (Fig. 2C). The potential CK2 phosphorylation
sites near the C-terminus, including Ser-505 and Ser-518 reported in the peptide array
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screen (11), were predicted with the highest confidence (Fig. 3A); . To directly assess if
ECD is a CK2 substrate, we performed an in vitro kinase assay with purified CK2 and
recombinant

full-length

ECD

protein

or

its

C-terminal

truncated

versions.

Phosphorylation was observed with full-length ECD (1-644) and its fragments
encompassing residues 1-567 or 1-534, whereas substantially less phosphorylation was
observed with the ECD 1-432 fragment (Fig. 3A & B). These results indicated that ECD
was indeed a substrate for CK2 in vitro, and that CK2-dependent phosphorylation occurs
predominantly within the C-terminal region of ECD.
CK2 is known to phosphorylate its substrates in clusters, with phosphorylation at
one site priming the substrate for phosphorylation at additional sites (27, 28). The Cterminal region contains two potential Ser clusters, a proximal cluster of S503, S505 and
S518, and a distal cluster of S572, S579 and S584 (Fig. 3C). To assess the contribution of
these clusters to CK2-dependent phosphorylation of ECD, we introduced Ser to Ala
mutations in these residues, individually as well as in combinations (Fig. 3C & D). While
S>A mutations of the Ser residues in the distal cluster (S572A, S579A and S584A;
designated as 3′S/A) had no appreciable impact on the level of phosphorylation in the in
vitro kinase assay, similar mutations in the proximal cluster (S503A, S505A and S518A;
designated as 3S/A) led to a considerable reduction in the CK2-mediated phosphorylation
(Fig. 3D). Importantly, Ala mutations of all six residues (S503, S505, S518, S572, S579
and S584; designated 6S/A) nearly completely abolished the CK2-mediated in vitro
phosphorylation of ECD (Fig. 3D). The autoradiography results were confirmed by
subjecting the same filters to blotting with anti-p-Ser antibody (Fig. 3D). Since we did
not observe a shift in the mobility of the 6S/A mutant on regular SDS-PAGE, perhaps
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reflecting a mechanism previously reported by Lee et al. (29), we performed gel analysis
of in vitro phosphorylated WT, 6S/A and phosphatase treated WT ECD after reacting
these with Phos-tagR a dinuclear metal complex that acts as a phosphate-binding tag and
can produce a mobility shift (30). As expected, the Phos-tag-bound WT ECD resolved as
a slower migrating band compared to its phosphatase-treated sample; notably, the 6S/A
mutant exhibited a faster mobility compared to phosphorylated WT ECD (Fig. S1A).
Collectively, these results show that the C-terminal Ser clusters of ECD, especially the
proximal one, can be phosphorylated by CK2. The small residual phosphorylation signal
observed with the 6S/A mutant of ECD may reflect an additional minor site of CK2mediated phosphorylation.
While these experiments confirmed and extended the concept of CK2 mediated
phosphorylation of ECD in vitro, to relate this post-translational modification to ECD
function it was important to assess if ECD is phosphorylated in cells on the same sites
and whether such phosphorylation is important for its function. Thus, we generated
pMSCV-puro vector-based retroviral constructs encoding the FLAG-tagged wild type
(WT), 3S/A or 6S/A mutants of ECD. These constructs were expressed in T98G cells,
and cells were metabolically-labeled with

32

P-orthophosphate. Equal amounts of

radioactive extracts (based on counts per minute) were subjected to anti-FLAG IP
followed by autoradiography. While the phosphorylation signal observed with the 3S/A
mutant was comparable to that on the WT ECD, the level of phosphorylation on the 6S/A
mutant was markedly reduced (Fig. 3E). To ascertain if the defective phosphorylation of
the cell-expressed 6S/A mutant reflects simply a lack of phosphorylation of the distal
serine cluster, we compared the levels of phosphorylation of FLAG-tagged WT vs 3′S/A
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mutant by anti-p-Ser immunoblotting of anti-FLAG IPs of lysates of T98G cells
transfected with the respective constructs. We did not observe any significant differences
in the anti-p-Ser signals of WT ECD vs its 3′S/A mutant (Fig. S1B). These results
establish that the two serine clusters in ECD identified in vitro as CK2 substrate sites are
the major sites of phosphorylation in cells. Next, T98G cells expressing FLAG-tagged
WT, 3S/A and 6S/A ECD proteins were left untreated or treated with a CK2-specific
inhibitor 4,5,6,7-Tetrabromo-2-azabenzimidazole (TBB) and their anti-FLAG IPs were
blotted with anti-p-Ser antibody (Fig. 3F). Notably, CK2 inhibition reduced the
phosphorylation signal in cells expressing the WT ECD or its 3S/A mutant, however cells
expressing the 6S/A mutant did not exhibit any change in phosphorylation (Fig. 3F),
indicating that CK2 is the primary cellular kinase responsible for phosphorylation of
ECD on two major serine clusters characterized here. However, it remains possible that
the additional Ser or Th residues of ECD are phosphorylated by other kinases depending
on the cell type or varying functional states.
Next, we assessed if the phosphorylation of ECD on CK2-dependent serine
clusters is relevant to its cell cycle regulatory function. We have previously demonstrated
that introduction of Cre recombinase in Ecdfl/fl MEFs, using adenovirus Cre, causes G1
cell cycle arrest that is largely rescued by introducing human ECD (6). We used this
approach to compare the extent of the rescue of cell cycle arrest induced by endogenous
ECD deletion upon introducing the wild-type ECD or its phospho-defective mutants. In
initial experiments, we expressed the WT human ECD or its 3S/A or 6S/A mutants in
Ecdfl/fl MEFs (Fig. 3G), and then assessed the ability of cells to progress though cell cycle
without or with Cre-induced Ecd deletion. In each case, the expression of exogenous
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human ECD proteins and the depletion of endogenous mouse Ecd were confirmed by
western blotting (Fig. 3G). As expected, deletion of Ecd in Ecdfl/fl MEFs arrested
proliferation with no recovery during the entire observation period (Fig. 3H) and ectopic
WT ECD significantly rescued the cells from growth arrest (Fig. 3H & S2A). Notably,
while the 3S/A mutant behaved comparably to WT ECD in rescuing cells from growth
arrest, the 6S/A mutant only exhibited a partial rescue in comparison to that seen with
WT ECD in repeated experiments (p<0.001; Fig. 3H) (p values shown in Supplemental
Table S1). Furthermore, we examined a mutant in which serine residues 503, 505 and
518 were removed by deletion (Δ499-527) in the cell cycle rescue experiment and
observed that this mutant behaved similar to WT ECD in rescuing the proliferation block
(Fig. S2A & B). Next, we generated a phospho-mimetic mutant in which the six serine
residues identified to be phosphorylated were mutated to aspartic acid residues (6S/D).
Notably, the phospho-mimetic mutant 6S/D was completely defective in cell cycle rescue
experiment (Fig. 3I & J). In these experiments, we also examined the 3′S/A mutant and
observed a partial rescue with this mutant (Fig. 3J). While the complete lack of rescue
seen with the 6S/D mutant of ECD was surprising, it has been reported that aspartic acid
phospho-mimics are unsuitable for biological readouts due to different chemical
properties of the two residues (31, 32)

Taken together, our results underscore the

importance of ECD phosphorylation for cell cycle progression.
Phospho-defective ECD mutants retain their ability to interact with PIH1D1
protein, as well as with other components of the R2TP complex
In view of the complete lack of any functional impact of mutating ECD on S503/505/518
residues, we first re-examined the previously reported dependence of ECD binding to the
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isolated phospho-reader domain of PIH1D1 (11). For this purpose, GST-PIH1D1 pulldown was carried out with lysates of HEK-293T cells transiently-transfected to express
WT ECD or its 3S/A and 6S/A mutants. Confirming previous findings (11), WT ECD but
not its 3S/A or 6S/A mutant was pulled down with GST-PIH1D1 (Fig. 4A). These results
suggested that either the R2TP association was unnecessary for ECD function in cell
cycle progression or an alternate mechanism may recruit ECD to the R2TP complex. To
distinguish between these possibilities, we first carried out anti-ECD IPs of U2OS and
MEF cell lysates, followed by anti-PIH1D1 blotting. These analyses confirmed the
interaction of endogenous ECD and PIH1D1 (Fig. 4B & C). To examine the nature of
ECD/PIH1D1 interaction in cells, we carried out anti-PIH1D1 immunoprecipitations
from HEK-293T cells expressing untagged (Fig. 4D) or GFP-tagged (Fig. 4E & S3A)
WT ECD or its phosphorylation site mutants (defective in binding to PIH1D1 in the pulldown assay) followed by blotting for ECD (Fig. 4D) or GFP (Fig. 4E & S3A) as well as
for the four R2TP complex components (Fig. 4D, 4E & S3A). Since a phosphorylated
DSpDD/E motif, conserved between human and mouse ECD proteins (Fig. 4F), was
previously found to promote the interaction of ECD with PIH1D1 in vitro (11), we also
examined a deletion construct (Δ499-527) of ECD that lacks the DSDD/E motif in
addition to the S6/A mutant lacking all CK2-phosphorylated sites. As expected, PIH1D1
IPs were able to co-IP RPAP3, RUVBL1 or RUVBL2 to a similar extent in all lanes (Fig.
4D & E). Notably, compared to the levels of endogenous ECD co-IP with PIH1D1 in
vector control lanes, increased amounts of ectopically expressed ECD were co-IPed in
WT ECD transfected lanes. Unexpectedly, however, the WT and mutant ECD proteins
were co-IPed with PIH1D1 to comparable levels (Fig. 4D, 4E & S3A). These results
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demonstrate that ECD interacts with the R2TP complex in cells but the phosphorylationdependent interaction of ECD with PIH1D1 is dispensable for this association. In further
support of this conclusion, we carried out anti-ECD and anti-PIH1D1 IPs and treated
these IP’s with lambda phosphatase, and then assessed the levels of coimmunoprecipitated PIH1D1. Notably, while the phosphatase treatment robustly
eliminated the phosphorylation signal on ECD (anti-p-Ser blot), no reduction in
PIH1D1or ECD co-immunoprecipitation was seen (Fig. S3B & C). Thus, while CK2phosphorylated ECD can directly interact with PIH1D1, as reported (11), this interaction
is not required for the association of ECD with the R2TP complex. Next, we examined
the ability of 6S/D or 3′S/A mutants of ECD to interact with PIH1D1. For this purpose,
lysates from 293T cells expressing FLAG tagged 3′S/A or 6S/D mutants were used for an
in vitro pull-down assay with GST-PIH1D1. As expected, GST-PIH1D1 was able to pull
down the 3′S/A mutant but failed to pull down the 6S/D mutant of ECD (Fig. S3D),
confirming that 6S/D does not mimic WT ECD for its interaction with PIH1D1.
A novel phospho-independent interaction of ECD with R2TP complex though
RUVBL1
Since disabling ECD binding to PIH1D1 in the 3S/A mutant had no impact on
ECD association with the R2TP complex in cells or on ECD function during cell cycle
progression, we used an unbiased approach to identify potential mediators of ECD’s
interaction with the R2TP complex. We used an in vitro tandem affinity purification
approach (23) to identify ECD interacting partners. For this purpose, full-length ECD was
tagged with GST on the N-terminus and with FLAG epitope on the C-terminus and the
twin-tagged recombinant protein was prepared in a glutathione-Sepharose bead-bound
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form. Cell lysates prepared from 76NTERT cells were incubated with these beads and
proteins in the complex were eluted by cleaving the ECD-FLAG part of the GST-ECDFLAG fusion on beads with PreScission Protease. The eluted ECD-FLAG, in complex
with cellular proteins, was subjected to a second round of affinity purification using antiFLAG antibody beads, and the protein complexes were eluted with a FLAG epitope
peptide. The proteins in the complex were separated by SDS-PAGE and visualized by
sliver staining (Fig. 5A), and bands only seen in lanes where recombinant protein was
incubated with cell lysates were excised and subjected to mass spectrometry. Proteins
with Mascot scores of >50 were considered potential interacting partners.
These analyses identified a known ECD binding partner PRPF8 (7) and in
addition revealed several new binding partners. Interaction of PRPF8 with ECD was
confirmed by immunoprecipitation (Fig. S3E). Among the new partners, RUVBL1 was
one of the top candidate proteins with a Mascot score of 168. To validate the purification
results, we expressed the FLAG-tagged WT ECD or its 6S/A mutant in 293T cells, and
performed co-immunoprecipitation experiments using an anti-RUVBL1 antibody. Both
the WT and 6S/A ECD proteins were co-immunoprecipitated with RUVBL1, suggesting
that ECD interacts with RUVBL1 and that this interaction is independent of ECD
phosphorylation (Fig. 5B). To further establish that ECD-RUVBL1 interaction is
independent of PIH1D1, we knocked down the endogenous PIH1D1 with siRNA and
then performed a co-IP experiment using an anti-ECD antibody. Notably, we observed
equal co-immunoprecipitation of RUVBL1 in both control and PIH1D1 knock-down
cells, confirming that ECD interaction with RUVBL1 is PIH1D1-independent (Fig. 5C).
Taken together, these results demonstrate that ECD associates with the R2TP complex
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though a novel interaction with RUVBL1, independent of ECD’s interaction with
PIH1D1.
Interaction with RUVBL1 is important for the role of ECD in cell cycle progression
Germline deletion of Ecd or Ruvbl1 is embryonic lethal (6, 18) and silencing of
either protein in cells leads to cell cycle arrest (6, 17, 18), suggesting that interaction of
ECD with RUVBL1 may play a role in the cell cycle regulation function of ECD.
Towards testing this hypothesis, we first expressed GFP tagged ECD or its several Cterminal deletion mutants in HEK-293T cells and performed co-immunoprecipitation
experiments using an anti-RUVBL1 antibody. Notably, only full length ECD protein (aa
1-644) co-immunoprecipitated with RUVBL1, while none of the C-terminal deletions of
ECD were able to co-immunoprecipitate with RUVBL1 (Fig. S4A & B). To validate
these results, we constructed several GST-tagged and His-tagged ECD deletion fragments
based on the predicted secondary structure (by Garnier Robson predictions and PONDR
VL-XT secondary structure prediction) and then examined the direct interaction of these
ECD mutant proteins with FLAG-RUVBL1 or endogenous RUVBL1, using pull-down
with glutathione-Sepharose or Nickel beads. As shown in (Figs. 6A, B & S4C), only the
full-length ECD interacts with RUVBL1, whereas all C-terminal or N-terminal deletions
rendered ECD defective in binding to RUVBL1. Next, we compared various FLAGtagged deletion fragments of ECD (150-438, 438-644, 1-438 and 150-644) (Fig. S4D)
with wild type ECD (1-644) for their abilities to rescue the growth arrest of Ecdfl/fl MEFs
upon adeno-Cre-mediated endogenous Ecd deletion, by analyzing cell proliferation by
cell counting or colony formation (Fig. 6D). In each case, the expression of exogenous
human ECD proteins and loss of expression of endogenous mouse Ecd in Cre-expressing
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cells was confirmed using Western blotting (Fig. 6C & S4D). As expected, deletion of
Ecd in Ecdfl/fl MEFs arrested cell proliferation, and ectopic WT human ECD significantly
rescued the cells from growth arrest (Fig. 6D). However, none of the deletion mutants
were able to rescue the cell proliferation block imposed by endogenous Ecd depletion.
These results demonstrate that only the full-length ECD, which interacts with RUVBL1,
supports cell cycle progression. The lack of rescue with ECD deletion fragments was not
due to lack of their expression (Fig. 6C & S4D). Notably, two deletion fragments (438644 and 150-644) that failed to rescue cell cycle arrest, still retained their ability to
interact with PIH1D1 (Fig. 6E), further underscoring the conclusion that interaction of
ECD with PIH1D1 is dispensable while its interaction with RUVBL1 is indispensable for
a role in cell cycle progression. PIH1D1 is known to directly interact with other
components of the R2TP complex, such as RUVBL1 (33). Re-probing of the same
membrane with antibodies against RUVBL1 and RUVBL2 showed the expected
interaction of PIH1D1 with RUVBL1 or RUVBL2 (Fig. S4E).
Our previous studies showed that ECD interacts with RB, a function important for
ECD function in cell cycle progression (6).

Notably, in addition to the expected

interaction of full-length ECD with RB, one mutant (150-644 aa) that is defective in
rescuing cell cycle arrest (Fig. 6D) was earlier shown to retain its ability to interact with
RB (6), suggesting that interaction with RUVBL1 is required for ECD to promote cell
cycle progression while interaction with RB in the absence of interaction with RUVBL1
is insufficient for this function. In further support of this conclusion cell cycle function
competent (3S/A) and deficient mutant (6S/A) of ECD show comparable interaction with
RB (Fig. S4F).
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Ecd deletion leads to reduced mitotic index and delayed mitotic progression
We have previously reported that the proliferation arrest upon Ecd deletion is not
associated with any increase in apoptosis (6) . To examine the effect of Ecd deletion on
mitosis, we used adeno-Cre to delete Ecd in Ecdfl/fl MEFs and measured the Median
Fluorescence Intensity (MFI) of phospho histone H3 (S10) as an indicator of the
proportion of cells in mitosis using flow cytometry (34). Ecd deleted cells showed a
marked decrease in the MFI (45.7) of pH3 (S10) as compared to control cells (89.8) (Fig.
7A), indicating that Ecd deleted cells are arrested prior to entering mitosis. Low levels of
pH3 (S10) were further confirmed by western blotting (Fig. 7B). Next, we assessed the
G2/M to G1 progression of MEFs arrested in the S phase by nocodazole treatment (Fig.
7C). Flow cytometry analysis revealed a significant impairment in G2/M to G1 phase
transition upon Ecd deletion as compared to control, in addition to a higher percentage
of Ecd deleted MEFs in the G1 phase (Fig. 7C, D & E). Taken together, these results
demonstrate a critical role of ECD in both G1 to S and G2/M to G1 transition. These
results are consistent with the known function of CK2 and RUVBL1 in cell cycle
regulation (35-37).
Discussion
Precise regulation of the entry into, progression though and exit from cell cycle is
fundamental to developmental programs and maintenance of adult tissues in multicellular
organisms. Notably, components of the cell cycle machinery and the pathways that
regulate their functions are commonly altered in cancer and other diseases (1). Thus,

225

elucidating how the cell cycle machinery is controlled is an important area of research in
cell and cancer biology.
We have previously shown that ECD, the mammalian orthologue of Drosophila
ecdysoneless gene, is required for embryonic development and progression of
mammalian cells though the G1-S phase of cell cycle progression (6). Here, we identify a
novel mechanism by which ECD functions as an essential element of mammalian cell
cycle progression. Using multiple complementary approaches, we demonstrate a novel
interaction of ECD with the R2TP chaperone complex, mediated by the RUVBL1
component of R2TP, which we establish is required for ECD to promote cell cycle
progression. We also identify a role for the CK2-dependent phosphorylation of ECD in
cell cycle progression, but contrary to predictions from a previous study (11), this role is
independent of the ECD interaction with PIH1D1, the phospho-reader component of the
R2TP complex.
Our findings establish that phosphorylation of ECD positively regulates its
function in promoting the cell cycle progression. Bioinformatics analysis followed by
mass spectroscopy-based phospho-proteomics identified a number of sites that could be
phosphorylated by cellular kinases but we focused on two clusters of potential CK2
phosphorylated serine residues since a recent study (11) showed that CK2-mediated
phosphorylation of two such serine residues in the context of a peptide created a binding
site for the phospho-reader subunit of the R2TP complex. CK2-dependent
phosphorylation of site-directed mutants of ECD in vitro, and in cultured cells, identified
six serine residues in two spatially separated clusters to be the major CK2
phosphorylation sites on ECD. Notably, however, ECD phosphorylation does not change
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during cell cycle progression. This is not entirely surprising since our in vitro analyses as
well as phosphorylation studies in cells in the presence of a CK2 inhibitor (Fig. 3 D & F)
establish that CK2 is the predominant kinase that phosphorylates ECD; CK2 is
considered to be constitutively-active and ubiquitous serine/theonine protein kinase (38).
Despite its constitutive activity though, numerous studies point to a role for CK2 in cell
proliferation and survival (39). Yet, the molecular pathways that mediate the function of
CK2 in cell proliferation are largely unknown. We suggest that phosphorylation of ECD
by CK2 provides one mechanism for CK2’s role in cell proliferation. While the overall
levels and the subcellular localization of ECD remain invariant during cell cycle
progression (Fig. 1 & 2), it remains possible that ECD phosphorylation at specific sites
may vary during cell cycle progression. As phospho specific antibodies against specific
serine residues on ECD become available, it should be feasible to test this notion further.
Our findings that ECD is indeed a CK2 substrate in vitro (Fig. 3) suggested that
CK2-dependent phosphorylation and subsequent interaction of ECD with the R2TP
complex could provide a potential mechanism by which ECD could promote the cell
cycle transit. Our co-IP studies in cell cultures demonstrate that ECD in fact is in a
complex that includes the four core subunits of the R2TP complex (Fig 4D & E).
Remarkably, however, multiple mutant ECD proteins, rendered incapable of directly
interacting with PIH1D1, including mutations of critical serine residues in the 3S/A
mutant or the 6S/A mutant or deletion of the region incorporating the major CK2
phosphorylation sites and the acidic motif DSDD that facilitates PIH1D1 interaction (11),
fully retained the ability to associate with the R2TP complex. Furthermore, the ECDR2TP association was retained in PIH1D1-depleted cells (Fig 5C). Thus, our results
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support a PIH1D1-independent mechanism of ECD association with the R2TP complex.
Importantly, S>A mutation of ECD residues that impart PIH1D1 binding (3S/A & Δ499527) had no impact on its ability to function in cell cycle progression. However, 6S/A
and 6S/D were defective in cell cycle rescue experiment, underscoring the importance of
ECD phosphorylation for its function that encompasses amino acids beyond PIH1D1
interaction. Thus, the role of phosphorylation in regulating ECD function during cell
cycle appears to be independent of mediating an interaction with PIH1D1. It remains
possible, however, that phosphorylation-dependent interaction of ECD with PIH1D1, and
consequently with the R2TP complex, is required for other functions of ECD aside from
its role in promoting cell cycle progression (6). For example, we have shown that ECD
overexpression in cells leads to p53 stabilization and increased p53-dependent target
gene expression, and induction of a senescence phenotype in primary fibroblasts (5).
ECD was also found to interact with thioredoxin-interacting protein (TXNIP), which was
shown to promote p53 stabilization (40). TXNIP has a number of other functions
including regulation of glucose uptake, oxidative stress and ER stress-induced apoptosis
(41, 42), Thus ECD phosphorylation and interaction with PIH1D1 may play a role in
regulating these functions. The availability of Ecdfl/fl MEFs in which ECD can be
conditionally deleted together with phosphorylation-defective mutants that we have
characterized here should allow these notions to be tested in the future.
In view of a novel, PIH1D1-independent mechanism of ECD association with the
R2TP complex, we sought to answer two key mechanistic questions: one, what the
determinants of ECD-R2TP association are, and second, whether this unique mode of
interaction is functionally relevant in the context of cell cycle progression role of ECD?
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Unbiased proteomics analysis of cellular proteins that interacted with a recombinant fulllength ECD protein, followed by biochemical analyses in cells, demonstrated that ECD
interacts with another component of the R2TP complex, RUVBL1 (Fig 5 & 6). Structurefunction studies of ECD using deletion fragments demonstrated a strong correlation
between the cell cycle progression function of ECD and its ability to interact with
RUVBL1, with only the full-length ECD competent at both functions (Fig. 6A, B, S4B &
C). Interestingly, the Δ499-527 mutant which interacts with RUVBL1 but not PIH1D1,
was able to rescue the cell cycle arrest caused by Ecd deletion (Fig. S2A). Thus, our
studies identify a novel interaction of ECD with RUVBL1 and suggest that this mode of
interaction with the R2TP complex is a key to the regulation of cell cycle progression by
ECD. Delineation of sequences in ECD and RUVBL1 that mediate their interaction
should help directly test if selective abrogation of this interaction is functionally critical
in cell cycle progression as well as to assess the potential role of ECD in other roles of
RUVBL1 within the R2TP complex. Interestingly, mouse ECD and RUVBL1 knockouts
are phenotypically similar, both being embryonic lethal at the blastocyst stage (6, 19).
RUVBL1 is essential for cellular proliferation as seen in knockout cells or upon
knockdown of RUVBL1 expression (18). A recent study demonstrated that RUVBL1
functions as a critical factor for p300 recruitment to OCT4 target genes (18). It is of
interest that ECD also interacts with p300 and promotes its transcriptional co-activator
function (8). Thus, ECD may function in close coordination with RUVBL1.
Given the evidence we present that ECD can physically interact with two distinct
components of the R2TP complex, it is conceivable that certain ECD functions require
both modes of interaction. Recent studies have shown that, aside from the R2TP
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complex, RUVBL1/2 are also parts of other functionally-relevant complexes, such as
chomatin remodeling complexes TIP60, SWR/SRCAP, INO80, and Fanconi anemia core
complex that controls DNA inter-strand crosslink repair and function, and regulate
telomerase biogenesis and mitosis(19, 43-45). Given the PIH1D1-independent interaction
of ECD with RUVBL1, potential roles of ECD via these alternative complexes will be of
great future interest.
An essential role of ECD in cell cycle progression was established by our
previous observation that ECD is essential for embryogenesis and its conditional deletion
in MEFs leads to a G1-S cell cycle arrest together with an inability to initiate an E2Fdependent transcriptional program essential for cell cycle progression (6). Notably, we
demonstrated that ECD competes with E2F for binding to the pocket domain of RB and
that the cell cycle progression defect in Ecd-null MEFs could be overcome by removing
the Rb-mediated suppression of E2F using a pocket-binding oncogene HPV16 E7. As a
key mechanism by which the R2TP complex regulates biochemical processes is by
facilitating protein complex remodeling, we speculate that interaction of ECD with the
R2TP complex, though RUVBL1, facilitates the ECD-RB complex formation and helps
dissociate RB from E2Fs, thereby de-repressing the E2F-mediated transcription and
promoting cell cycle progression. Consistent with this speculative model, our previous
studies showed that binding to RB was not sufficient for the cell cycle progression
function of ECD, as we identified one ECD mutant that was able to interact with RB but
was defective in cell cycle rescue.
Our previous studies demonstrated that ECD is overexpressed in breast and
pancreatic cancer patient tissues, and ECD overexpression correlates with poor prognosis
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and poor survival in breast cancer patients (9, 10).

It is noteworthy that several

components of the R2TP/prefoldin complex, including PIH1D1, RUVBL1 and RUVBL2,
are also overexpressed in various cancers and are predicted to play important roles in
oncogenesis (46, 47). A comprehensive meta-analysis of The Cancer Genome Atlas
(TCGA) datasets (46) revealed that expression of many RUVBL complex genes was
significantly higher in breast and colorectal carcinomas when compared to their normal
tissue controls. These investigations suggested a correlation between RUVBL complex
component overexpression and increased mTORC1 signaling and metabolic processes
necessary for tumor cell growth (46). Another study demonstrated that PIH1D1 is
overexpressed in various breast cancer cell lines where it plays a major role in rRNA
transcription (48). Our recent studies showed a co-oncogenic role of ECD with Ras when
introduced into immortal human mammary epithelial cells (49), further suggesting the
potential collaborative role of ECD and the R2TP or other RUVBL-containing complexes
in cell cycle regulation and oncogenesis.
A positive role of ECD in pre-mRNA splicing was reported recently based on
rescue of splicing defects in the prothoracic gland of Ecd deficient flies by human ECD
and interaction of ECD with a complex containing the spliceosome component PRP8 (7,
50). Our affinity purification/Mass Spectrometry analyses confirmed the interaction of
ECD with PRPF8. The R2TP complex regulates mRNA and ribosome biogenesis by
facilitating the assembly of small nucleolar ribonucleoproteins (snoRNPs), which are
known to be involved in splicosome modification (51, 52). Upregulation of R2TP and
snoRNP components is thought to promote ribosome synthesis in cancer cells (47).
Whether overexpressed ECD in tumors may function in concert with R2TP and other
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RUVBL1-containing complexes to promote oncogenesis needs further investigation.
Taken together, studies presented here demonstrate that CK2-mediated phosphorylation
and interaction with RUVBL1 are essential for ECD’s ability to regulate cell cycle
progression.
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Figure Legends
Figure 1: ECD localization and expression do not change during cell cycle
progression. 76NTERT cells were cell cycle arrested by culturing in growth factor-free
DFCI-3 medium for 72 h and then switched to growth factor-containing DFCI-1 medium
to initiate cell cycle progression. (A) Cells were fixed in 70% ethanol at the indicated
time points, stained with propidium iodide and subjected to FACS analysis. (B) Lysates
were collected at the indicated time points and subjected to western blotting for ECD or
β-Actin. ImageJ software was used to quantify ECD signals at various time points during
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cell cycle progression and expressed as relative to β-Actin signals. (C) Nuclear and
cytoplasmic fractions were isolated from cells at various time points during cell cycle
progression and subjected to western blot analysis with anti-ECD antibody. PARP and
GAPDH served as positive controls for nuclear and cytoplasmic proteins respectively. All
experiments were carried out in triplicates. H.E., higher exposure.
Figure 2: ECD is phosphorylated, predominantly on serine residues. (A) T98G cells
were serum-deprived for 48 h, last 4 h in phosphate-free medium, and then cultured for
indicated times in complete DMEM medium containing 100 µCi sodium [32P]orthophosphate per 10-cm plate. ECD or RB (used as positive control) were
immunoprecipitated, resolved by SDS PAGE, transferred to PVDF membrane and
subjected to autoradiography to detect phosphorylation signal. (B) T98G cells transiently
transfected to express FLAG-tagged ECD were cultured for 6 h in phosphate-free DMEM
and then metabolically [32P]-labeled, as described above. Anti-FLAG IPs were visualized
by autoradiography. (C) Anti-FLAG IPs of T98G cells transfected with FLAG-tagged
ECD were western blotted with anti-p-Ser or anti-p-Thr antibodies. In vitro
phosphorylated GST-PERK kinase domain was used as a positive control for serine and
theonine phosphorylation. The extra band observed in GST-PERK lane is likely a
cleavage product of PERK. Arrows point to bands of interest.
Figure 3: Phosphorylation of ECD is important for its ability to rescue cell cycle
arrest in Ecd null MEFs. (A) Schematic of ECD protein, its C-terminal deleted
constructs, and CK2 phosphorylation sites predicted by KinasePhos 0.2 tool
(http://kinasephos2.mbc.nctu.edu.tw/). (B) ECD is predominantly phosphorylated near
its C-terminus. In vitro kinase reactions of full length (1-644) ECD and various C-
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terminal deletion fragments (1-567, 1-534, and 1-432) with human recombinant CK2
were separated by SDS-PAGE, transferred to PVDF membrane and subjected to
autoradiography to detect [32P] signals. Purity of proteins was assessed by Coomassie
brilliant blue staining (CBB). (C) Schematic representation of various point mutants.
Black rectangles, WT Ser residues; white rectangles, mutant Ala residues. (D) CK2
phosphorylates ECD at 6 sites. His-tagged wild type ECD or its point mutants were
purified by Nickel affinity purification and subjected to an in vitro kinase assay, as
described above. [32P] labeling was detected using autoradiography and the filters were
subsequently subjected to western blotting with anti-p-Ser antibody and re-probed with
anti-ECD antibody for equal loading. Purity of recombinant proteins was assessed by
CBB staining. (E)

CK2-dependent phosphorylation of ECD at multiple residues in

cultured cells. T98G cells expressing FLAG-tagged ECD or its phosphorylation site
mutants 3S/A or 6S/A were metabolically labeled with [32P], as described above. FLAGtagged ECD and its mutants were immunoprecipitated and subjected to autoradiography.
IP of cells expressing WT ECD were subjected to phosphatase treatment is shown. The
blot was re-probed with anti-ECD antibody for equal IP loading. (F) Inhibition of CK2
reduces ECD phosphorylation. T98G cells expressing FLAG-tagged ECD or its
phosphorylation site mutants 3S/A and 6S/A were treated with CK2 inhibitor TBB (50
µM) for 4 h, subjected to anti-FLAG IP and western blotted with anti-p-Ser or anti-FLAG
antibodies. The intensity of anti-p-Ser signals was quantified using the ImajeJ software
and normalized relative to FALG-ECD signals. (G) Phosphorylation of ECD at six CK2
sites is important for its cell cycle progression function. Ecdflox/flox MEFs stably
expressing vector control, wild type human ECD or its indicated mutants were infected
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with control (ctrl) adeno-GFP or adeno-GFP-Cre (cre) viruses for the indicated times and
lysates were analyzed by anti-ECD and -tubulin (loading control). Note that human
ECD-reconstituted cells express both endogenous mouse (mEcd higher band) and ectopic
hECD or its mutants (hECD, lower band). (H-J) Analysis of hECD or its mutants for
rescue of Ecdfl/fl MEFs from cell cycle arrest induced by Cre-mediated Ecd deletion.
Ecdfl/fl MEFs expressing vector (V), WT hECD or its 3S/A, 6S/A, 6S/D or 3’S/A mutants
were infected with control (ctrl) or Cre adenoviruses, followed by cell counting at the
indicated time points. The Cre/Ctrl cell number ratios at each time point were plotted to
assess the level of rescue relative to vector-expressing MEFs. Simulation’s correction
was applied to control for multiple testing in the calculation of the mean ratio. The
experiment is representative of thee repeats.
Figure 4: ECD Phosphorylation in living cells is dispensable for its interaction with
PIH1D1 and other components of the R2TP complex. (A) In vitro interaction of GSTPIH1D1 with ECD and its mutants. GST-PIH1D1 was immobilized on glutathionesepharose beads and incubated with lysates of HEK-293 cells expressing FLAG-tagged
WT ECD or its 3S/A or 6S/A mutant. (B & C) Interaction between endogenous ECD and
PIH1D1 was confirmed by immunoprecipitation of ECD from U2OS or MEFs followed
by western blotting with anti-PIH1D1 antibody. (D & E) Lysates of HEK-293T cells
transfected with untagged (D) or GFP-tagged (E) WT, 3S/A, 6S/A or Δ499-527 ECD
were subjected to immunoprecipitation with anti-PIH1D1 antibody and immunoblotted
with the indicated antibodies. (F) Alignment of mouse and human ECD sequences in the
region containing the DSDD/E motif. ‘V’ is vector transfected cells.
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Figure 5: ECD interacts with RUVBL1. (A) Tandem affinity purification identified
RUVBL1 as an ECD-interacting protein. 76NTERT cell lysates were incubated with
glutathione-sepharose bead bound GST-ECD-FLAG and protein complexes eluted by
cleaving ECD-FLAG portion with PreScission protease. Eluted ECD-FLAG in complex
with bound proteins was further affinity purified using FLAG beads and then eluted using
excess FLAG peptide. The presented gel corresponds to 5% of the final eluates visualized
by silver staining. Arrows point to the gel slices that were analyzed by mass
spectrometry. Top and middle arrows point to slices that identified PRPF8 and RUVBL1,
respectively. (B) Interaction between endogenous RUVBL1 and ECD. Lysates of HEK293T cells expressing FLAG-tagged WT ECD or its 6S/A mutant were subjected for antiRUVBL1 IP followed by anti-FLAG blotting. (C) PIH1D1 knockdown does not affect
RUVBL1-ECD association. Lysates of U2OS cells transfected with PIH1D1 or
scrambled control siRNA 48 hours earlier were subjected to anti-ECD IP followed by
blotting with antibodies against the indicated proteins. ‘V’ is vector transfected cells.
Figure 6: Interaction with RUVBL1 is important for ECD function in cell cycle
progression. (A & B) Interaction between FLAG-RUVBL1 and ECD. GST-tagged or
His-tagged full length ECD or its truncated mutants immobilized on glutathionesepharose or nickel beads respectively, were incubated with lysates of HEK-293T cells
expressing FLAG-tagged RUVBL1. (C) Western blotting to show the expression of WT
human ECD or its deletion mutants in Ecdfl/fl MEFs with control or Cre adenovirus
infection (arrowheads point to the human ECD or mutants). Also note that anti-ECD
antibody blot does not detect the C-terminally deleted ECD 1-438 mutant. (D) Colony
formation assay. Ecdfl/fl MEFs expressing full length WT ECD (1-644) or its truncations
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were infected with ctrl or Cre adenoviruses, colonies were stained with crystal violet after
10 days and solubilized dye absorbance was read at 590 nm. Histogram shows the
relative rescue efficiency of each construct as compared to vector control cells. Error bars
represents mean ± SD of thee independent experiments. Statistical comparison used
student’s two tailed t test. (E) Interaction of FLAG-tagged ECD or its deletion fragments
with PIH1D1. Lysates of HEK-293T cells expressing the indicated FLAG-tagged ECD
fragments were used for GST-PIH1D1 pull-down followed by anti-FLAG blotting. ‘V’ is
vector transfected cells.
Figure 7: Ecd deletion leads to a mitotic block. (A) Ecdflox/flox MEFs infected with
control (blue) or Cre adenoviruses (red) were fixed in 70% ethanol, stained with antipH3(S10) and analyzed by flow cytometry. Median Fluorescence Intensity (MFI),
representing the peak channel number on the X-axis, is shown. (B) Lysates of control
(Ctrl) or Ecd deleted (Cre) Ecdflox/flox MEFs were blotted with the indicated antibodies.
(C) Control (Ctrl) or Ecd deleted (Cre) MEFs were treated with 100 ng/ml nocodazole for
20 h and cells switched to nocodazole-free medium to initiate cell cycle progression for
the indicated time points. Cells were stained with propidium iodide and analyzed by
FACS for cell cycle analysis. (D) Graph shows the percentage of cells entering the
G1 phase after release from nocodazole treatment at various time points. Data points are
mean ± S.D. of results from thee independent experiments (* p ≤ 0.05 by two tailed
Student's t test). (E) Deletion of Ecd in the experiment shown in C confirmed by western
blotting.
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